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ABSTRACT 
 
Prostate cancer is the second common type of cancer worldwide and in Palestine. 
The use of different treatment options helped prostate cancer survivors to get cured or to 
live for longer periods of time. Because of the several complications of treatment options, 
issues related to quality of life (QOL) became highly important in the decision of which 
option to use.  
Many studies examined QOL of prostate cancer survivors and barriers to health 
care; but none was conducted in a developing country. The purpose of this study was to 
evaluate the level of QOL and to assess the barriers to health care as perceived by 
prostate cancer survivors who live in Gaza Strip.  
 The UCLA-PCI instrument was used to evaluate QOL. Barriers to health care 
were assessed by using a semi-structured interview. With a response rate of 97.98%, 
findings revealed that the scores of the general quality of life of prostate cancer survivors 
living in Gaza Strip were generally lower than those reported in the literature. The scores 
of Prostate-Specific Index fell within the range of scores reported in the literature. After 
calculating the t test, the differences between the results of this study and the results 
reported in the literature were found to be significant. The use of hormonal therapy and 
prostatectomy were found to be the most common treatment modalities used for 
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treatment of prostate cancer in Gaza. Participants who were treated with prostatectomy 
reported higher scores of PCI QOL than those treated with hormonal therapy. 
Participant reported several barriers to health care. These barriers were 
categorized under five major categories: 1) barriers due to unavailability, 2) 
organizational barriers, 3) geographical barriers, 4) socioeconomic barriers, and 5) 
barriers related directly to the blockage imposed on Gaza. Within each category several 
subcategories emerged.  
 Results served to recommend for several policy changes. The suggested health 
policy changes include: a) requesting physicians to inform patients about the pros and 
cons of different treatment modalities, b) introduce a prostate cancer screening policy, c) 
reconsider the referral policy to increase radiation therapy, and d) set policies designated 
to eliminate barriers to health care. 
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CHAPTER I 
INTRODUCTION 
 
Because people live longer than ever before, the chances for people to develop 
chronic diseases including cancer, especially those types of cancers that appear at older 
ages such as prostate cancer among men, increase. Worldwide, the American Cancer 
Society (ACS) (2007a) estimates that the number of people who will be diagnosed with 
cancer will exceed 12 million new cancer cases in 2007 with approximately half of them 
residing at economically developed countries. According to the same report, an estimated  
6.7 million will die from cancer in 2007, with approximately two thirds of them residing 
in developing countries (American Cancer Society, 2007a).  
 
Most Common Types of Cancer 
 
Prostate cancer is the second common type of cancer worldwide and it is the 6th 
leading cause of cancer –related deaths among men worldwide (American Cancer 
Society, 2007a). The three most common types of new cancer cases among men in 
developed countries are prostate, lung and bronchus, and colorectal cancers. Prostate 
cancer is ranked as the second most common cause of cancer-related deaths in developed 
countries (see Table 1-1). While the most common three types of new cases of cancer in
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developing countries are lung and bronchus, stomach, and liver, prostate cancer ranks as 
the 6
th
 common type of cancer and the 6
th
 common cause of deaths due to cancer in these 
countries (Table 1-1) (American Cancer Society, 2007a). The variation of the numbers of 
prostate cancer between developed and underdeveloped countries can be related to one of 
two reasons: increased detection and the fact that prostate cancer can be slow growing 
and therefore not detected until death from some other cause. To illustrate the variance of 
the incidence of cancer –including prostate cancer- and cancer related deaths between 
developed and underdeveloped courtiers, a comparison of cancer incidence and death 
related to cancer from Palestine and USA will be used). First, it could be due to the early 
screening of prostate cancer using prostate-specific antigen (PSA), which is used in early 
detection of prostate cancer in developed countries. Due to the use of PSA, incidence of 
prostate cancer increased rapidly between 1988 and1992, then declined sharply in the 
United states from 1992-1995 (American Cancer Society, 2007b). Additionally, the  
 
Table 1-1: Comparing New Cases of Prostate Cancer and Deaths Related to Prostate 
Cancer Worldwide, Developed Countries and Developing Countries. (Source: American 
Cancer Society, 2007a) 
 
  
  
New cases Deaths  
% 
Rank Cases Rank Cases 
Worldwide 2 782,647 6 253,906 32.4% 
Developed  
Countries  
1 566,841 3 143,834 25.4% 
Developing 
Countries 
6 194,914 6 106,537 54.7% 
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availability of other diagnostic technologies that help in early diagnosis of prostate cancer  
such as transrectal ultrasound and the improved techniques for prostate biopsy may have 
contributed to the increase in diagnosis over this period (Hoff & Pow-Sang, 2001). 
Second, it could be due to the fact that prostate grows slowly and can go 
undetected. According to the American Cancer Society (2008), autopsy studies showed 
that many older men (and some younger men) who died due to other diseases also had 
prostate cancer that never caused a problem to them while they were alive and neither 
they nor their doctors were aware of.  Furthermore, the American Cancer Society (2010) 
estimates that one man out of each six American men will develop prostate cancer during 
his life time.   
The probability of developing invasive prostate cancer increases with age. The 
probability increases from 2.59% (1 in 39) between the ages 40-59 to 7.03% (1 in 14) at 
the ages 60-69 to 13.83% (1 in 7) at the age of 70 and older (American Cancer Society, 
2007b). While prostate cancer is considered one of the most common cancers among 
males, the survival rates have improved in recent years. Between 1996 and 2002, the 
five-year relative survival rates for prostate cancer in the United States (the chance of 
living 5 years after being diagnosed with prostate cancer) was 99.9% at all stages of 
cancer and 100% if the cancer was local (American Cancer Society, 2007b).   
In Palestine, according to the Ministry of Health (MoH) annual report (2006), a 
total of 1,623 (1,168 in the West Bank & 455 in Gaza Strip) new cancer cases were 
reported in 2005 with an incidence rate of 43.1 per 100,000 population, (49.2 per 
100,000 in the West Bank and 32.7 per 100,000 in Gaza Strip). Of the reported new 
cases, 44.8% of them were males, and 55.2% were females.  
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The most common reported types of cancer among Palestinian males (Figure 1-1) in 
2005 was lung cancer (13.8% of total new cancer cases among males) followed by 
prostate cancer (11.3% of total new cases among males with an incidence rate of 4.6 per 
100,000 males). About 134 new prostate cancer cases were reported in the years 1998 
and 1999. Most of the reported cases (110) were reported in West bank and the rest of 
cases (24) were reported in Gaza Strip (Ministry of Health, 2005). In general, 106 new 
prostate cancer cases (Table 1-2) were reported in Gaza Strep between the years 1995 
and 2000. The majority (78.3%) of these cases were reported after the age of 60 (Table 
1-3) with a peak incidence (25.5%) between the ages of 65-69. The total incidence rate  
of prostate cancer in Gaza Strip between 1995 and 2000 was 3.45 per 100,000 of the 
population (Najjar, Awad, & Thabet, 2002).  
 
Figure 1-1: Common Types of Cancer among Males in Palestine. (Source: MoH, 2006) 
13.8 
11.3 
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Table 1-2: Distribution of New Prostate Cancer Diagnoses by Year in Gaza Strip, 
Palestine 1995-2000. (Source: Najjar, Awad, & Thabet, 2002) 
 
Year  Number of Reported Cases 
1995  16 
1996  17 
1997  28 
1998  11 
1999  13 
2000  21 
Total  106 
 
 
Table 1-3: Incidence Rate of Prostate Cancer by Age Group in Gaza Strip, Palestine 
1995-2000. (Source: Najjar et al., 2002) 
 
Age group 
   
Cases  Percent  Rate per 100,000 
45-49 3  2.8  4.44 
50-54 7  6.6  14.02 
55-59 13  12.3  32.26 
60-64 24  22.6  60.77 
65-69 27  25.5  86.30 
70-74 14  13.2  65.19 
75+ 18  17.0  76.02 
Total 106  100  3.45 
 
Of the total 1,048 deaths that occurred in 2005, malignancy was the third leading 
cause of death (10.3% of total death cases) in total population of Palestine after heart 
disease (21% of total death cases) and cerebrovascular diseases (11% of total death 
cases) (MoH, 2006). Cancer was the second leading cause of death among males 
(10.6%) and among the young population between the age of 20-59 years old (18.5%). 
The most common cause of death related to cancer among the total population was  
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Trachea, Bronchus & lung cancer which constituted 15.4% of all cancer-related deaths. 
Prostate cancer was the ninth leading cause of cancer-related deaths (5.3%) among the 
total Palestinian population and the second leading cause (9.5%) of cancer-related deaths 
among males (MoH, 2006).  
In the United States, the number of people who were living with cancer in the 
year 2005 was estimated to be about 11.1 millions. About 1,479,350 new cases of cancer 
were estimated to be diagnosed in year 2009 (these numbers don‟t include some types of 
skin cancer which are believed to be around one million new case) (American Cancer 
Society, 2009). Prostate cancer is the most common type of cancer diagnosed in men in 
the United States. Of the 1,479,350 new cases expected to be diagnosed in 2009, an 
estimated 192,280 new prostate cancer cases were expected to be diagnosed in 2009 
(American Cancer Society, 2009). 
Cancer is the second leading cause of death in the United States after heart 
disease. According to the American Cancer Society (2009), 25% of deaths occur in the 
United States due to cancer. Of the 562,340 expected deaths in 2007 due to cancer, about 
27,360 of them were expected to be due to prostate cancer which is considered the second 
cause of cancer-related deaths in males after lung and bronchus cancer (American Cancer 
Society, 2009).  
 
Treatment of Prostate Cancer 
 
Depending on age, stage of cancer, and other disease conditions, treatment for 
prostate cancer may include surgical removal of the prostate gland (prostatectomy), 
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radiation therapy, or watchful waiting (American Cancer Society, 2007b; Fleming, 
Wasson, Albertsen, Barry, & Wennberg, 1993) and watchful observation (Hoff & Pow-
Sang, 2001). Hormonal or chemotherapy can be added to treatment regimen depending 
on the case (American Cancer Society, 2007b; American Cancer Society, 2009; Fleming, 
et. al, 1993).  
In Gaza Strip, the most common type of primary treatment used to treat men with 
prostate cancer is surgical treatment. About 62.5% of total prostate cancer patients were 
treated surgically, 28.6% received chemotherapy, and 66.7% received hormonal therapy 
(Najjar et al., 2002). Men with prostate cancer do not have the advantage of being treated 
with radiation therapy as the Palestinians were denied by the Israelis to have this type of 
treatment. On some occasions, the Palestinian‟s Minister of Health (MoH) refers some 
patients to receive radiation therapy treatment in neighbor countries such as Egypt. In the 
last 3 years (2007-20010?), due to the sanctions imposed on Palestinians in Gaza Strip 
after the 2006 elections and the partial or complete closure of the borders between Gaza 
Strip and Egypt, very few patients were referred to be treated outside Gaza Strip.  
The use of each treatment modality has its own complications and side effects and 
each of the available treatment modalities has several long-lasting complications that 
may negatively impact the quality of life (Albaugh & Hacker, 2005). For example, the 
complications of radical prostatectomy include urinary symptoms and impotence due to 
trauma and removal of the neurovascular bundle adjacent to the gland (Woolf, 1995; 
Clark et al., 2003; Turini et al., 2003; Ward et al., 2004; Albaugh & Hacker, 2005).  
Compared to surgical removal of the prostate, radiation therapy causes fewer 
sexual side effects (D‟Amico et al. 1997), but still causes some erectile problems for men 
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(Potosky et al. 2004) and other urinary complications such as urinary incontinence and 
irritation (Brandeis, Litwin, Burnison, & Reiter, 2000). Radiation can also cause several 
bowel related complications such as frequency, urgency, diarrhea, fecal incontinence, 
pain during bowel movement, proctatitis, and blood in the stool (Sommers & Ramsey, 
1999; Albaugh & Hacker, 2005).  
Hormonal therapy commonly leads to sexual problems such as impotence; 
decreased libido, and erectile dysfunction; gynacomastia (increase breast size in men); 
weight gain, hot flashes, sleep disturbances, fatigue, altered mood and depression; and 
osteoporosis (Sommers & Ramsey, 1999; Potosky et al., 2002; Penson & Litwin, 2003;  
Turini et al., 2003; Albaugh, & Hacker, 2005). Melmed, Kwan, Reid, & Litwin( 2002) 
further added that hormonal therapy is associated with diminished quality of life (QOL) 
because of subsequent deterioration in physical function and pain as measured by the 
domains in the SF-36 health assessment tool. 
In spite of introducing no treatment, watchful waiting has its own psychological 
consequences. These consequences include stress, anxiety, and fear of the unknown 
(Chodak & Warren, 2006). On the other hand, men who choose watchful waiting may 
also report some bladder problems such as frequency, urgency, incomplete bladder 
emptying as the growing tumor will lead to obstruction of the bladder neck. Watchful 
waiting may also result in metastasizing to other organs including bone and severe bone 
pain and fractures will negatively impact their QOL (Chodak & Warren, 2006; Albaugh, 
& Hacker, 2005).   
Chemotherapy therapy also has side effects that includes, but is not limited to, 
nausea, vomiting, alopecia (hair loss), diarrhea, bone marrow suppression (which affects 
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the production of red and white blood cells therefore causes anemia and lowers the 
immune system of the patient) (Kalant, Grant, & Mitchell, 2007).    
The diagnosis of cancer, treatment, and complications and side effects of 
treatment modalities can result in considerable suffering for the patients and affect their 
physical, psychological, and emotional well being. Such alteration of patients‟ well being 
will affect their quality of life. Survivals of prostate cancer in developing countries, 
including Gaza Strip, may not have the same quality of life as their counterparts in other 
parts of the world as they do not have the privilege of radiation therapy and have several 
barriers to health care whether due to availability of services or accessibility of health 
care. Therefore, prostate cancer may be diagnosed later, at more advanced stages 
requiring the use of more aggressive therapy such as hormonal and chemotherapy in their 
treatment regimen. Late diagnoses of their prostate cancer and the use of hormonal and/or 
chemotherapy may worsen their health related quality of life.  
 
Policy Implications 
 
Because the survival rate for prostate cancer is favorable regardless of the type of 
treatment, the treatment decision may depend on some specific health-related outcome 
that may affect the quality of life of the patient (Potosky et al., 2000). For men who live 
in Gaza Strip and are diagnosed with prostate cancer, the chances of getting treated with 
radiation therapy are small because of the blockade imposed against Gaza Strip for the 
last three years. The use of radiation therapy produces fewer complications than surgical 
treatments (Potosky et al., 2000) and the use of chemotherapy (in 28.6% of cases) and 
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hormonal therapy (in 66.7% of cases) in patients who have prostate cancer in Gaza Strip 
(Najjar, et al., 2002) may produce additional side effects and complications for these 
patients. The lack of radiation therapy along with the presence of several barriers to 
health care may affect the quality of life for patients in this population.  
The reported results about the level of quality of life of Gaza men who were 
diagnosed with prostate cancer were compared with the results of quality of life of 
prostate cancer survivors reported in the literature to examine if there was any difference 
in the scores of their quality of life. After examining the results of this study, several 
recommendations for policy makers were made. These recommendations included 
requesting treating physicians to discuss with their patients, the pros and cons of the 
different treatment options, plan to provide radiation therapy as a long strategic goal and 
to provide referrals for radiation therapy at the short term goal, form a plan for prostate 
cancer screening, and eliminating different barriers to health care. 
The budget of the Palestinian ministry of health is very limited. It was only 
134,222,222 US dollars in 2004 excluding the expenditures for treatment abroad. The 
cost of treating 31,744 patients abroad was more than 58 million US dollars which 
constituted about 45.9% of the actual health expenditures at that year (Ministry of Health, 
2005). The result of this study provides the Palestinian health policy decision makers 
with a background about the importance of establishing a radiation therapy center in 
Gaza Strip which can contribute to the improvement of quality of life of most of cancer 
patients including those who have prostate cancer and will save several millions of 
dollars that can be used in another venue to improve the overall health of the Palestinians.  
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Furthermore, the results of this study served to make recommendations for health 
policy makers in Gaza Strip to eliminate barriers to health care reported by participants. 
Eliminating or reducing any identified barriers will help to improve the quality of the 
services provided to prostate cancer men who live in Gaza Strip and will improve their 
quality of life.  
Such issues are not as easy as they may sound as the Palestinian decision making 
regarding several issues is contingent upon the overall political situation in the area. The 
results of this study should inform Palestinian decision makers, along with the results of 
other similar studies in the event that what Kingdon (1995) called the “policy window” 
will open and they will have the opportunity to introduce their plans to improve the 
health status of the Palestinians. This window does not open often and when it does, it 
may stay open for only a short period of time. In fact, it is anticipated that the window 
will open with the inauguration of the new president for the United States who promised 
to work hard to bring peace to the Middle East.  
The barriers to health care identified in this study will also be introduced to 
Palestinian health care decision makers for assessment and possible modification to the 
current health care system. Such changes will help men with prostate cancer and other 
categories of patient, to better utilize and access the health care system and consequently 
improve their quality of life.  
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Purpose of the Study 
 
 The purpose of this study was to evaluate the quality of life of prostate cancer 
survivors of men residing in Gaza Strip and to assess the barriers to health care they face 
through their treatment period. The results of this study should assist health care 
providers in counseling patients on the method of treatment for prostate cancer that offers 
the patient the best quality of life and help patients make their decision about the 
preferred treatment approach to their prostate cancer. The result of this study will help 
policy makers to evaluate the current policy or adopt a new policy toward the available 
prostate cancer treatment modalities to ensure better quality of life for prostate cancer 
survivors who live in Gaza Strip.  
Furthermore, the study will help to identify the barriers that prostate cancer 
survivors face through their treatment journey. Identifying such barriers will help policy 
makers to change or manipulate current policies in an attempt to overcome these barriers. 
Additionally, the study seeks to provide information for health care providers to meet the 
concerns and needs of prostate cancer survivors through reporting quality of life issues.  
 The specific aims of this study are to: 
1. Describe the level of perceived quality of life among men with prostate cancer 
who live in Gaza Strip. 
2. Examine if there are any differences in the level of perceived quality of life 
among men with prostate cancer who live in Gaza Strip and receive treatment and 
men who finished their treatment.   
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3. Identify barriers to health care that face men with prostate cancer who live in 
Gaza Strip during their treatment period. 
 
Problem Statement 
 
A few decades ago, a diagnosis of cancer was usually associated with fear of 
death, disablement, and physical limitation from not only the cancer itself, but also from 
debilitating treatment and its complications. When a man is diagnosed with prostate 
cancer, additional fears of becoming impotent or infertile are other major concerns 
(D‟Amico et al. 1997; Turini et al., 2003; Potosky et al., 2004; & Albaugh & Hacker, 
2005).  However, due to medical advancements in treatment and early diagnosis for most 
kinds of cancer, including prostate cancer, increasing numbers of patients are surviving 
those cancers, remain free from cancer for the rest of their lives, or live with less pain 
and/or physical limitations. To help these people live in a more decent life, quality-of-life 
issues should be considered for this vulnerable group of patients and barriers that impede 
the availability and accessibility to health care services should be overcome and 
eliminated to help them live through their experience of surviving cancer and its 
treatment and live in a better quality of life.  
 Therefore, assessing quality of life issues for prostates cancer survivors and 
identifying barriers to their health care will help them to access health care, improve 
quality of provided care, and help health care professionals to be more sensitive to their 
patients‟ needs and concerns to improve the quality of life for this vulnerable population. 
This issue is more evident in developing countries as they lack the medical advancements 
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their counterparts in the developed countries enjoy (American Cancer Society, 2007a). 
When it comes to the Palestinian population in Gaza, quality of life for prostate cancer 
survivors and barriers to health care will be even more evident as this vulnerable 
population resides under blockade and economic sanctions since April 2006 which 
affects the drug supply and equipment needed for their treatment. Such blockage deprives 
patients, including prostate cancer patients, the opportunity to travel to Egypt or other 
countries to receive treatment. The impact of the blockade may affect the quality of life 
of this group of patients and contribute to several barriers to health care (World Health 
Organization: West bank & Gaza (2010) 
Despite a relatively large number of studies that examined quality of life of 
prostate cancer survivors and barriers to health care in developed countries, little is 
known about the quality of life of prostate cancers and barriers to health care in the 
developing countries and none is known about the quality of life of prostate cancer 
survivors and barriers to health care among the Palestinian population of Gaza. This lack 
of knowledge stems from the fact that, to date, no research was performed to examine 
these topics in this particularly vulnerable population.  
 
Conceptual Framework 
 
The revised Health Promotion Model (HPM) was chosen to serve as the 
conceptual framework for this study. The original Health Promotion Model was initially 
introduced by Dr. Nola Pender in 1996 (Pender, 1996), and then revised in 2002 (Pender, 
Murdaugh, & Parsons, 2002). This model attempts to explain the complex 
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biopsychosocial processes that motivate humans to practice activities that are directed 
toward enhancing their health and well-being (Pender, 1996, p. 51-52) rather than 
preventing disease occurrence.  
Even though Pender (1996) recognizes that fear or threats to health may serve as 
motivators for people to avoid illness, she argues that such avoidance-oriented models of 
health behavior have limited usefulness when it comes to adolescents? and adults who 
see themselves as invulnerable to illness. In contrast to avoidance-oriented models of 
health behavior, the applicability of the Health Promotion Model is not limited to those 
who have fears or threats to their health and therefore it has the potential to motivate 
people toward promoting their health and wellness across the life span including those 
who do not have any apparent fears or threats to their health (Pender, 1996, Pender et al., 
2002). 
The revised Health Promotion Model is based on several assumptions that include 
(Pender et al., 2002:63): 
1. Persons seek to create conditions of living through which they can express their 
unique human health potential. 
2. Persons have the capacity for reflective self-awareness, including assessment of 
their own competencies. 
3. Persons value growth in directions viewed as positive and attempt to achieve a 
personally acceptable balance between change and stability. 
4. Individuals seek to actively regulate their own behavior. 
5. Individuals in all their biopsychosocial complexity interact with the 
environment, progressively transforming the environment and being 
transformed over time. 
6. Health professionals constitute a part of the interpersonal environment, which 
exerts influence on persons throughout their lifespan. 
7. Self-initiated reconfiguration of person-environment interactive patterns is 
essential to behavior change.” (Pender et al., 2002:63) 
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 As the HPM attempts to “depict the multidimensional nature of the persons 
interacting with their interpersonal and physical environments as they pursue health” 
(Pender et al., 2002, p. 61), it integrates several constructs and propositions from the 
expectancy theory (Feather, 1982) and the social learning theory (Bandura, 1986).  The 
theoretical statements derived from the HPM provide a basis for investigative work on 
health behaviors. The Health Promotion Model is based on the following theoretical 
propositions (Pender, et al., 2002, p. 63-64): 
1. Prior behavior and inherited and acquired characteristics influence beliefs, 
affect, and enactment of health-promoting behavior. 
2. Persons commit to engaging in behaviors from which they anticipate deriving 
personally valued benefits. 
3. Perceived barriers can constrain commitment to action, a mediator of behavior 
as well as actual behavior. 
4. Perceived competence or self-efficacy to execute a given behavior increases the 
likelihood of commitment to action and actual performance of the behavior. 
5. Greater perceived self-efficacy results in fewer perceived barriers to a specific 
health behavior. 
6. Positive affect toward a behavior results in greater perceived self-efficacy, 
which can in turn, result in increased positive affect. 
7. When positive emotions or affect are associated with a behavior, the probability 
of commitment and action is increased. 
8. Persons are more likely to commit to and engage in health-promoting behaviors 
when significant others model the behavior, expect the behavior to occur, and 
provide assistance and support to enable the behavior. 
9. Families, peers, and health care providers are important sources of 
interpersonal influence that can increase or decrease commitment to and 
engagement in health-promoting behavior. 
10. Situational influences in the external environment can increase or decrease 
commitment to or participation in health-promoting behavior. 
11. The greater the commitment to a specific plan of action, the more likely 
health-promoting behaviors are to be maintained over time. 
12. Commitment to a plan of action is less likely to result in the desired behavior 
when competing demands over which persons have little control require 
immediate attention. 
13. Commitment to a plan of action is less likely to result in the desired behavior 
when other actions are more attractive and thus preferred over the target 
behavior. 
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14. Persons can modify cognitions, affect, and the interpersonal and physical 
environment to create incentives for health actions.” (Pender et al., 2002, p. 
63-64). 
 
 According to the revised HPM (Figure 1-2), there are three main constructs that 
influence human behavior toward health promotion. The first two sets of constructs are: 
individual characteristics (which include the following two constructs: prior related 
behavior and personal factors), and behavior-specific cognitions and affect (which  
includes the following six variables: perceived benefits of action, perceived barriers of 
action, perceived self-efficacy, activity-related affect, interpersonal influence, and 
situational influence). These two sets of constructs will lead to a “commitment to a plan 
of action” which will propel individuals toward embracing and practicing behaviors that 
promote their health unless if there were some “immediate competing demands and 
preference” that the individual can‟t avoid or resist intervenes. If the “commitment to a 
plan of action” was not derailed by the “competing demands and preference,” the result 
will be the third variable, the “behavioral outcome” which includes the desired health-
promoting behavior (Pender et al., 2002, p. 63-64).  
The behavior-specific cognitions and affect constructs are considered of major 
importance and constitute a significant core for intervention by health care providers 
because they can be modified by specific interventions (Pender, et al., 2002, p. 63-64). 
The HPM includes activities that are directed toward developing resources that 
enhance or maintain one‟s well-being. It can be inferred that there are two phases 
embedded in the model to promote health; the decision making phase and the action 
phase. The decision making phase includes factors that motivate individuals to maintain 
and enhance their health-promoting behaviors and indirectly influence patterns of their  
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Figure 1-2: Revised Health Promotion Model. Sources: (Pender et al., 2006, p.50).  
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health behaviors while the action phase clarifies how barriers and cues to action trigger 
activities in health-promoting behaviors (Polit & Beck, 2004). Based on the revised  
Health Promotion Model (Pender et al., 2002), there are many factors involved in the  
patient‟s decision making about treatment options for prostate cancer, including 
psychological, socio-cultural, biological, and environmental factors, other‟s experience, 
barriers to health care, as well as prior related behavior.  These and other factors will 
form how the patient thinks about and evaluates the benefits, obstacles, and 
complications of the different treatment options and in turn influence his decision about 
making the right choice of the available treatment options.  
Assessing barriers to health care and quality of life for prostate cancer survivors 
of men residing in Gaza Strip will help in the decision making process by providing more 
information to those who will be newly diagnosed with prostate cancer. Those new cases 
will be better able to assess the perceived benefits, perceived barriers, and the perceived-
self efficacy of each treatment option and how it will affect their quality of life. Assessing 
barriers to health care and evaluating the quality of life for people who had different 
methods of treatments will help to guide those newly diagnosed men to assess the 
perceived benefits, the perceived barriers, and the perceived self-efficacy of each 
treatment modality and make their decisions based upon the quality of life and the 
magnitude of barriers they are expecting from each treatment modality.  
Other factors that may intervene in decision making include interpersonal 
influences and situational influences. Interpersonal influences include the effect of 
family, peers, friends, other men who received different treatment modalities, and health 
care professionals on their decision. Situational influences include the ability to pursue 
20 
specific treatment modalities especially that most of the decisions to be made are 
suspended and depend completely on the political situation in the area. For example, if a 
patient chooses to receive radiation therapy, which is not available in Gaza Strip, and 
needs a referral to Egyptian, Israeli, or other hospitals outside Gaza Strip, he may not be 
able to have such a treatment for several months or years because of the Israeli closure of 
the borders of the Gaza Strip. Other choices for treatment will be affected by this 
blockade since the closure of borders affects the availability of hormonal and 
chemotherapy choices and affects the availability of instruments and anesthetic agents 
that are required for the surgical choice.   
Since the Health Promotion Model proposes that health promotion involves 
activities directed towards enhancing or maintaining an individual‟s well-being, assessing 
quality of life for prostate cancer survivors of men residing in Gaza Strip and identifying 
barriers to health care will be of great benefit. Such assessments will also help those who 
are receiving treatment and those who already have received treatment. Knowing the 
factors that impact quality of life and identifying barriers to health care may lead to 
changes in current policies to reshape the environment to serve to enhance quality of life 
of prostate cancer survivors by eliminating those barriers to health care and factors that 
deter quality of life and enhance factors that improve quality of life of prostate cancer 
survivors.   
Assessment of quality of life of prostates cancer survivors and identifying barriers 
to health care will also enhance the knowledge of health care professionals about the 
factors and behaviors that enhance quality of life and try to reinforce these factors and the 
barriers and factors that interfere with quality of life and try to avoid them and find 
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suitable solutions to come over them. Assessing quality of life of prostate cancer 
survivors and identifying barriers to health care will help policy makers in Palestine to 
change current policies (or adopt new ones) that relate to treatment options available to 
treat prostate cancer and to overcome barriers to health care and improve the quality of 
life of life of prostate cancer survivors.  
 After going through the process of decision making about making the decision of 
treatment option or about health promotion after receiving treatment, the patient will 
chose the option that he thinks it will give him the best quality of life and will promote 
his health in his surrounding circumstances. The patient, then, will set an action of plan 
for health promotion. This plan, of course, will depend upon the situational factors that 
may enhance or disrupt his action plan. 
 
Research Questions 
 
This study addressed the following questions: 
1. What is the level of the perceived quality of life of prostate cancer survivors who 
live in Gaza Strip? 
2. Are there any differences of the perceived quality of life issues reported by 
prostate cancer survivors who live in Gaza Strip and currently receiving treatment 
and those who had finished their treatment? 
3. What are the barriers to health care faced by prostate cancer survivors living in 
Gaza Strip during their treatment period?  
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Summary 
 
 Prostate cancer is the most common type of cancer among males in the developed 
countries and it is the second common type of cancer among males in Palestinian and in 
the world. There are several treatment modalities that are available to treat prostate 
cancer. Radiation and surgical removal of the prostate gland are the most common types 
of treatment. In Gaza Strip, surgical removal of prostate cancer is the most commonly 
used method of treatment. Hormonal and chemotherapy are used as adjunct methods for 
treatment. Radiation therapy is rarely used to treat prostate cancer patients of Gaza as up 
to the moment; there is no radiation therapy center available in Gaza. Some patients are 
referred to other countries to receive radiotherapy, which exhaust the already limited 
budget of the Palestinian ministry of health. Each of the available treatment modalities 
will have a different impact on the quality of life for prostate cancer survivors.
 Assessing barriers to health care and the quality of life of prostate cancer 
survivors of men living in Gaza strip will help health care providers to identify and 
address the barriers they face, provide them with more information about the impact of 
each treatment modality on their quality of life, and inform their decisions about the 
method of treatment. The result will help Palestinian policy makers to change the related 
current policies or adopt new polices that will help to overcome barriers to health care 
and improve the quality of life of prostate cancer who reside in Gaza Strip. 
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CHAPTER II 
LITERATURE REVIEW 
 
This chapter involves several parts of literature review that that relates to the 
contents of this dissertation study.  This involves a general background about Gaza Strip, 
the health care system and policy process in Palestine, the policy process and 
pathopysiology of prostates cancer. This is besides a review of the literature that relates 
to quality of life of cancer patients involving prostate cancer and finally literature that 
relates to barriers to health care.  
 
A Preview about Gaza Strip 
 
The territories of the Palestinian National Authority (PNA) (Figure A-1) consist 
of two geographically separated areas known as the West Bank and Gaza Strip. The Gaza 
Strip is a narrow strip of land that lies along the southeastern coast of the Mediterranean 
Sea. It is about 41 KM (about 25 miles) long and 6 to 12 KM (4-7.5 miles) in width.  The 
geographical area of the Gaza Strip is estimated at 360 square kilometers (about 139 
square miles) (Ministry of Health, 2004). In July, 2008, the population of Gaza was 
estimated to be 1,500,202 (Central Intelligence Agency, 2009).  
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In 1967 Israel occupied Gaza Strip and West Bank. After series of demonstrations 
against Israeli occupation, Israel with the Palestinian Liberation Organization (PLO) 
signed several agreements between September 1993 and September 1999 that resulted in 
interim self-government for Palestinians in Gaza and West Bank populated areas. Israel 
kept control on most of the land between the Palestinian cities. The Palestinian National 
Authority (PNA) became responsible for administering civilian issues such as education, 
health, and municipality in the Palestinian-populated areas of the West Bank and Gaza 
(Central Intelligence Agency, 2009).  
In September 2005, Israel decided to withdraw its military soldiers and settlers 
from Gaza Strip and keeping control over all borders of Gaza Strip. This allowed it to 
control the entrance of all goods to Gaza including medical supplies. The only way 
Palestinians can leave Gaza Strip is through the borders with Egypt which was 
administered by Palestinians and monitored by Europeans. After the result of the 2006 
elections which resulted in the win of the Islamic Resistant Movement (HAMAS) of the 
Palestinian Legislative Council, the international community lead by Israel and the 
United States refused to deal with a government lead by HAMAS and economic 
sanctions and blockade were imposed against Gaza Strip including the port between Gaza 
and Egypt. Sanctions and blockage were tightened after taking one Israeli soldier as a 
prisoner by some Palestinian fighters in June 2006. In June 2007, clashes between 
HAMAS and FATAH, the other major political group in Palestine, ended with HAMAS 
taking over all government and military institutions in Gaza (Central Intelligence 
Agency, 2009). 
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After that date, the Palestinians have two governments, one headed by HAMAS 
and resided in Gaza, and the other one appointed by President Abbas and resided in 
Ramallah at West Bank. As a result, sanctions and blockade against Gaza were severely 
tightened until Israel started to prevent fuel and electricity to get to Gaza. The port 
between Gaza and Egypt now is completely blocked. For further information about Gaza 
Strip, please refer to appendix A. 
 
Health Care System and Health Policy in Palestine 
 
 The health care system in Palestine is relatively a novice system. It became 
independent from the Israeli system in 1994. For any health care system, there are several 
requirements that should be available to be a successful system.  
 
Component of a Successful Health Care System 
 
According to Janecka (2009), “a system consists of a large number of variable 
components engaged in ongoing relationships” (p. 2) to achieve a certain goal. Usually, 
systems have integrated subsystems and are internally adaptive to the surrounding 
environment to be successful. Failure of a system to adapt will result in chaos and 
therefore failure (Janecka, 2009). In its report issued in 2000, the World Health 
Organization (WHO) defined a health care system as “all the activities whose primary 
purpose is to promote, restore or maintain health” (p. 5). Further, WHO (2000) identified 
three fundamental objectives for health care systems. These objectives are: “improving 
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the health of the population they serve; responding to people‟s expectations; and 
providing financial protection against the costs of ill-health” (p. 8). Since these objectives 
are not always met, the result will be public dissatisfaction of their local health care 
systems (WHO, 2000).  
For a successful health care system, it should incorporate all of its subsystems into 
the larger system (Janecka, 2009). A health care system consists of health care services, 
health care professionals, health organizations, and a government. The health care system 
has three integrated components: clients who need health services, professionals who 
provide health care services, and the public and private health care institutions that 
regulate, organize, finance, and coordinate these services (Library Index, 2009). Others 
added components to the health care system such as accessibility, affordability, 
equitability, sustainability, and good quality (Meadowcroft, 2008; WHO, 2000). For 
example, Meadowcroft (2008) mentioned that at the United Kingdom‟s health care 
system, they tried to isolate the ability to access health care from the ability to pay and 
make it available to citizens regardless of their income, wealth, occupation, or 
contribution. Furthermore, Georgetwon University, Child Development Center (2009) 
added more components that relate to children health but can be applied to general health 
care systems. Besides access to health care services and treatment, these components 
include: management of health care data and information, coordination care, 
collaboration among systems, monitoring and evaluation, education and training, and 
funding strategies.  
Given the fact that health care systems are the means to implement countries‟ 
health care policies and approaching the nations‟ health needs make them important 
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(WHO, 2006). Therefore, evaluating the performance of the health care system is a 
crucial issue. In order to evaluate any program, its goals and how they were implemented 
should be reviewed (Bamberger, Rugh, & Marby, 2006). Therefore, the performance of 
any health care system is evaluated through its achievement of its goals and how these 
goals were implemented (Roemer, 1991 as cited by WHO, 2000). Based on that, the 
WHO (2000) depicted the relationship between the function of a health system and its 
outcome in a figure that was revised in 2006. This figure (Figure 2-1) identifies that 
system functions (stewardship, resources creation, financing, and service delivery) 
determine the outcomes of the system. If these functions were implemented efficiently  
 
 
Figure 2-1: Health Systems Functions and Outcomes. Source: WHO (2006, p. 5) 
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and in good quality, the system will successfully provide the intended outcomes. The 
figure also assumes that equity is applied during the process of implantation.   
Finally, WHO recommended an operational framework that consists of "five steps 
for integrated health care system strengthening at the country level. This framework 
includes the following (WHO, 2006, p.17):  
 
“Building evidence for analysis of systems issues 
 
 
Identifying the key systems constraint on national health goal. 
 
 
Getting political support. 
 
 
Developing a strategy for overcoming systems constraints. 
 
 
Identifying a platform for advocacy and discussion”. 
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The Health Care System in Gaza 
 
Before the establishment of the Palestinian National Authority (PNA) in 1994, the 
Palestinian health care system was highly connected to the Israeli system. The 
department of health was chaired by an Israeli officer assigned by the Israeli 
administration. A report by the WHO described the Palestinian health care system in 
1989 as „disturbing‟. The report referred this disturbance to the lack of a structured health 
care system and to the lack of independency from the Israeli system (World Health 
Organization, 2001).  
The health care system in Gaza Strip consists of four main health providers: the 
Ministry of Health, the non-governmental organizations (NGOs), the United Nations 
Relief and Work Agency (UNRWA), and the private sector. The governmental health 
services are open to all Palestinians who hold health insurance. The UNRWA offers its 
services to the Palestinian refugees (people who were expelled from their cities and 
villages by Israelis in the war of 1948) who live in refugee camps (Ministry of Health, 
2005).  
The Ministry of Health is the principal health care provider in Gaza Strip and 
Palestine (MOH, 2006). Furthermore, it is responsible for ensuring a well-governed 
health system in Palestine. Besides providing health care, the MoH is responsible for 
regulation and legislation, public health activities, surveillance, human resources 
development, and financing (World Health Organization, 2005). It runs 12 out of the 24 
hospitals available in the Gaza Strip and 1,548 beds out of a total of 2,053 beds. The rest 
of the available beds are operated by 10 non-governmental organizations (NGOs) and 
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two private hospitals (Ministry of Health, 2006). The ratio of beds to population is 14.2 
beds per 10,000 people. Of the 2,053 beds available in Gaza, only 50 beds are designated 
for oncology patients (Ministry of Health, 2006). These beds are distributed between the 
two major hospitals: Dar-Al-Shifa Hospital and the Gaza European Hospital.  
The most common type of health insurance available in Gaza Strip is the 
governmental health insurance as there were 178,076 families (about 1.17 million of the 
population) covered in 2006 by the governmental health insurance (Ministry of Health, 
2006). Governmental health insurance covers the total expenses of treatment for 
hospitalized patients. There is a little copayment for outpatients (i.e. about 75 American 
cents per each prescribed drug and about 25 cents for each laboratory test).  Children 
under the age of three are treated freely if their parents don‟t have a health insurance and 
patients with chronic diseases, including cancer, do not pay the co-payment for the 
prescribed drug. Any patient presented to the emergency room is not denied treatment 
even if he/she doesn‟t have a health insurance.  
The budget of the Palestinian Ministry of Health is very limited. It was only 
134,222,222 US dollars in 2004 excluding the expenditures for treatment abroad 
(Ministry of Health, 2005). Because some care, especially tertiary care, is limited or not 
available in Palestine, patients who need such care are referred by the MoH to receive 
such care at one of the neighboring countries such as Egypt, Jordan, or Israel and in some 
other cases to some European countries (The RAND Palestinian State Study Team, 
2007). The cost of referring patients to receive treatment abroad is expensive and 
consumes a huge portion of the already limited budget for the MoH. For example, the 
cost of treating 31,744 patients abroad was more than 58 million US dollars which 
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constituted about 45.9% of the actual health expenditures for 2004 (Ministry of Health, 
2005). The majority of patients referred to treatment abroad are patients who needs eye 
surgery, who have heart disease, and patients with cancer. In most cases, the health 
insurance covers the total cost of treatment abroad or at least it covers a big portion of the 
cost depending on the financial capacity of the patient. Given the limited budget, the 
MoH worked on reducing the number of referrals by expanding the Palestinian health 
care capacity and by inducing more restrictive criteria for referrals abroad (The RAND 
Palestinian State Study Team, 2007).  
 
Criticism for the Palestinian Health Care System 
 
To evaluate the performance of the Palestinian health care system, it was 
reviewed by several organizations in response to the donor countries requests who 
wanted to ensure that the money they donate produces some enhancement of the system. 
Examples of these reviews are the study conducted by the RAND Palestinian State Study 
Team between September 2002 and May 2004 (The RAND Palestinian State Study 
Team, 2007) and the Health Sector Review (HSR) which was conducted in 2003-2005 
and was reported on by Dr. Yehia Abed (Abed, 2007). 
The RAND Palestinian State Study Team (2007, p. 227) identified several 
minimal components for a successful health care system that they used as the base to 
review the health care system in Palestine. Besides effective governance and sufficient 
financial resources, these criteria included (The RAND Palestinian State Study Team, 
2007, p. 227):  
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• maintain an effective and well-regulated public health system 
• provide reasonable access to high-quality preventive and curative services for all 
Palestinians 
• maintain high-quality programs for training health professionals 
• achieve health outcomes at the population level that meet or exceed international 
guidelines, such as those recommended by the World Health Organization 
(WHO) 
• be effective, efficient, and financially viable 
• contribute to peace and encompass the possibility of cooperation with 
neighboring countries on issues of common interest.  
 
The RAND review concluded that the Palestinian health system starts with many 
strengths, such as a health care system that included the high value placed by the society 
on health; the availability of highly qualified, motivated, and experienced health care 
professional in many areas including administration, management, research, clinicians 
and public health workers; plans for national health system developments; a strong base 
for nongovernmental and governmental institutions; and a relatively healthy population. 
In spite of those strengths, the same report included several issues of concern. These 
concerns included the poor coordination and implementation of health policies and 
programs between Gaza Strip and West Bank and between the nongovernmental and the 
governmental sectors of the health care system, the under-qualification of many health 
care providers, the weakness of the licensing and continuing education system, and 
deficits in operating the budget of MoH and the governmental health insurance system 
(The RAND Palestinian State Study Team, 2007).   
Furthermore, both the RAND and HSR review reported several issues and pitfalls 
of the health care system in Palestine that are of great concern. Some of these pitfalls 
were included in both reports and some were only reported in one of the two reports. For 
example, the HSR (Abed, 2007) mentioned that the donors and other local stakeholders 
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were dissatisfied with the performance of the MoH especially in issues related to 
efficiency, effectiveness, and sustainability of the health care sector and the inability of 
the PNA to prioritize health services and interventions. Further, the report included that 
“budget allocations were made with little reference to the size and type of priorities, 
inputs-outputs matching or inefficiency concerns” (p. 9) and that planned activities were 
unrelated to the available budget. In fact, the report added that there was often  little 
relation between actual expenditures of the MoH and the allocated budget. The HSR 
attributed such inadequacy of budgeting to the lack of necessary tools for economic and 
financial analysis that would help in improving the utilization of the available scarce 
resources. The HSR also reported about other inefficiencies within the Palestinian health 
care system. For example, the report stated that the employment process has a number of 
inefficiencies. A lack of qualified staff and clinical and non-clinical qualifications were 
also reported. Additionally, some activities of health care schools (medical, dental, and 
nursing) did not meet the international standard for that field. 
The RAND report described the Palestinian health care system as lacking a 
systematic process at the national level to ensure that development of health care system 
is matching the goals of the national health plan. The report gave the example that the 
only two plans developed in 1994 and 1999 are similar in structure, approaches, and aims 
to illustrate the inadequacy of the health care system to meet its objectives. To illustrate 
the inefficiency of the health care system, the report added that most of the goals of the 
first plan were not met and were repeated in the second plan (The RAND Palestinian 
State Study Team, 2007). The second plan was supposed to cover the period between 
1999 and 2003 and up to this moment, a new national health plan is not issued.   
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Both reports concluded that there was a great shortage in many areas especially 
those related to management, planning, budgeting, procurement, accounting, and data 
analysis. For example, the RAND report mentioned that the MoH had deficits in 
“exercising its managerial authority over the health system” and that there was a lack of 
coordination between the four main health care providers in Palestine and within the 
MoH offices in Gaza and West bank especially in areas related to health policy 
development and implementation (The RAND Palestinian State Study Team, 2007, p. 
245). The report also mentioned that the health care system lacks a consistent national 
process that reviews the new projects to insure the adequacy of developing a new, 
efficient infrastructure for the health care system. Additionally, both reports added that 
the system lacked modern standards for minimal enforcement for accreditation of health 
care facilities and health care professionals including physicians, nurses, and pharmacists. 
And in fact, when these standards were available, they were not enforced adequately.  
Another issue that both reports included was the quality of health services. 
Dissatisfaction was mentioned by both reports about the provided health services by both 
clients and providers. In fact, the RAND report included that the clients input was limited 
in the planning process and that clients described the health services provided by the 
MoH as inferior compared to services offered by neighbor countries and the private 
sectors. Therefore, people who can afford treatment in a neighbor country or within a 
private facility will mostly do so. Such perceived inferiority of the provided services 
contributed to the increase in requests for referrals for treatment abroad. The HSR 
reported that there was a weak enforcement of the referral system for treatment abroad. 
The report further added that some cases that could be treated locally or at a lower tier are 
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sometimes treated at a higher tier which would leave negative impact on the quality and 
efficiency of the entire health care system. Finally, a report by the World Health 
Organization (2005) indicated that there is an inadequate, incomprehensive reporting 
system for health information with insufficient data analysis capacity at the central level. 
Such inadequate availability of data will deter the health planning and policy 
development activities along with research and evaluation.  
The RAND report mentioned that the Palestinian health care system, as many 
other health care systems, function much better at the planning and policy making level 
than at the implementation level that contributed to the lack of achievement of the many 
health care plans and objectives. The gap between policy development and policy 
implementation was reported heavily in the literature. In fact, Shafritz and Russell (1997) 
mentioned that the bureaucracy of implementation may distort the goals of the program 
or the policy. The report further added that the MoH had limited success to develop, 
implement, and enforce policy for the entire Palestinian health care system because of the 
fragmentation of decision making between Gaza Strip and West Bank (The RAND 
Palestinian State Study Team, 2007).  
Both, the RAND report (The RAND Palestinian State Study Team, 2007) and the 
HSR report (Abed, 2007) had attributed these inefficiencies to several reasons. For 
example, the HSR report attributed such inefficiencies to the poor coordination between 
the PNA, the MoH, the Palestinian health organizations and the international community 
and to the lack of resources. The RAND report added that the deficits could be attributed 
to lacking of the necessary statuary authority or lacking the political ability or will to 
exercise this authority, especially that most of the ministries at the NPA were suffering 
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from a weak level of authority over their sectors, inefficient management practices such 
as being autocratic and adopting non-participatory process in policy and decision making. 
Further, the World Health Organization (2005) added more reasons for the inefficiency of 
the Palestinian health care system. One reason could be the high dependence of the 
Palestinian health care system on external donations which made up to 48% of the total 
health expenditures which might also be a cause for lack of long-term sustainability. 
Another reason could be the fragmentation of responsibilities. An example was provided 
by the WHO report included the method used for collecting health-related information as 
data were collected by both the MoH and the Palestinian Central Bureau of Statistics 
(PCBS).  
Finally, both the RAND and HSR reports, in addition to other literature, made 
recommendations that may contribute to reform of the Palestinian health care system. 
Some of these recommendations included: strengthening coordination between different 
health care providers and stakeholders, between Gaza Strip and West Bank, and between 
primary, secondary, and tertiary levels in regard of integrating health planning and health 
policy development, reviewing and upgrading standards for accreditation of health care 
facilities and health educational programs, and licensing of health care professionals; 
adopting a gate keeping process for referrals for treatment abroad and enforcing more 
rigorous, restrictive referral system and developing the local capacity to limit the number 
of referrals; developing policies that contribute to the development of human resources, 
financing of health care programs, development of research and evaluation programs, 
development of a health information system, and improving health promotion and disease 
prevention activities; explicitly assigning the responsibility for implementation of policy 
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decisions to the appropriate stakeholders along with continuous monitoring and providing 
incentives for successful performance. Furthermore, a report by the World Health 
Organization (2005) recommended the improvement of a fully comprehensive and 
integrated health information reporting system that could contribute to the improvement 
of health policy, planning, research and evaluation of the Palestinian health care system. 
The World Health Organization (2000a) further recommended the improvement of 
human resources as a fundamental issue for reforming, developing, and improving any 
health care system. Besides planning and training, human resources development may 
include developing effective continuing education programs including designing special 
postgraduate programs that meet the health care needs of the country, and introducing 
new trends of health management. 
 
Health Policy and Health Reform in Palestine 
 
Public policy is defined as “a set of actions taken by a government to control the 
system, to help solve problems within it or caused by it, or to help obtain benefits from 
it” (Walker 2000, p. 13). A policy is a statement enabling or constraining execution of 
some type of action by one or more actors in relation to various aspects of some situation. 
(Uszok, et al., 2003, p. 2).  Shafritz & Russell (1999) added that any policy is a decision 
and that the policy may include taking no actions toward a certain issue. Furthermore, 
Guy Peters (2004) concluded that anything done by the government is labeled as „Policy.‟ 
According to Peters (2004), a policy then has three levels. The first level is policy choice, 
which is the decision made by decision makers. The second level is the policy output 
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which represents the programs designed to achieve the goal of the policy choice. The 
third level is policy impact which is the effect of the policy and the programs on the 
citizen.  
Based on the above definitions, health policy is defined as “the way nations, 
states, cities, and communities distribute resources to competing interventions and 
competing populations based primarily on anticipated benefits. Health policy reflects the 
values of the society or community in terms of how and to whom health resources are 
distributed” (Patrick & Erickson, 1993, p. 419). A health policy could also be defined as 
“a program of action whose aim is to improve health conditions of the people” (Neema, 
2005, p. 2). Adding to those definitions, Garvin and Eyles (2001) included that health 
policy should be adaptive to the situations and circumstances to the local health needs 
and objectives. The objective of public health policy is usually set to meet the community 
needs of maintaining, promoting or restoring of the community‟s health (Gunning-
Schepers & Stronks, 1999).  
Following the Oslo Peace Accord in 1993, the Palestinian Ministry of Health 
(MoH) was established and started to operate from Gaza Strip. The MoH inherited a 
devastated and fragmented health care system to start with. The Palestinian health care 
system was heterogeneous with respect to its organizations and its actors as there were 
four health care providers working independently of each other (Barghoutis and Lennock, 
1997 {as cited by Mataria, et al., 2004} and Barghouti and Diabes, 1996 {as cited by 
Mataria, et al., 2004}).  Prior to the establishment of the MoH, the Palestinian Health 
Council was established and one of its goals was to produce a strategic national health 
plan. The first strategic national health plan was produced in 1994 while the second plan 
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was produced in 1999 by the MoH. One of the major objectives of the MoH was to 
provide comprehensive health care services and to promote an equitable and efficient 
utilization of health care services to the Palestinian population (Ministry of Health, 1999). 
Most of the objectives produced in the first national plan were not met and therefore were 
repeated in the 1999 national strategic plan (The RAND Palestinian State Study Team, 
2007). In fact, most of the objectives of the second national plan which were supposed to 
cover the period between 1999 and 2003 were partially implemented. This could be 
related to the deteriorating situation after the start of the second uprising in 2000 (World 
Health Organization, 2005). The WHO (2005) further added that the delay for developing 
a new strategic health plan is a good indication for the limited capacity of the MoH for 
policy development.  
The donor countries provided a substantial assistance to help in rebuilding the 
ailing health care system. Activities to reform the ailing health care system were directed 
at setting up ministerial structure, developing a national health care information system, 
reviewing and promoting the governmental health insurance system, providing training in 
certain health areas such as women‟s health, and helping the four sectors that provide 
health care to act in participatory planning and collective policy development for the 
Palestinian health care system (Giacaman, Abdul-Rahim, & Wick, 2003). In spite of 
these achievements made by the MoH, Giacaman, et al. (2003) mentioned that it was 
evident that quality of care was not improved nor were the most important health needs 
addressed. 
The attempts of the MoH to reform the existing health care system were met with 
many obstacles. Some of the obstacles to health sector reform included the ongoing 
40 
conflict in the area, the weakened Palestinian institutions and state structures, the limited 
capacity of the MoH to implement reforms, the functioning nature of the NPA which is 
characterized by authoritarianism and dependence, and the policy vacuum, as there is a 
lack of general development policy (Giacaman et al., 2003). The WHO further added that 
the geographical separation and the dispersal of the Palestinian population between West 
Bank and Gaza Strip contributed to the lack of a unified health policy authority (World 
Health Organization, 2001). Such separation also contributed to lack of communication 
and coordination within the two entities of the MoH (World Health Organization, 2005). 
Another reason that was added by Abed (2007) is the lack of the necessary tools for 
financial and economic analysis that could be used to improve the use and allocation of 
the scarce resources within the public sector.  
Another issue that Giacaman et al. (2003) considered as an important impediment 
to the health reform was the donors‟ policies and practices. Giacaman et al. included that 
donor countries have their own preferences that may not match the actual needs of the 
Palestinians and that their approaches and mechanisms are neither flexible nor adaptive to 
the reality on the ground. Because of donors‟ inflexibility; requirements for rapidly 
measurable outcomes; and time limits, quick fixes solutions were adopted. Such quick 
fixes and swiftness of developing plans to meet the requirement of the donor countries 
contributed to the lack of sustainability of the Palestinian health care system, constituted 
a major threat for proper and adequate health policy development, and created more 
fragmentation than cooperation (Giacaman et al., 2003). The consequences of such lack 
of coordination in policy development and implementation slowed progress in achieving 
the goals of the strategic national health plans, decreased the viability of the health care 
41 
system, and undermined the public confidence in the health care system and 
organizations especially those operated by the MoH (The RAND Palestinian State Study 
Team, 2007).  
Because of the several obstacles that face the Palestinian health care system along 
with the instability of the political and economic situations within the area, the health 
policy and planning capacity in Palestine were described as weak and limited (World 
Health Organization, 2005). In fact, WHO (2005) further described the MoH‟s attitude 
toward recognizing the needs for change as lukewarm. On the other hand, The RAND 
Palestinian State Study Team (2007) report mentioned that the success of the MoH to 
develop, implement, and enforce policy for the health system as a whole is limited and 
that the MoH had limited success in taking control of its managerial authority over the 
health system. The RAND report related such limited success to several presumed 
reasons; MoH lacking resources or expertise for implementation of effective planning 
and coordination at the national level, lacking the necessary statutory authority, lacking 
the political will or ability to exercise such authority, and the concentration and 
domination of the planning process and/or policy development within the hands of a 
small number of stakeholders or specific personalities.  
Several examples were reported in the literature to illustrate the weakness of the 
planning and policy making process within the Palestinian health sector. For example, 
Abed (2007) mentioned that the referral system for treatment abroad is weakly enforced 
as there were some cases that received treatment at a higher level (was treated abroad) 
that could have received treatment at a lower level (within the MoH‟s facilities) of care. 
Such lack of policy enforcement had a negative impact on the efficiency and quality of 
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the care provided. WHO (2005) gave the example of the limited regulatory system within 
the health sector as there is virtually no regulation, accreditation, or licensing for the 
private health sector operating within the Palestinian territories. In fact, the lack of 
effective licensing policies extends to the licensing of the health care providers including 
physicians, nurses, pharmacists, and health education facilities (Abe, 2007 & The RAND 
Palestinian State Study Team, 2007A draft of Patients‟ Bill of rights was produced more 
than15 years ago by the Palestinian Council of Health which has not been adopted by the 
policy making authorities (The RAND Palestinian State Study Team, 2007).   
The RAND report (The RAND Palestinian State Study Team, 2007), the HSR 
(Abed, 2007), and the WHO report (World Health Organization, 2005) made some 
recommendations to improve the areas of policy development and policy implementation. 
The major recommendation in the three reports was to enhance the coordination between 
the different governmental and nongovernmental stakeholders of health and between the 
West bank and Gaza Strip regarding strengthening the integration of planning, policy 
development, and policy implementation. Other recommendations evolved about 
adopting specific policies such as those relating to accreditation and regulation of 
facilities offering health care and health education institutions, licensing and certification 
of health care professionals, and referral policy for treatment abroad.  
 
Prostate Cancer Screening Policy in Gaza Strip 
 
One of the primary prevention tools for prostate cancer is screening (Harris & 
Lohr, 2002). In fact, early detection through screening was described by Brawer (1995) 
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as the only feasible possibility to reduce cancer-related mortality. The other two 
possibilities for reducing cancer-related mortality are improving therapy and reducing 
incidence. Prostate cancer population screening or mass screening was defined by Aus, et 
al., (2005) “as the examination of asymptomatic men” who are at risk (p. 548). The goal 
of early detection of prostate cancer is to identify men who are asymptomatic and to 
detect the disease in the early stages since treatment will be most likely to be effective 
(Harris & Lohr, 2002; Frankel, Smith, Donovan, & Neal, 2003; American Urological 
Association (AUA), 2009).  The AUA added that there are two widely used tests in 
prostate cancer screening; Prostate-Specific Antigen (PSA) and Digital Rectal 
Examination (DRG). DRE is done by inserting a lubricated finger in the rectum to feel 
the size prostate gland. Enlarged prostate could be a sign for prostate cancer. PSA is a 
blood test that measures the level of Prostate-Specific Antigen which is normally 
produced in small amounts by the prostate gland. The level of PSA increases in the case 
of prostate cancer. Since the PSA test was approved by U.S. Food and Drug 
Administration in 1986, it was used widely to screen for prostate cancer (Lin, Lipsitz, 
Miller, & Janakiraman, 2008).  
Although screening using PSA test may help in detecting prostate cancer in the 
early stages, an issue of concern is that PSA level is increased not only in the case of 
prostate cancer, but its concentration may be affected by other conditions such as age, 
prostate size, prostatitis, benign prostatic hyperplasia, ejaculation, prostate biopsy, or 
surgery (Frankel, et al, 2003; Lin, et al., 2008). In spite of the fact that PSA detects most 
prostate cancers, in some cases, it may give false negative results (American Urological 
Association, 2009). Furthermore, PSA is not diagnostic for prostate cancer. The only way 
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to confirm prostate cancer is through biopsy which in turn when it is done can cause 
some complications such as discomfort, bleeding and rarely sepsis. Because of that, there 
is a debate about the use of PSA in prostate cancer screening, since if the result was 
positive, it will be accompanied by anxiety and some patients will go for unnecessary 
biopsy, which has several complications (Frankel, et al., 2003). In fact, in an extensive 
review of the literature, Harris & Lohr (2002) and Ilic, O‟Connor, Green and Wilt, (2007) 
did not find direct evidence that connect screening to reduced mortality; nor did they find 
sufficient evidence to either confirm or refute the use of routine use of mass screening for 
prostate cancer. The fact that some prostate cancers detected by screening are clinically 
unimportant and that the survival rate for patients with prostate cancer could reach to 10 
years if it was not detected adds to the debate (Frankel, et al., 2003; Ilic, et al., 2007).  
On the other hand, Brawer (1995) argues that since the level of PSA is elevated in 
most of cases of clinically diagnosed prostate cancers, it will serve as an incentive for the 
role of screening for early detection of prostate cancer. Furthermore, several studies 
reported that screening for prostate cancer contributed to decreasing the number of deaths 
due to prostate cancer. For example, Bartsch et al. (2001) reported on a study performed 
in Austria where free PSA offered freely for men aged 45 to 75 years in the state of 
Tyrol. The study reported that there were 22 fewer deaths in 1998 and 18 fewer deaths in 
1999 than expected related to prostate cancer among men aged 40 to 79 years. Further, 
the study reported that there was a significant drop of mortality rate due to prostate 
cancer compared to the rest of Austria.  
In another study performed in Quebec to assess the impact of prostate cancer 
screening on mortality related to prostate cancer, more than 46,000 men aged 45 to 80 
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years were randomized between screening and no screening groups; Labrie et al. (1999) 
found that there were 137 death reported due to prostate cancer between 1989 and 1996 
among the 38.005 unscreened men. On the other hand, there were only 5 deaths reported 
among the 8,137 screened men. The death rate was calculated to be 48.7 per 100,000 in 
the unscreened group and 15 per 100,000 among the screened group with a 3.25 odds 
ratio in favor of participants in the screening group.  
After eleven years of initiating the Quebec study, Labrie et al. (2004) reported 
that there was a 62% reduction of a cause-specific mortality rate among the group of men 
who participated in the screening group. In their conclusion, Labrie et al. (1999) 
concluded that if PSA screening was started for men at the age of 50, results would 
identify those who are at higher risk for prostate cancer. Coupled with the treatment for 
localized prostate, the approach of early diagnosis and treatment will contribute to 
decreasing mortality rate due to prostate cancer, which therefore will improve quality of 
life for men who are diagnosed early with the disease.   
In spite of the ongoing debate about the efficiency of screening for prostate 
cancer, the American Cancer Association (ACA), (2007) and the American Urological 
Association (AUA), (2009) recommend that prostate cancer screening be done for men 
starting at the age of 50 years. And for those who are at higher risk such as those who 
have a family history and African Americans, the ACA recommends to start testing at the 
age of 45 years while the AUA recommends starting screening at the age of 40.  
In Palestine, there is no policy regarding screening for prostate cancer and 
therefore, PSA and DRE are not routinely done for men who are 50 years or older. DRG 
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and PSA test are done when a patient complains of urinary problems in an attempt for a 
primary diagnosis of prostate cancer.  
 
A Brief Overview of the Policy Process 
 
Policy making in general and health policy in particular is a very important issue 
for any society. Walker (2000, p. 13) defined public policy as “a set of actions taken by a 
government to control the system, to help solve problems within it or caused by it, or to 
help obtain benefits from it.” Weimer and Vining (1999) think that policy is a client-
related advice relevant to decision making and informed by social values. Further, Gupta 
(2001) added that policy involves advising those who govern. Scott (2005) thinks that 
policy is a value-based and needs a value-creating advice and that a value-adding policy 
requires a good policy framework and research-based evidence. The starting point of any 
policy process is agenda setting. Gupta (2001) and Shafrtiz and Russell (1999) started 
their policy process or policy cycle with agenda setting. According to Gupta (2001), the 
policy process has six components: agenda setting, policy formulation, policy adoption, 
policy implementation, policy evaluation, and policy change or policy termination 
(Figure 2-2). In a similar way, Shafritz and Russell (1999) included five steps of the 
policy process which are agenda settings, policy decision or non-decision, policy 
implementation, policy regulation and feedback.  
Gupta (2001) mentioned that the policy cycle will not start if the agenda was not 
clear and unless an issue captures the government‟s attention. He mentioned that there are  
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so many problems or issues that loom and move around in the society that do not capture 
the attention of policy makers and therefore will not be included in the agenda setting and 
therefore, will not be resolved. He also added that not everything needs the government's 
attention.  
Therefore, it is hoped that introducing the results of this study to the health policy 
makers in Gaza Strip will work as a motivator for them to improve QOL of prostate 
cancer survivors and to eliminate the barriers they face in utilizing health care services. 
Also it is hoped that the health decision makers to be politically astute and use the 
chances when policy windows open (Kingdon, 1995). Policy windows may open for 
short times, such as when there is a chance that the Israelis decide to let medical supplies 
to enter Gaza or some humanitarian organizations will succeed to bring some drugs and  
 
Figure 2-2: Gupta Policy Process. Source: Gupta (2001) 
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medical supplies through the sea or the Egyptian borders. In such occasions, MoH staff 
need to request exactly what is missing in their drug and medical supply stores so that 
some supplies will not duplicate and expire while setting on the shelves and other drugs 
and supplies will be missing.  
 
Anatomy of Prostate Gland and Pathophysiology of Prostate Cancer 
 
The prostate gland (Figure 2-3) is a single chestnut-shaped gland about the size of 
the peach pit (about 4 centimeters across and 3 centimeters thick) and encircles the 
proximal part of the urethra, just inferior to urinary bladder (Marieb & Hoehn, 2007;  
Shier et al., 2007). The prostate gland secretes alkaline thin, milky secretions that work to 
neutralize the acidic fluids containing the sperm cells which remain relatively immobile 
in the acidic secretions of the epididymis. Prostatic secretions also enhance the motility of 
sperm and work to neutralize the vaginal acidic secretions (Shier et al., 2007).        
Prostate cancer is one of the most common cancers in males. It is the second most 
common cancer worldwide and the most common cancer among American males 
(American Cancer Society, 2007a). The incidence age-standardized rate (ASR) is higher 
in the westernized countries (the highest ASR is in the United States followed by 
Sweden) and lowest in Asian countries (McCance & Huether, 2006). This could be 
related to the fact that adults in United States and western countries consume more red 
meat and fats and fewer amount of fruits and vegetables (Nelson, De Marzo, & Isaacs,  
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2003) and to the fact that there is more screening for Prostate-Specific Antigen (PSA) 
which helps in early diagnosis of prostate cancer (Bartsch et al. 2001). 
According to the National Cancer Institute‟s (NCI) Surveillance Epidemiology 
End Results (SEER) report, it is estimated that about 186,320 American men will be 
diagnosed with prostate cancer and about 28,660 men will die of cancer of the prostate in 
2008. According to the same report, the incidence and death rates (Table 2-1) are much  
                                                                                                              
 
Figure 2-3: Anatomy of Prostate Gland. Source: Wikipedia, 2009.  
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higher among black Americans (Ries, Melbert, & Krapcho, 2008). While the majority of 
prostate cancer among American men occurs after the age of 55 years (Table 2-2), the 
median age for the occurrence of prostate cancer between the years 2001 and 2005 was 
estimated to be 68 years (Ries et al., 2008). By the age of 85, about one in six American 
men will have prostate cancer during their lifetime and 3% will die from it (McCance & 
Huether, 2006). While the incidence of prostate cancer is relatively high, the good news 
is that the widespread use of preventive measures such as screening for Prostate-Specific 
Antigen, a protein that increases in the presence of prostate cancer, and digital rectal 
examination along with the availability of different treatment modalities that are used 
early to treat prostate cancer helped to decrease the age-adjusted death rate (Bartsch et al., 
2001). 
 
 
Table 2-1: Incidence and Death Rates of Prostate Cancer in The USA According to 
Race/Ethnicity. Source: NCI‟s SEER report ((Ries et al., 2008). 
 
Race/Ethnicity Incidence Rate Death Rate  
All Races  163.0 per 100,000 men 26.7 per 100,000 men 
White 156.7 per 100,000 men 24.6 per 100,000 men 
Black 248.5 per 100,000 men 59.4 per 100,000 men 
Asian/Pacific Islander  93.8 per 100,000 men 11.0 per 100,000 men 
American Indian/Alaska Native 73.3 per 100,000 men 21.1 per 100,000 men 
Hispanic 138.0 per 100,000 men 20.6 per 100,000 men 
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Table 2-2: Incidence of Prostate Cancer in the USA According to Age. Source: NCI‟s 
SEER report ((Ries et al., 2008). 
 
Age group Percentage Median Age 
Under age of 20 Approximately 0.0%  
 
 
 
68 years 
20 - 34 Approximately 0.0% 
35 -  44 0.6% 
45 -  54 8.6% 
55 -  64 28.0% 
65 -  74 36.1% 
75 -  84 22.0% 
85 + years 4.7% 
 
 
Risk Factors for Prostate Cancer 
 
There are several risk factors that may contribute to the development of prostate 
cancer. These factors include the following: 
1. Age: the chance for prostate cancer increases with age as it is considered the 
disease of the elderly. More than 70% of prostate cancers are diagnosed after the 
age of 65 (Held-Warmkessel, 2007 and Munden, 2007). 
2. Racial and ethnic factors: incidence rate and death rate are much higher among 
African Americans than among Whites. Native Americans and Asians have the 
least incidence for prostate cancer (Held-Warmkessel, 2007 and Munden, 2007).  
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3. Family history and genetics: the chance to develop prostate cancer increases if 
there is a family member having the disease. Chances will be much higher if that 
family member was a first-degree (brother or father) family member (Held-
Warmkessel, 2007). Besides that, some investigations in the last few decades 
identified some genes that are associated with prostate cancer (Nelson, et al., 
2003).  
4. Diet: incidence of prostate cancer increases with diet high in saturated fats 
(Munden, 2007), high fat-diet, high-calorie diet, and high consumption of red 
meat (Held-Warmkessel, 2007).  
5. Hormones: androgens are needed to promote prostate growth; therefore, incidence 
is higher among men who receive androgen steroids as anabolic agents or for 
medical purposes (McCance & Huether, 2006). 
6. Smoking: long history of tobacco smoking may increase the risk for prostate 
cancer (Held-Warmkessel, 2007). 
7. Occupational and exposure history: men who work as farmers and those who are 
exposed to pesticides are at higher risk to develop prostate cancer (Held-
Warmkessel, 2007). 
8. Sexuality: incidence of prostate cancer may increase with sexually transmitted 
diseases such as syphilis, gonorrhea, and human papillomavirus types 16 or 18 
(Held-Warmkessel, 2007). 
9. Vasectomy: it was identified as a possible risk factor (McCance & Huether, 
2006). 
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Clinical Manifestations of Prostate Cancer 
 
Usually, prostate cancer goes asymptomatic and symptoms appear with advanced 
cases (McCance & Huether, 2006). Usually, symptoms are due to obstruction of urinary 
flow (Figure 2-4). The symptoms usually develop progressively and include: slow urine 
stream, hesitancy, incomplete bladder emptying, dysuria (difficulty in urination), 
frequency and nocturia (frequency of urination during night time) (McCance & Huether; 
2006 and Munden, 2007). Prostate cancer may also cause rectal obstruction and difficulty 
in deification. In later stages, when cancer is metastasized to other organs, patients may 
have severe symptoms depending on the site of metastasis such as bone pain, pathologic 
fractures, enlarged lymph nodes, liver enlargement, edema of lower extremities, and 
mental confusion (McCance & Huether, 2006).  
 
 
Figure 2-4:  Comparison of Normal Prostate and Prostate Cancer. Source: UCLA Health 
System, 2009. 
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Usually, the diagnosis of prostate cancer is suspected after patients complain of 
urinary symptoms. Confirmation of the diagnosis is based upon rectal digital examination 
followed by elevated blood level of PSA which therefore prompt immediate medical 
attention to initiate proper treatment (Visser, et al., 2003). To confirm diagnosis, a tissue 
biopsy and microscopic tissue examination of the prostate will help to distinguish 
between benign and malignant masses of the prostate (Munden, 2007).   
 
Treatment Options and their Complications 
 
There are different treatment options to treat prostate cancer. The choice of the 
treatment option depends on several factors that include: the anticipated effect of 
treatment for a given patient, risk factors, patient‟s preference, patient‟s concerns about 
complications, risk for complications of surgical procedure and anesthesia, patient‟s age, 
life expectancy, other health problems, stage of tumor, and expected side effects and 
complications (Held-Warmkessel, 2007; McCance & Huether, 2006). 
Treatment options include: 
 no treatment (watchful waiting);  
 surgical treatment (includes total prostatectomy, transurethral resection of the 
prostate, or cryotherapy);  
 nonsurgical treatments such as radiation therapy, (Munden, 2007);  
 hormone therapy, or chemotherapy; 
 and any combination of these (Held-Warmkessel, 2007; McCance & Huether, 
2006).  
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Treatment options are not free from complications as each treatment modality has 
it own complications. Complications of surgical interventions include urinary 
incontinent, urethral stricture, and impotence. These are in addition to the ordinary 
complications for anesthesia and surgery (Lu-Yao, McLerran, Wasson, &  Wennberg, 
1993).  
Complications of radiation therapy include impotence; incontinence; frequent 
bowel movement; painful hemorrhoids; strictures; and acute cystitis, proctitis, and 
enteritis (Held-Warmkessel, 2007). Complications of hormonal therapy may include 
psychological effects, loss of libido, hot flashes, impotence, osteoporosis, gynecomastia 
(enlargement of breasts), and breast tenderness (Held-Warmkessel, 2007). Finally, the 
complications of chemotherapy may include fatigue; anemia; leukopenia (decreased 
count of white blood cells); thrombocytopenia (decreased count of platelets); nausea and 
vomiting; alopecia (hair loss); phlebitis (inflammation of veins), thrombosis (formation 
of blood clots inside blood vessels); and drug and dose dependence (Held-Warmkessel, 
2007). 
The prognosis and survival rates for prostate cancer have improved greatly in the 
past five decades. Nowadays, about 85% of prostate cancer cases are discovered in the 
early stages while the malignancy is still localized in the region. In these stages, the 5-
years survival rate is 100% and it declines at 10 years to 84% and to 56% at 15 years 
(American Cancer Society, 2007a).  
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Quality of Life and Cancer 
 
In the past few decades, advances in medicine and medical technology have 
enabled many patients to survive once considered fatal conditions such as cancer. As 
these people now live longer, a desire to understand their experiences, how the disease, 
its complications, and related treatments impact their lives has evolved. Such a desire has 
led researchers to examine and evaluate patients‟ experiences and their responses toward 
their diagnoses and the related treatment; QOL specifically, has become an important 
determinant of healthcare outcomes (Ferrans, 2005). These efforts have resulted in the 
development of quality of life (QOL) and health related quality of life (HRQOL) 
concepts and the development of several scales that measure them (Head, 2007). In fact, 
providers of cancer care have been front-runners in the evaluation of QOL as they 
recognized the need to assess outcomes more broadly than response to the tumor and 
length of survival (Ferrans, 2005).  
 
Definitions of Quality of Life 
 
The concept of QOL has proven to be difficult to define in the last few decades. In 
mid 70s, Campbell (1976) defined QOL as "a person's own sense of well-being, as 
derived from his or her current experience of life as a whole" and he perceived that “the 
quality of life lies in the experience of life” (Campbell, 1976, p. 118). Further, he added 
that when a person conceptualizes his/her well-being, that individual will compare his/her 
perception at the present situation with a situation that he/she aspires to, expect, or feels 
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that he/she deserves. If the perceived life matches with the aspired-to life, the result will 
be satisfaction, otherwise dissatisfaction will be the result. Further, he added that the 
major determents of well-being are psychological factors which are subjective to that 
individual‟s judgment (Campbell, 1976).  
In med 80s, Caiman (1984) tried to offer a definition of the concept of QOL and 
referred it as the “gap” between the individual's expectations and experience (Calman, 
1984). He called for QOL assessment based upon the patient's own list of problems and 
priorities and the estimation of the "gap" followed by the development of a plan for 
modifying QOL in which the patient is fully involved (Caiman, 1984). Ferrans (l996) 
offered a definition of QOL, reflective of characteristics of multidimensionality and 
subjectivity of QOL.  In her attempt to define QOL, Ferrans (1996) stated that, "the 
essence of quality of life lies in the experience of life" (p. 295) and that the person is the 
only proper judge of his/her own quality of life since people differ in what they value. 
Further she added that each person will value his/her QOL based upon his/her own 
experience (Ferrans, 1996). Based upon that, Ferrans (1990, 1996) defined quality of life 
as “a person‟s sense of well-being that stems from satisfaction or dissatisfaction with the 
areas of life that are important to him/her” (Ferrans, 1990, p. 15 and Ferrans, 1996, p. 
296) 
The World Health Organization Quality of Life (WHOQOL) Group (1993, p.153) 
and (1996, p. 17) defined quality of life as:  
individuals' perceptions of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, 
standards and concerns. It is a broad ranging concept, incorporating in a complex 
way a person‟s physical health, psychological state, level of independence, social 
relationships, personal beliefs and relationship to salient features of the 
environment.   
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The concept of QOL is a general concept that can be applied to evaluate several 
dimensions of life. To distinguish between QOL in its more general sense and the 
requirements of clinical medicine and clinical trials, the term health-related quality of life 
(HRQOL) is frequently used in order to remove ambiguity (Fang & Hao, 2003).   
In health care research, modified definitions of quality of life have included: "the 
degree of satisfaction with present life circumstances perceived by the person" (Young & 
Longman, 1983, p. 220), "patients' appraisal of and satisfaction with their current level of 
functioning compared to what they perceive to be possible or ideal" (Cella & Cherin, 
1988, p. 70), and "a personal statement of the positivity or negativity of attributes that 
characterize life" (Padilla, Ferrell, Grant, & Rhiner, 1990, p. 108).  These definitions 
stress the patients‟ appraisal of the advantages and disadvantages of the available 
treatments modalities and therefore provide information on whether or not the 
consequences of the disease and the complications of treatments are tolerable or not 
(Cella & Tulsky, 1990).      
It can be noticed from the provided definitions that the concept of QOL has a 
subjective nature since it reflects one‟s individual feelings toward his/her own life. Such 
a way to look at QOL applies to survivors of prostate cancer as the whole experience of 
cancer is very personal. Therefore, the concept of QOL, including prostate cancer 
survivors, depends upon the unique experiences of each individual (Ferrans, l996). 
Therefore, it is important to consider individuals‟ differences and how they are satisfied 
with their own lives. Therefore; according to Caiman‟s (1984) and Cella & Cherin‟s 
(1988) definitions, a good quality of life is obtained when the hopes of that individual 
are fulfilled or when he/she perceives and judges his/her current status as adequate 
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according to his/her own judgment and evaluation of his/her own status. While poor 
QOL exists when those hopes are unmet based upon the experience of that individual, or 
un met based upon the standards that he/she considers as ideal. Similarly, Cella & 
Cherin (1988) linked the reality of experience with the desired ideal in defining QOL as 
the patient's appraisal of and satisfaction with his/her current level of functioning 
compared to what he or she views as ideal. In cases of chronic diseases or life-
threatening conditions, patients are faced with the necessity of adjusting to their new 
health conditions. According to Sprangers & Schwartz (1999), a „response shift‟ takes 
place during the process of adaptation for a chronic disease or life-threatening 
conditions. This „response shift‟ involves changes in patient‟s internal standards, values, 
and the way he/she conceptualize his/her QOL. 
Indeed, the concept of QOL was generally described as multidimensional by 
several scholars. These dimensions include individuals‟ perceived physical health, 
psychosocial wellbeing, social or socioeconomic resources, functional ability, spiritual 
well-being, and satisfaction with life (King, 2006; Dunn et al., 2006). According to 
Fairclough (2002), besides being influenced by individuals‟ physical and social 
environment, QOL is also influenced by emotional and existential reactions to that 
environment. To Fang and Hao (2003), HRQOL encompasses 5 major domains 
“physical status and functional abilities, psychological status and well being, social 
interactions, economic and/or vocational status factors, and religious and/or spiritual 
status” (p. 196).  
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Measuring Quality of Life 
 
Since QOL concept is subjective, it is difficult to measure, but in general, the 
individual of concern will be the best source of information about the level of his/her 
QOL (Aaronson et al., l999) and therefore, his/her perspective has equal validity to that 
of the practitioner when it comes to monitoring the effects and outcomes of disease and 
treatment (Leplege & Hunt, 1997).  
While the assessment of quality of life is valued, the difficult task is to measure a 
subjective concept with components that cannot be directly observed such as social 
functioning and spirituality (Bottomley, 2002). In his book, measuring the effect of cancer 
of quality of life, Osoba (1991) outlined several reasons for developing quantitative 
measures, and he acknowledged that many feel that QOL is far too subjective to evaluate 
via a standardized measure, but he believed that rigorous psychometrics could result in 
valuable tools to measure quality of life. 
What seems interesting is that patients‟ expectations are always changing as they 
adjust to disease (Carr, Gibson, & Robinson, 2001). Fang and Hao (2003) argued that 
QOL means different things to different people and it varies according to the person‟s 
current situation. In case of chronic diseases, including cancer, patients develop 
psychological adaptation to their condition (Muldoon, Barger, Flory, & Manuck, 1998) 
which will lead to changes in the way they perceive their lives and therefore their QOL. 
In fact, such adjustment to disease will lead to a shift in their responses to QOL 
assessment over time as their expectations have changed which often contribute to 
difficulties in interpreting data (Varricchio, 2006).  
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Quality of Life among Men with Prostate Cancer 
 
The literature has extensively evaluated the quality of life of prostate cancer 
survivors, both who received different modalities of treatment and those who did not. The 
results showed several key elements that affect QOL of prostate cancer survivors that can 
be divided into two categories; physical and non-physical categories. The physical 
category covers areas such as urinary, bowel, and sexual functions, while the non-
physical category covers areas such as body image, emotional and social issue, and other 
issues that impact quality of life of prostate cancer survivors.  
 
Impact of Physical Outcomes on Quality of Life 
 
The Prostate Cancer Outcomes Study (PCOS) was one of the largest and most 
popular studies that evaluated health-related quality of life (HRQOL) in prostate cancer 
patients. The PCOS was initiated by the American National Cancer Institute (NCI) in 
1994. The purpose of this study was to “investigate variations in the initial treatment of 
prostate cancer, and to describe HRQOL outcomes in a large, heterogeneous cohort of 
newly diagnosed prostate cancer patients treated in community medical practices” 
(Potosky et al., 1999, p. 1917). 
A total of 11,137 men, diagnosed with a biopsy-proven prostate cancer between 
the beginning of October, 1994 and the end of October, l995 in 6 of the Surveillance and 
Epidemiology End Results (SEER) cancer registries were eligible for the PCOS. A pre-
specified sampling design was used to ensure adequate representation of eligible patients 
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and a sufficient number of minority participants. Of the total number sampled (n=5,672), 
62% of participants (3,486) completed survey questionnaires about their HRQOL at 6, 12 
and 24 months after initial diagnosis. The PCOS survey instrument was designed to focus 
on urinary, bowel, and sexual dysfunctions. Selected scales from the Medical Outcomes 
Study (MOS) were included; however, to “…minimize respondent burden and to focus 
on disease-specific function, we excluded three scales of the SF-36 [physical and social 
function scales and general health perceptions]” (p. 1721). The five scales which were 
included focused upon bodily pain, depression/anxiety, vitality, role limitations related to 
physical health, and role limitations related to emotional health (Potosky et al., 1999). In 
their commentary at the PCOS, Potosky et al. indicated that the huge data collected in 
this study should “provide important new information concerning the diagnosis and 
management of prostate cancer in the United States to benefit patients, clinicians, and 
policy makers” (p. 1723). 
Several studies reported on findings from this large (PCOS) database. Stanford et 
al. (2000) used a sample of 1291 Black, White, and Hispanic participants from the PCOS 
who had localized prostate cancer and were treated with prostatectomy. The objective of 
the study was to “measure changes in urinary and sexual function in men who have 
undergone radical prostatectomy for clinically localized prostate cancer” (p. 354). Age of 
participants ranged between 37 and 79 years. They had a radical prostatectomy surgery 
within a six months period after being diagnosed with prostate cancer. Measurement of 
sexual and urinary functions were performed at six, twelve, and twenty-four months after 
the initial diagnosis. The results revealed that 20.5% of participant regained full urinary 
control after 6 months and 31.9% regained full control after 2 years of diagnosis. About 
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40% of participants reported occasional urinary leakage and about 7% reported frequent 
urinary leakage, while 1.6% reported that they did not have any urinary control after two 
years. At the end of the two year assessment, the level of urinary bother was improved 
and only 8.7% of participants reported that urinary incontinence was a moderate or a big 
problem. The results also showed that about 60% of participants reported that they did 
not have hard erection enough to have penetrating sex and the rest of them had no 
erection at all. Furthermore, about 42% of participants reported that their impotence 
bothered them moderately to severely 18 months (2 years after diagnosis) after having the 
surgery.  
Another study that used the data from the PCOS was Potosky et al. (2000).  
Potosky and his colleagues used the data from PCOS to compare HRQOL for 1591 
patients aged between 55 and 74 years who had participated in the PCOS and were 
treated either by radical prostatectomy or external radiation. After adjusting for estimates 
of differences (such as age at diagnosis, baseline functions, and socioeconomic factors) 
between the group that received radical prostatectomy and the group who received 
external beam radiation, the results showed that 9.6% of the patients who had radical 
prostatectomy had experienced urinary incontinence compared to 3.5% of those who had 
radiation therapy. Urinary incontinence was defined as “having no control or frequently 
leaking or dripping urine” (Potosky et al. 2000, p. 1586). About 13.8% of patients who 
had radical prostatectomy reported leakage of urine compared to 2.3% of patients 
received radiation therapy. More patients from the radical prostatectomy reported having 
more urinary frequency and reported that they were bothered by their urinary function 
than patients from the radiation therapy group. When asked about their bowel elimination 
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function, more patients who received radiation therapy reported that they had bowel 
dysfunction than patients received radical prostatectomy. When asked about their 
sexuality, 79.6% of patients who had radical prostatectomy reported impotence compared 
to 61.5% of the patients receive radiation therapy. Sexual bother was reported by more 
younger patients (55-59 years) who had radical prostatectomy (59.4%) than patients 
received radiation therapy (25.3%) from the same age group. When compared the 
HRQOL for the two groups, Potosky et al. (2000) reported that they did not observe 
statistically significant differences among the two groups in the five examined domains. 
In spite of that, the researchers reported that more patients from the radiation therapy 
group (22.7%) said that their overall health was fair or poor compared to 11.5% of radical 
prostatectomy group.  
Penson et al. (2003) used the data of the PCOS in order to determine if there is a 
“relationship between primary treatment, urinary dysfunction, sexual dysfunction, and 
general health-related quality of life (HRQOL) in prostate cancer” (p. 1147). A sample of 
5,672 men with prostate cancer was randomly selected from the 11,137 who originally 
participated in the PCOS. Participants had received 4 methods of treatment: radical 
prostatectomy, radiation therapy, hormone ablation therapy, and watchful waiting. 
Participants were surveyed at 3, 6, 12, and 24 months after receiving treatment. After 
controlling for covariates, the researchers assessed the effect of the four treatment 
modalities on the general HRQOL after two years of initiating treatment. The results 
showed that in spite that participant reported urinary and sexual bothers, there were no 
statistically significant differences in the general health-related quality of life outcomes 
among participants in the four groups. 
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Reis, Netto, Reinato, Thiel, and Zani (2004) compared the impact of urinary 
incontinence and erectile dysfunction QOL and the willingness to undergo treatment 
again in patients treated by radical retropubic prostatectomy and patients treated with low 
dose radiation (LDR) brachytherapy. Self-reporting questionnaires were mailed to a 158 
patients who had clinical localized prostate cancer and were treated by either with radical 
prostatectomy or LDR brachytherapy between July 1992 and November 2001. The 
questionnaire consisted of 11 questions; five to assess sexual function, four to assess 
urinary continence, and 2 to assess satisfaction with treatment and willingness to receive 
the same treatment again. With a response rate of 43% (n = 56), results indicated that:  
84.8% of the prostatectomy group and 23.07% in the brachytherapy group reported some 
degree of erectile dysfunction, 17.6% patients treated by prostatectomy and 9.5% treated 
with brachytherapy suffered from urinary incontinence. As both treatment modalities 
affected sexual function and urinary continence, Reis et al. (2004) concluded that they 
negatively impacted levels of quality of life. In spite of reported treatment-related 
morbidity and impact on QOL, most patients (88.2% of prostatectomy group and 95.5% 
of the brachytherapy group) would elect to have the same treatment performed again 
(Reis et al., 2004). This reinforces Pender‟s Health Promotion Model (Pender, 1996 & 
Pender et al., 2002) that people will follow health promoting behaviors that maintain or 
enhance their well-being by extending their lives. 
Namiki et al. (2004) assessed health-related quality of life (HRQOL) of Japanese 
men with localized prostate cancer after a radical retropubic prostatectomy in order to 
assist Japanese urologist in their discussion about treatment options with their patients 
who are diagnosed with prostate cancer. The study was a longitudinal survey of HRQOL 
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that started with a 104 participants who had a radical retropubic prostatectomy after being 
diagnosed with localized prostate cancer. 32 participants dropped out or became 
ineligible for the study as they received adjunct treatments such as hormonal or radiation 
therapy. Namiki et al. (2004) used RAND 36-Item Health Survey 1.2 (SF-36) to assess 
the general HRQOL and the University of California, Los Angeles Prostate Cancer Index 
(PCI) to assess the specific prostate cancer HRQOL. The participants were interviewed 
before surgery and at 3, 6 & 12 months after the surgical procedure (Namiki et al., 2004). 
The results of this study revealed that patients who had a retropubic prostatectomy 
experienced significant decline in some domains such as the physical domain as 
participants reported role limitations due to body pain and physical problems after three 
months of the surgical procedure. But Namiki et al. (2004) reported that most of these 
problems had significantly improved at the 6-month interview. The scores for mental 
health status were also decreased after the surgical procedure but had recovered to the 
base line after one year. Furthermore, the results of this study revealed that most of the 
participants suffered from urinary bother within the first three months after surgery. 
However these symptoms started to disappear and participants, especially younger 
participants, started to report improvements after 6 and 12 months, but it did not came 
back to the baseline before the surgery. In regard to bowel elimination, no problems were 
reported by participants regarding this domain. Finally, participants reported that they 
had a substantial score of sexual dysfunction and deterioration of sexual bother, 
especially those who are relatively younger patients whose scores were much worse. In 
spite of that, the majority of participants reported good general HRQOL. The researchers 
related that to the fact that the majority of the participants were older (mean for age was 
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66.6 years) than participants in other related studies. Therefore, Namiki et al. (2004) 
suggested to urologic surgeons to discuss this issue in more details with younger patients 
during preoperative counseling related to treatment options.  
In another study, Shrader-Bogen et al. (1997) mailed self-administered 
questionnaires to 354 men who received either prostatectomy or radiotherapy in a cross-
sectional study in order to identify and compare their self-reported QOL and side effects 
of treatment 1-5 years after treatment. With a response rate of 86.4 (n =306), only 274 of 
them met the eligibility criteria to participate in the study. Forty eight percent of 
participants were treated with prostatectomy while the other 52% received radiotherapy. 
The results of Shrader-Bogen‟s et al. (1997) revealed the following: a) adverse changes in 
bowel function (such as diarrhea, urgency, and bleeding with bowel movement) were 
reported more frequently by patients who received radiotherapy than those who received 
prostatectomy, b) after adjustment for age, patients treated with prostatectomy reported 
significantly more treatment-related urinary symptoms and side effects (such as leaking, 
increased leaking with coughing or sneezing, and greater use of protection) than patients 
received radiotherapy. The only urinary symptom that was reported more frequently by 
radiotherapy patients was nocturia, c) patients treated with prostatectomy had 
significantly worse sexual dysfunction than radiotherapy patients as a side effect to 
treatment. About 70% of the prostatectomy patients were unable to have an erection and 
an additional 15% were unable to have a sufficient erection for vaginal penetration. On 
the other hand, 50% of the radiotherapy patients were unable to achieve erection and an 
additional 27% were unable to have a sufficient erection for vaginal penetration. This 
difference in ability to achieve erection between the 2 groups was statistically significant 
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even though the radiotherapy group was 9 years older than the surgery group, d) about 
69% of the prostatectomy patients reported that they were “not very satisfied” or “not at 
all satisfied with their sexual function compared with 62% of the radiotherapy patients, e)  
prostatectomy patients reported more effect of sexual function on their overall QOL than 
radiotherapy patients, but after adjustment for age, this difference was no longer 
significant. 
Using a control group (n = 2412), Bacon et al.  (2002) studied 1201 men who 
were diagnosed with prostate cancer between 1993 and 1998. Both groups were recruited 
from participants of the Health Professionals Follow-Up Study (HPFS). Men participated 
in the control groups were free from diseases that may affect their QOL such as cancer, 
cardiovascular disease, diabetes, stroke, renal failure, and Parkinson‟s disease and they 
were age-matched with their counterparts in the treatment group. Bacon et al (2002) used 
three common scales (the Medical Outcomes Study Short Form–36 Health Status Survey 
(SF-36), the Cancer Rehabilitation Evaluation System–Short Form (CARES-SF), and the 
University of California at Los Angeles (UCLA) Prostate Cancer Index) to evaluate 
QOL. The findings showed that bowel symptoms had the greatest effect on QOL, 
followed by sexual and urinary symptoms. 
The result of Bacon et al. (2002) reflected that sexual symptoms were strongly 
associated with QOL and reductions in QOL were particularly evident for men who had 
some sexual function before being diagnosed with prostate cancer. Sexual bother had the 
greatest effects on the physical function, vitality, and mental health domains of QOL.     
Although urinary symptoms were significantly affecting QOL, they were the least 
predictive of QOL after cancer diagnosis and their effect were more evident on men who 
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had moderate to severe urinary symptoms before diagnosis. Urinary symptoms had the 
greatest impact on the physical function, general health, vitality, and mental health 
domains of QOL and to a lesser degree on the domains of the psychosocial and marital 
interaction domains. Bowel symptoms (rectal urgency, loose or liquid stools, crampy 
pain, and bowel movement distress) were the greatest area that impacted level of QOL, 
especially the role and social functioning domain. In general, psychosocial domains of 
QOL were just as strongly impacted as were the physical domains of quality of life 
(Bacon et al., 2002).  
Although the literature suggests that there are issues concerning urinary and 
sexual functioning after a radical prostatectomy, Litwin, Melmed, and Nakazon (2001) 
came to the conclusion in their longitudinal study after a radical prostatectomy that 
urinary and sexual function continue to improve even beyond two years postoperatively. 
Therefore, patients who have had a radical prostatectomy should be encouraged that 
recovery may continue for months after surgery. 
 
Impact of Non-Physical Issues on Quality of Life 
 
The previous part of the literature examined QOL of men who had received 
treatment for prostate cancer and how the complications of their treatment impacted their 
quality of life. Other scholars took another path of examining the effect of treatment and 
its complications on prostate cancer survivors and how they impact their body image 
which in turn affects QOL.  
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In an ethnographic, qualitative study, Oliffe (2005) explored men‟s experiences of 
impotence following prostatectomy as a treatment from prostate cancer and how such 
experiences affected their perceived masculinity. A total of 15 Anglo-Australian men 
with localized prostate cancer who were treated with prostatectomy were recruited for 
this study. Participating men were heterosexual and had current female partners at the 
time of the study. The average age for participants was 57 years and all of them were 
sexually active and had no erectile dysfunction before the interviews. An in depth 
analysis of the contents of the semi-structured interviews reveled that participants and 
their partners had focused on survival and traded life with impotence. One participant 
expressed his feeling: “If you are alive you can do whatever you can do; if you are dead 
then you can‟t do anything. So the first objective is to be alive” (Oliffe, 2005, p. 2252).   
In spite of this trade off, many participants tried several means such as vacuum 
erection devices, Viagra, and penile injection to try to get erection in an attempt to have 
penetrative sex and felt disappointed and worthless when they were not succeeding to 
have penetrating sex. Many of them also showed surprise and distress at the reduction of 
the penis size after the surgery. Regardless of these findings, participants reveled that 
their impotence did not affect their masculinity and they perceived their impotence as 
part of the nature of aging (Oliffe, 2005).  
In a qualitative study conducted in Sweden by Hedesting, Sandman, Tonic, and 
Widmark (2005), 10 patients with localized prostate cancer and treated with external 
radiation therapy were recruited.  Participants were 60-70 years old and were not having 
any chronic diseases that may affect their health outcomes and quality of life. They had 
received the radiation therapy 6 months to three years prior to the interview. The aim of 
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the study was to “gain deeper understanding of how men live after external beam 
radiotherapy of local prostate carcinoma” (Hedesting et al., 2005, p. 310). Analysis of the 
interviews showed 4 themes: to “bear the emotional experience of the illness alone, a 
sense of being exposed, striving for a sense of having control in a new life situation, and 
striving to reconcile with a new life situation” (p. 312).  
Men reported that they did not initiate talks about their disease- related emotions 
and thoughts including those related to their prognosis and future. Participants who had 
waning erection ability described their experience as being mutilated. In general, men felt 
emotionally distressed of getting their bodies exposed especially in the presence of 
female care providers and reported a sense of being exposed when asked about their 
waning sexual function (Hedesting et al., 2005).   
In an attempt to examine the impact of hormonal therapy on patients with prostate 
cancer and how they cope with body changes and how it will affect their spousal 
relationships, Navon and Morag (2003) interviewed 15 Israeli patients who have received 
hormonal treatment for their prostate cancer. Participants had received continuous 
hormonal therapy ranging from six months to three years. Participant reported that some 
changes had occurred to their appearance and affected their body image and their 
emotional status. Examples for these changes were diminished sexual organs, 
development of breasts, disappearing of their chest and limbs hair, and gaining wait at 
their hip and buttocks areas. These were besides reporting having the experience of hot 
flashes. Such feminization characteristics resulted in disturbance of body image and 
resulted in feelings of revulsion, self-loathing and disgust with their appearance. One 
participant reflected:  
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I started developing breasts and gaining weight, particularly in the backside, like a 
woman. My penis has shrunk, it‟s dead in fact…so since the treatment, I started 
feeling self-abhorrence. Hot flashes have set in, like in menopausal women. . . . I 
feel revolted, it‟s dirty and unpleasant. It makes me feel different from other 
people. I find it hard to look at my body. It makes me hate myself (p. 1382). 
 
While tried to convince themselves that these physical changes were worthy 
sacrifices to stay alive, all participants tried to conceal their physical changes from others 
and used loose clothes to camouflage their enlarged breast and buttocks and their hairless 
legs. Nevertheless, these changes had a great impact on their body image. One participant 
descried his feelings:  
Whenever I saw my body, I wondered, „Who am I? A woman? A man?‟ It‟s a 
very confusing situation. I believe I‟m neither one thing nor another; that‟s the 
only way I can think about myself without becoming confused. To tell the truth, at 
first, every time I looked at myself, I became depressed. I know that it makes no 
sense, but it was only when I took the mirror out of the room that I stopped 
thinking about my appearance. As time went on, I developed all sorts of methods 
for consoling myself. Each time that my body‟s appearance disgusts me anew, I 
tell myself that the main thing is I‟m alive. Being alive is worth it all. . . . Even 
concerning the size of my organ, I tell myself: „Well, it means that the disease has 
shrunk (p. 1383).  
 
At the spousal relationships, in spite that many participants reported that they 
continued to have good relationships with their wives; some reported that they became 
repugnant to their wives because of their appearance and their impotence. Such feelings 
of rejection from wives had its negative impact on participants‟ emotions (Navon & 
Morag, 2003). 
In a similar qualitative study, Harden et al. (2002) interviewed 6 focus groups of 
22 men with prostate cancer and 20 of their spouse-caregivers with the goal to “explore 
the experiences of couples living with prostate cancer, the impact of the illness on their 
quality of life, their ability to manage symptoms, and their suggestions for interventions 
that would help them to improve their daily experiences.” (p. 701). Two groups consisted 
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only of patients, another two groups consisted of spouse-caregivers only, and the last two 
groups consisted of mixed patients and spouse caregivers.  
Four major themes came out of the analysis: enduring uncertainty, living with 
treatment effects, coping with changes, and needing help. Beside living and coping with 
changes due to treatment effect (urinary symptoms, sexual dysfunction, hormonal 
change, and weight gain) participants reported struggling with treatment choices (in many 
cases, information were not understood by patients and/or their families), interruptions of 
life patterns, emotional distress (Harden et al., 2002).  
According to Harden et al (2002), the effects of treatments had a great emotional 
impact on patients and their spouses-caregivers especially those related to sexual 
dysfunction and side effects of hormonal therapy (such as fluctuations in mood {feeling 
depressed and crying easily} and hot flashes). The male group participants mentioned 
their feelings of being incomplete and grieved the loss of an integral part of their 
marriage. One man said:   
You go to sleep holding hands; it‟s the best you can do. You sleep in the same 
bed, and you‟re afraid to hold each other because somehow you feel like you are 
starting something that you can‟t finish, and she‟s the same way (Harden et al., 
2002, p. 705). 
 
Sexual dysfunction and changes due to hormonal therapy posed a serious threat to 
men‟s identity and sense of masculinity and therefore their body image. One man 
summarized his feelings:  
You don‟t have that [sexual] power anymore. It‟s sad fooling yourself. . . . I used 
to go out with female friends and tease them . . . say anything so I would feel 
masculine. That was the power I had. Now I can‟t flirt anymore . . . because of 
that medicine [hormones] (Harden et al., 2002, p. 705). 
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Besides men‟s feeling of losing the “sense of power”, women reported a 
decreased sense of femininity or sexual attractiveness as their husbands showed less 
interest in them as a result of the effects of the hormones (Harden et al., 2002). 
In an attempt to explore how prostate cancer and its treatment affect men‟s 
bodies, their roles, and sense of masculinity, Chapple and Ziebland (2002) conducted 
unstructured interviews with 52 men from the United Kingdom who suffered from 
prostate cancer. Findings showed that many men were hesitant to disclose their suffering 
and to consult their doctors, because “boys don‟t cry” and it is not “macho” to do so and 
they perceived it as a threat to their masculinity. Chapple and Ziebland (2002) argued that 
such a perception reinforces the notion that “masculinity” is a social construction.   
However, while prostate cancer and the side effects of surgical and radiotherapy 
treatments sometimes led to serious complications such as impotence and incontinence, 
the use of hormonal therapy was reported to have an additional, sometimes profound 
effects on libido, energy, ability to work, breast enlargement, body shape and 
competitiveness. These side effects reduced some men‟s sense of masculinity (Chapple & 
Ziebland, 2002).  
Participants perceived that loss of body control over urination and bowel 
movement causes embarrassment for them. Along with their inability to work (due to 
treatment-induced fatigue), they perceive such lack of control to affect their masculinity 
and their body image. A man summarized his feelings about urinary incontinence: 
I experienced this pain in the bladder and trouble passing water and passing water 
far too often to get involved in doing anything else and this obviously lead to a 
lack of confidence and you don‟t feel like leaving home (….) (Chapple & 
Ziebland, 2002, p. 828). 
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While many of the interviewed men denied the effect of being impotent (as they 
saw themselves as getting old for having sex), one participant described the effect of 
impotence on him: 
Yes, yes I mean I feel that I‟ve lost all masculinity, I am not a man any more. I 
mean I am just not. I mean if I was just walking with my wife, very slowly these 
days, and somebody accosted her I would sort of run away. I have no masculinity 
left (Chapple & Ziebland, 2002, p. 834).  
 
Chapple and Ziebland (2002) concluded that the physical body as well as the 
culture should be considered when trying to explain what it means to be masculine, and 
how illness may affect men‟s sense of masculinity.  
In a longitudinal study performed in Australia with the aims to compare effects of 
different pharmacological treatments on HRQO and to “examine the role of appraisal and 
coping in HRQOL” in patients with non localized prostate cancer, Green, Pakenham, 
Headley, & Gardiner, (2002, p. 401) randomly assigned 65 men with non localized 
prostate cancer into four groups. The first group did not receive any treatment. The other 
three groups received three different types of hormonal therapy. The mean age for 
participants was 75.5 years at the beginning of the study. Another group of volunteers 
from the community who had no prostate cancer and was matching the patients groups in 
age, marital status, general health and occupational status was included in the study. A 
base line assessment using different scales that measure HRQOL, existential satisfaction, 
coping, and self-efficacy was followed by another assessment after a six months period. 
 Findings showed that patients who were receiving hormonal therapy reported 
significantly worse deterioration of sexual dysfunction than those who did not receive 
treatment and the community volunteers groups. On the other hand, there were no 
differences between the five groups concerning the existential, emotional, social, 
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cognitive and physical functions. Findings also reported that those who received 
hormonal therapy had lower HRQOL in issues related to sexual, subjective cognitive 
function, and social roles, but they had higher HRQOL in other issues such as urinary 
functions. Furthermore, Green‟s et al. study reported that regression analysis revealed 
that medical, appraisal, and coping variables had an association with HRQOL and that 
higher self-efficacy was associated with better HRQOL.   
Another longitudinal study (Andel & Kurth, 2003) aimed to examine the impact 
of immediate androgen deprivation therapy (ADT) upon health-related quality of life 
(HRQOL) in asymptomatic men with lymph node positive prostate cancer and compared 
it with the HRQOL of men who did not receive therapy revealed similar findings (Andel 
& Kurth, 2003). 91 men with histologically proven lymph node positive prostate cancer 
participated in the study. These patients were showing no symptoms at the time of 
diagnosis. While most of them received hormonal therapy, 18 patients chose to receive 
no therapy. A cross-sectional survey was performed by completing extended self-
administered questionnaire at 6 months after initial diagnosis and subsequently every 12 
months. The questionnaire included the European Organization for Research and 
Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C30), a global 
measurement of QOL (the Selby Uniscale), the c), the Sexual Behavior Questionnaire 
(SBQ) and self-constructed questions about the occurrence of hot flushes. 
 The used scales covered several dimensions of QOL. The EORTC QLQ-30 
covered the areas of physical function, role function, emotional function, social function, 
and global health status/QOL. The Selby Uniscale measures one‟s energy level in 
comparison to others and the SBQ measures issues related to relationships and sexuality. 
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Data were collected approximately 6 months after the initial diagnosis and subsequently 
every 12 months. At the 6 months and 18 months after the initial diagnoses 
questionnaires, men receiving ADT had statistically significant differences with respect 
to the areas directly related to hormonal treatment. They reported more erectile 
dysfunction, decreased sexual interest, activity, and pleasure and more frequent hot 
flashes. At the times related to emotional functions and HRQOL, men received ADT had 
reported statistically significant levels of being more emotionally distressed and worse 
HRQOL. However, these statistically significant differences disappeared at the 
questionnaires done 18 months after the initial diagnoses (Andel & Kurth, 2003). 
 
Barriers to Health Care and Utilization of Health Care Services 
 
According to the Oxford Dictionary (2009), the ward barrier means “an obstacle 
that prevents movement or access” or “an obstacle to communication or progress.” The 
term barriers to health care was defined by (American Medical Student Association, 
2009) as “obstacles within our health care system that prevent vulnerable patient 
populations from getting needed health care, or that cause them to get inferior health care 
compared to advantaged patient populations”. On the other hand, multiple authors of the 
major modes of health-related behaviors defined barriers to health care as “beliefs the 
individual holds concerning the costs associated with taking a health action” (Cummings, 
Becker, & Maile, 1980 as cited by  McCullock-Melnyk, 1988, p. 196). 
The literature reported many barriers to health care utilization which can be 
grouped into several categories. The American Medical Student Association mentioned 
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four groups of barriers to health care; a) Geographic barriers, b) Cultural barriers, c) 
Socioeconomic barriers, and d) Organizational barriers. On the other hand, Health 
System Problems, Choice Regional Health Network (2009) identified six categories of 
barriers to health care: a) perceptions on the value of insurance; b) financial barriers; c) 
primary care and treatment barriers; d) health status improvement; e) consumer 
knowledge of the system; and f) customer service. Finally, McKinlay (1972) reviewed 
the literature related to the utilization of health services and came out with six approaches 
that explain the utilization behavior for health services: a) the economic approach, b) the 
sociodemographic approach, c) the geographic approach, d) the sociopsychological 
approach, e) the sociocultural approach, and f) the organizational approach. 
Regardless of the number of approaches and categories of barriers to health care, 
the literature in the USA had reported extensively on these barriers. In her extensive 
review of the literature, McCullock-Melnyk (1988) concluded that the following barriers 
were the most often ones that were reported in the literature: cost (direct cost and cost of 
lost work), time lag to the appointment, waiting time, travel time, availability of 
transportation, proximity to the health care providers, issues related to health insurance 
coverage, lack of primary health care providers, provider/consumer ratio, prior negative 
experience, and differences between provider and patient in regard to cultural and social 
characteristics. The Center for Universal Design and The North Carolina Office on 
Disability and Health (2009) added that communication skills and the pattern of 
communication between providers and clients, especially those who are disabled, is a 
major barrier to health care that could lead to frustration among that vulnerable group of 
clients.  
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Others reported on specific barriers to specific groups of patients or clients. For 
example, Beckman, Buford, and Witt (2000) found that the most common barriers for 
pregnant women to seek prenatal care were long waiting time in spite of having a 
previous appointment and the cost of getting care. Margolis, Carey, Lannon, Earp, and 
Leininger (1995) identified limited availability of health care providers, lack of 
transportation, lack of continuity of care, and lack of belief in getting benefit from 
preventive care services as the major barriers to health care for underserved children.  
Based upon the data from the Medical Expenditure Panel Survey Household 
Component, Weinick, Zuvekas, and Drilea (1997) found that inability to afford health 
care services was reported by about 60% of families as the major barrier for family 
members to receive the needed health care. The second major barrier (reported by about 
20% of families) to health care was health insurance-related issues such as the refusal of 
health insurance companies to approve, cover, or pay for the care; having preexisting 
health conditions that the insurance doesn‟t cover; inability to obtain required referrals 
for care; and refusal of some physicians to accept some family‟s insurance plans. Other 
barriers reported by families included problems related to transportation, child care 
limitation, physical barriers, time-related barriers, issues related to lack of information, 
and sometimes refusal of services. Finally, Weinick et al. (1997) added that there were 
some variations of barriers among families with different health and demographic 
characteristics including perceived health status, race/ethnicity, and health insurance 
status.  
Regarding Palestine and Gaza Strip, there are no specific studies that aimed to 
address the issue of barriers to health care. Nevertheless, some reports about the health 
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care system in Palestine include some of the barriers to heath care in general. In a report 
prepared to the WHO, Dr. Abed (2007) included several barriers to health care. For 
example, the report included issues such as lack of coordination in health policy making 
between Gaza Strip, West Bank, governmental section, and nongovernmental 
organization and the inability of the Palestinian National Authority (PNA) to prioritize 
the provided health services and intervention. Such lack of coordination and inability for 
prioritizing health services impacted negatively the efficiency, effectiveness and 
sustainability of the provided health services. This in return affected the level of 
satisfaction of many donors which in return may affect the amount of money they donate 
to the MoH. Knowing that about 50% of the budget of MoH comes from donating 
courtiers reflects the impact of reducing the donated money on the availability of many 
services provided by the MoH. Also, Abed (2007) included that there is a lack of several 
services and he attributed this lack to the inability of the MoH to finance such services. 
Other barriers reported by Abed included the great shortage of qualified personnel in 
areas of health management, planning, budgeting, accounting, and data analysis. The lack 
of qualified personnel was attributed to the inefficiency in the employment process, 
inadequate licensing system for health care professionals, and to the fact that schools for 
health care professionals don‟t meet the international standards. Such shortage in 
availability of provided health services and lack of qualified personnel affected the 
quality of provided health services and lead to client and staff dissatisfaction (Abed 
2007).  
Most of the barriers reported by Abed (2007) were repeated in another report 
prepared by the RAND Palestinian State Study Team (2007) which also included some 
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criticism about the lack of standards for referring patients to be treated abroad. The 
RAND report along with a report prepared by the World Health Organization (2005) 
included that the Palestinian health system lack a health information system that includes 
data base that would be of benefit for future health planning and health-related policies.  
One of most frequently models used to explain the utilization of health services is 
Anderson Model. The model was initially developed by Dr. Ronald Anderson in the 
1960‟s as part of his dissertation (Anderson, 1995). The initial model tried to help in 
providing reasons for families‟ use of health services, defining and measuring equitable 
access to health care, and assisting in developing policies to provide equitable access to 
health care services. As things in health care arena changed rapidly after developing the  
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initial model, the model was revised up to four times (Figure 2-6 represents the fourth  
revised model). The model hypothesized that the use of available health services is  
determined by several factors that include societal, health services, system, and individual 
factors (Figure 2-7). The individual factors include individual‟s predisposition to use 
health services, enabling factors that impede or enable use of services, and individual‟s 
need for the services (Anderson and Newman, 2005). For example, predisposing factors 
include factors related to demographic, social structure, and belief variables. 
Demographic variables include sex, age, marital status, and past illness. Social 
structure variables include level of education, occupation, race/ethnicity, family size, and 
religion. Finally, beliefs variable includes values about health and illness, attitude toward 
available health services, and knowledge about the disease. Enabling factors include 
factors that relate to family and community. Family variable includes income, availability 
of health insurance, type and access to available sources. Community variable includes 
issues related to ratios of health professionals and facilities to a given population, price of 
provided services, region of country, and urban-rural character. Finally, the need factor 
includes the individuals‟ perceived level of illness or evaluated level of illness.  
In order to promote health services, Anderson (1995) thinks that a factor should 
be mutable and therefore will be a point for policy change. Some factors included in the 
model are un-mutable such as age, sex, race and ethnicity. Others are mutable such as 
beliefs, level of education and offered health services. Therefore, Anderson (1995) thinks 
that enabling the use of health services is a high mutable policy variable that will enable  
clients to utilize health services and it can be inferred that removing the barriers to health 
care utilization is a high mutable policy variable too. Such an assumption motivates  
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Figure 2-7: Factors Influencing Utilization of Health Care Services. (Source: Anderson & 
Newman, 2005, p. 4) 
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Summary  
 
Prostate cancer is one the most cancers that affect men especially when they get 
older. Several risk factors such as age, ethnicity, and diet increase the chance to develop 
prostate cancer. When discovered while localized, prostate cancer is curable, while it is 
not if discovered in advanced stages. Then the goal of treatment becomes palliative rather 
than curative. Several treatment options including prostatectomy, radiation therapy, 
hormonal therapy, and watchful waiting are available to treat prostate cancer. Each of the 
available treatment options has its pros and cons and the consequences of treatment 
usually affect the level of QOL of prostate cancer survivors.     
In spite of the numerous definitions of quality of life, they all have something in 
common which is that quality of life is subjective and it can be perceived differently by 
different people who have the same physical conditions. The literature about quality of 
life of patients having prostate cancer have reported that there were several domains that 
impacted the quality of life of prostate cancer survivors. The physical domains included 
dysfunction in the urinary, sexual, and bowel elimination which were reported to affect 
men‟s quality of life. Other issues that were reported to have an effect on quality of life 
were related to body image, emotional statues, social roles and relationship with spouses.   
In spite of the abundance of literature about quality of life of patients having 
prostate cancer, the researcher observed that the reported literature came from developed 
countries such North America, Europe, Australia, Japan, and Israel. Unfortunately, the 
researcher could not find any study that had evaluated QOL of prostate cancer survivors 
in any developing country. Such lack of literature about the QOL of prostate cancer 
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survivors in the developing countries raises the question if there are any differences of 
QOL of prostate cancer survivors among those who live in the developed courtiers and 
those who live in the developing countries.  
The same issue was noticed about the literature about barriers to health care. 
There are several studies that were conducted in the USA and reported about the barriers 
to health care, but there were no studies that reported about the same topic in the 
developing countries. Nevertheless, the available literature categorized barriers to health 
care under several categories that range from 4-6 categories. Among the categories of 
barriers to health care were those related to economic, cultural, geographical, 
organizational, time-related factors, and factors related to customer service. 
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CHAPTER III 
METHODOLOGY 
 
This chapter aims to discuss the methodology employed for this dissertation 
study. It presents the study design, participants sampling and setting, definition of study 
constructs, the instrument used to measure quality of life and its validity and reliability, 
data analysis, and ethical considerations. 
 
Study Design 
 
The design for this study is a cross-sectional, descriptive design that contains both 
quantitative and qualitative approaches. This design will help in describing the study 
variables at a certain, fixed point of time. The advantage of cross-sectional design is that 
it is practical, simple, economical, and easy to conduct (Polit and Beck, 2004, Neuman, 
2006). Because data in cross-sectional designed are collected at fixed points of time, 
results may be ambiguous or misleading. Other limitation of cross-sectional design is the 
inability to infer changes over time (Polit, and Beck, 2008). On the other hand, in this 
design, the investigator will have less “ability to establish an in-depth development of the 
phenomena being studies” (LoBiondo-Wood and Haber, 2006, p. 246).  
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The study included both the quantitative and qualitative approaches in data 
collection. The use of both quantitative and qualitative approaches strengthens the design 
and reduces any weaknesses in either approach (Patton, 2002 and Punch, 2005). It will 
also provide richer and more in-depth data that will reduce biases of the use of a single 
method (Neuamn, 2006 & Creswell, 2003) and will add to the richness of the study. 
Furthermore, Neman (2006) argues that the use of triangulation method will make the 
study fuller and more comprehensive and one method will cover for the limitations of the 
other (Creswell, 2003). For example, quantitative data gives the researcher hard data and 
when used with qualitative data it answers the question why. 
 
Participants, Sampling, and Settings 
 
 The study population for this study included all male adult patients who had been 
diagnosed with prostate cancer and received, currently receiving treatment, or did not 
receive any treatment for prostate cancer and reside in Gaza Strip. The number of patients 
who had been diagnosed with prostate cancer between the years of 1995 and 2000 was 
106 cases (Najjar et al, 2002). Unfortunately, there were no available data about the 
actual number of patient diagnosed with prostate cancer in Gaza. The number of patients 
who are living with prostate cancer in Gaza Strip is estimated to be around 250 to 300 
patients. All prostate cancer patients living in Gaza Strip were recruited to participate in 
this study whether they were receiving treatment or not at the time of data collection 
between August and November, 2009. 
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The sampling frame for this study included all male patients who were diagnosed 
with prostate cancer and live in Gaza Strip prior to and during the data collection process. 
This included patients who were receiving treatment and who had finished their treatment 
at the time of data collection took which took place between August and November, 
2009. The plan was to obtain contact information about patients who were diagnosed 
with prostate cancer and live in Gaza Strip from the Palestinian National Cancer Registry. 
But access to all prostate cancer was not possible because cases diagnosed after 2007 
were not registered at the Palestinian Cancer Registry due to political chaos that prevails 
in the region. Further, it was not possible to obtain a list of prostate cancer patients from 
the Palestinian Cancer Registry due to the high bureaucracy that prevails at the 
governmental systems. Therefore, the researcher had to go to the oncology outpatient 
clinics at the two centers providing oncology treatment in Gaza Strip (Shifa Hospital and 
Gaza European Hospital) and identified a list of 171 patients who were receiving 
treatment at the time of data collection or had previously received treatment at one of the 
two centers.  
The process of identifying participants was much easier at Gaza European 
Hospital as it has a computerized system which helped the researcher to identify cases 
that were diagnosed with prostate cancer by punching the diagnosis into the system. The 
process was much more complicated at Shifa Hospital as the researcher and his assistant 
had to manually examine the medical records of all oncology patients that were available 
at the registrar office to identify patients who had been diagnosed with prostate cancer.  
Participants were interviewed, privately, at one of the health care facilities that 
offer treatment for prostate cancer, when they came to receive their treatment, at their 
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homes (when participants preferred to), or at other convenient places to the participants.  
In the event where it was difficult to reach to some participants in person, they were 
interviewed over the phone. According to Babbie (2001), interview survey usually has a 
high response rate. He described a response rate of 80-85% of interview survey as a 
“completion rate” (p. 258). Babbie added that another advantage of this method for data 
collection is decreasing the numbers of “don‟t knows” and “no answers” (p.258). 
The questionnaire was not sent by mail to the patients for three reasons. First, it 
was expected that a relatively sizable proportion of participants will not be able to read 
and write as the latest available data about the level of illiteracy in 2002 revealed that the 
level of illiteracy was 13.2% among male Palestinians 55-64 years old and was as high as 
59.4% among male Palestinians over the age of 65 years (Palestinian Central Bureau of 
Statistics, 2009). Such high percentage of illiteracy might affect the adequacy of data and 
response rate if questionnaires were to be mailed to participants. Second, the postal 
system in Gaza Strip is not well developed as there are no postal codes and the majority 
of streets have no names which would make the mailing process very hard. Third, the 
availability of the interviewer will help to answer any inquiry by participants if they need 
any clarifications about any item of the questions involved in the questionnaire.  
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Definition of Study Constructs 
  
Constructs of interest for this study are defined as follows:  
Prostate Cancer Survivor: any adult male patient who had been previously 
diagnosed with prostate cancer and live in Gaza Strip regardless if he received, is 
currently receiving, or didn‟t receive treatment at all for prostate cancer. 
Quality of Life: Ferrans‟ (1990, 1996) definition of quality of life was used as the 
operational definition for QOL for this study. She defined QOL as “a person‟s sense of 
well-being that stems from satisfaction or dissatisfaction with the areas of life that are 
important to him/her” (Ferrans, 1990, p. 15 and Ferrans, 1996, p. 296). 
Barriers to health care: any obstacle within or outside the Gazan health care 
system that patients with prostate cancer who reside in Gaza Strip think that it prevents 
them from getting needed health care. 
 
Instrument 
  
The questionnaire used (Appendix A for the Arabic Version and B for the English 
version) in this study to measure quality of life of prostate cancer survivors was based on 
the University of California Prostate Cancer Index (UCLA-PCI), including the RAND 
36-Item Health Survey v2 (SF-36 v2) Health-Related Quality of life (Appendix C). The 
UCLA-PCI was developed by a group of researchers at the University of California, Los  
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Angeles (UCLA) to measure health-related quality of life (HRQOL) in patients who were 
diagnosed and treated for prostate cancer. A permission from Dr. Litwin (Appendix D) 
was obtained to translate and use the instrument for the purpose of this study. Besides 
addressing HRQOL issues related to prostate cancer, the instrument also addresses the 
general HRQOL as those patients may have other co-morbidities or health related issues 
that may impact their quality of life. The index consists of three parts : (a) the RAND 36-
Item Health Survey v2 (SF-36 v2), items 1-11; (b) the UCLA Prostate Cancer Index, 
items 12-28; and (c) the Socio-demographic data, items 29-34 (Litwin, 1994). The 
researcher used the qualitative approach to assess the barriers to health care using a semi-
structured interview technique.  
Semi-structured interview allowed participants to talk about whatever issues they 
think that they were barriers to health care and allowed them “to tell their stories in the 
manner they chose” (Green, McSweeney, Ainley, Bryant, 2009, p. 50).  In this technique, 
the interviewer asks a predetermined questions and probes participants‟ when necessary 
to enhance the depth and richness of their responses (Holstein & Gubrium, 1997 and 
Patton, 2002). Further, Willig, (2001, p. 22) thinks that this technique will “generate 
novel insights for the researcher” and enable him/her to “maintain control of the 
interview” and the original research questions. 
The RAND 36-Item Health Survey was originally produced and published by the 
RAND researchers and now it is used as the principal tool to measure general HRQOL 
(Litwin, 1994). The SF-36 is a Short-Form health survey with multiple purposes (Ware, 
2000) and was described as the most widely evaluated tool that assesses health outcome 
for patients regardless of their age, diseases, or type of treatment (Garratt, Schmidt, 
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Mackintosh, & Fitzpatrick, 2002). The SF-36 was designed to satisfy the minimum 
psychometric standards that are necessary for group comparisons. In response to some 
deficiencies identified in the original version of SF-36, a second version (SF-36 v2) was 
introduced in 1996. Improvements were introduced to make it shorter, more simple, less 
ambiguous, and more comprehensible and readable by patients, which would increase 
response rate (Ware, 2000).  
The SF-36 v2 consists of 36 items that assess the eight health domains considered 
by the medical outcomes study to represent the most frequently used concepts in relevant 
health surveys and those that are affected by several diseases and treatment (Ware, 2000). 
These domains cover the following areas:  physical functioning, role physical (role 
limitation due to physical health problems), bodily pain, general health, vitality 
(energy/fatigue), social functioning, role emotional (role limitation due to emotional 
problems), and mental health (psychological distress and psychological well-being). It 
also includes an item in which the patient makes a statement about the evaluation of their 
health status (Ware & Sherbourne, 1992; Ware, 1993; and Ware 2000). The scores 
recorded for each scale range from 0 to 100, with the higher scores referring to a better 
QOL.  
The second part of the instrument is the UCLA Prostate Cancer Index (UCLA-
PCI). It is a self-administered questionnaire that contains 20 items that quantifies and 
covers six health-related domains that are prostate-specific to HRQOL. These domains 
are urinary functions and bother (six items), bowel functions and bother (five items), and 
sexual functions and bother (nine items). The urinary, bowel, and sexual scales focus on 
the problems of urinary incontinence, bowel difficulties, and sexual difficulties 
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respectively while the bother scales focus on how much these patients are troubled by 
these dysfunctions. The UCLA-PCI is available for public at the Patient-Reported 
Outcome and Quality of Life Instruments Database (2009) and at the University of 
Kentucky Department of Surgery (2009) websites.  
The third part of the instrument, which contains six items, is pertaining to 
demographic data and brief medical history. Besides including information about age, 
ethnicity, level of education, occupational, and marital status, it includes a 12-items 
medical conditions check list. This check list has a list of 12 other diseases or health-
related conditions that were selected based on the comorbidity index. The list includes the 
following:  diabetes, heart attack/chest pain, stroke, amputation, circulation problems in 
legs or feet, asthma/emphysema/breathing problems, stomach ulcer/irritable bowel, 
kidney disease, major depression, seizures, alcoholism/alcohol problems, and drug 
problems. The participants need to check each item in the list as present or absent. 
In the original instrument, the items for SF-36 v2 and UCLA-PCI are answered 
using a Likert scale or yes/no answers. But the instrument is accompanied by scoring 
instructions for each item (appendix E). The final score is converted to scores that range 
from 0 to 100, with higher scores meaning better health states and HRQOL.  
 
Validity and Reliability of the UCLA-PCI Including SF-36 
 
The UCLA-PCI including the SF-36 showed to be valid and reliable. To test the 
validity and reliability of the instrument, after conducting a four focus groups discussion 
(n=50) of patients who have prostate cancer and their spouses, Litwin et al. (1998) 
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conducted a cross sectional study with 245 participants who had prostate cancer in the 
control group and 273 participants who had no prostate cancer in the comparison group. 
Litwin et al assessed the psychometric properties of the instrument by measuring test-
retest reliability, internal consistency reliability, and construct validity. They further 
compared the performance of the instrument with other established instruments that 
measure cancer-related HRQOL. The results showed that the test-retest reliability of the 
instrument ranged from 0.66 to 0.93. The internal consistency of the instrument ranged 
from 0.65 to 0.93. Furthermore, the results showed that the items targeted the function 
and the bother of the three main domains (urinary, bowel, and sexual functions) 
correlated substantially with one another: urinary (r = 0.71), bowel (r = 0.65), and sexual 
(r = 0.73) with a p < 0.001, indicating that the UCLA-PCI demonstrated good 
psychometric properties and performed well in this patient population and interpreted the 
high response rate among participants as an indication for how easy the use of the 
instrument was by the participants. 
Besides Litwin‟s et al. (1998) study, several other studies reported that the 
UCLA-PCI was reliable and valid to be used in elderly men patients who have been 
diagnosed with early or late prostate cancer (Litwin et al., 1995, Lubeck, Litwin, 
Henning, & Carroll, 1997, Litwin & McGuigan 1999, Litwin, McGuigan, Shpall, & 
Dhanani, 1999, and Saigal, Gornbein, Reid, Litwin, 2001). For example, Saigal et al. 
(2001, p. 407) reported that the PCI has shown to be both valid and reliable with “test 
retest reliability intraclass correlations of 0.77 in five of six scales and alpha coefficients 
of 0.65–0.93 in populations of older men with and without prostate cancer”. 
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On the other hand, several studies reported about the validity and reliability of the 
SF-36 as a solo instrument that measures general HRQOL (Ware & Sherboure, 1992; 
McHomey, Ware, & Raczek, 1993; Ware, Snow, Kosinski, & Gandek, 1993; Benjamin-
Coleman & Alexy, 1999; Sneed, Paul, Michel, Vanbakel, & Hendrix, 2001; Walters, 
Munro & Brazier, 2001). For example, the reliability of the SF-36 was established in a 
study based on the Medical Outcome Survey (N=3445) showed that the coefficient for 
the instrument ranged from 0.77 to 0.92 (Ware, et al., 1993). Reviewing several studies 
that examined the reliability and validity of SF-36, Sneed et al. (2001) reported that its 
reliability and validity were well documented. For example, the median scale reliability 
across 14 reviewed studies exceeded 0.80-0.91. Furthermore, Sneed et al concluded that 
“the SF-36 was better able to differentiate physical and emotional aspects of QOL” in 
their sample (p. 332). In another study aimed to the validity and reliability of the SF-36 
tool, using 1980 participants (response rate = 83%), Brazier et al. (1992) reported that the 
SF-36 was reliable as Cronbach‟s alpha was > 0.85 and reliability coefficient was more 
than 0. 75 for all domains except social functioning domain. Brazier et al. further added 
that their study provided evidence of the construct validity of the instrument.  
 
Translation and Modification of the Instrument 
 
The first part of the study, the SF-36 v2, was translated into the Arabic language 
and showed to be reliable and valid. In their study, Sabbah, Drouby, Sabbah, Retel-Rude, 
and Mercier (2003) used a random sample of 524 Lebanese who were 14 years and older 
and living in urban and rural areas of the southern part of Lebanon. The SF-36 was 
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translated into Arabic then back translated into English. Some expressions were modified 
due to cultural differences. Words used to measure distance such as miles, yards, blocks 
were replace by words using the metric system. Words like playing golf and bowling 
were translated to activities such as gardening and sport activities to refer to moderate 
activities. The result of Sabbah‟s et al. (2003) showed that the translated version of the 
SF-36 had acceptable internal consistency with a Cronbach‟s alpha >0.70 and factor 
analysis results showed that the factor correlation of the Arabic version were comparable 
to that found in the original SF-36. A permission to use the Arabic version of the SF-36 
in this study was obtained from the main researcher, Dr. Ibtissam Sabbah (Appendix F).  
 The second part of the instrument which relates to prostate-specific QOL (UCLA-
PCI) was also translated into the Arabic Language and some modifications were 
considered to fit into the cultural and religious variability pertaining to the people living 
in Gaza Strip. Examples of modifications included omitting “anal intercourse” when 
translating item 16 as it is not religiously or culturally accepted.   
The demographic and brief medical part of the instrument was replaced by 
another that describes the population of Gaza and was placed at the beginning of the 
questionnaire. Also, some additional questions were added to the instrument to address 
issues that were not included in the initial instrument. Examples of these questions 
include; when the patient was diagnosed with prostate cancer and what type of treatment 
did he receive. Finally, an open question was also added to help the investigator to assess 
the barriers to health care that faced men who have prostate cancer.  
The instrument was translated by the principal researcher and then was reviewed 
by two experienced nurses, who had at least five years of nursing experience and had 
97 
good command of both the English and the Arabic languages. Conceptual rather the 
literal meaning was the goal of translation. After translating the instrument into the 
Arabic language, it was then back translated into the English language by a third 
bilingual nurse. Back-translation is a standard procedure for translating a research 
questionnaire from English to other languages (Kim et al., 1995).  
The instrument used in this study was proven to be valid and reliable as 
mentioned in the previous section. Before using the instrument in this study, the content 
validity of the translated instrument was examined. Five expert nurses, who have at least 
10 years of experience, were asked to evaluate the content relevance (to both general 
quality of life and prostate-specific quality of life) of each item of the instrument and the 
entire instrument as a whole. They were asked to rank each item on a four point scale 
where 1= not relevant, 2= somewhat relevant, 3= quite relevant, and 4= highly relevant. 
Then each item was dichotomized where any item that was rated 1 or 2 was considered 
not relevant and any item rated 3 or 4 was considered relevant (Polit and Beck, 2006). 
Then, item content validity index (I-CVI) of these ratings was calculated by figuring out 
the proportion of items that were rated as relevant by all five experts. According to Polit 
and Beck, an I- CVI of 80% or above indicates a good content validity. The response of 
the five nurses revealed the following: two nurses reported all items as highly relevant. 
The other three nurses reported that, with the exception of 2-5 items rated as somewhat 
relevant, all of the items were highly relevant. When the response for each item was 
dichotomized, all items were labeled as relevant and therefore, the I-CVI was 100% for 
each item which reflects a good content validity (Polit and Beck, 2006).  
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Pilot Testing 
 
After translating the instrument, it was introduced to ten patients who were 
randomly selected from the list of patients identified by the researcher and were 
diagnosed with prostate cancer to evaluate its clarity and to determine whether it was 
friendly and easy to understand. The pilot study also investigated the following: (1) how 
long it takes to complete the questionnaire; (2) whether participants felt they had enough 
opportunity to share their views; (3) suggestions for changes; (4) other comments.  
Participants in the pilot study reported that it was friendly to use the instrument 
and that the items were easily understood. Only one suggestion was addressed about the 
wording of questions. That was about another Arabic expression to the English 
expression “sexual intercourse” to help less educated people to more understand what 
meant by this item. Other than that, participants in the pilot study did not suggest any 
changes in the wording of the instrument. The suggestion was taken into consideration 
and was added into bracket. Finally, the average time to answer the questionnaire was 
between 25-40 minutes.   
 
Data Analysis 
 
The Statistical Package for Social Science (SPSS), version 16, was used to 
compute and analyze the quantitative data. All responses provided by participants were 
entered into a personal computer. The responses then were recoded using the 
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accompanied scoring instructions (appendix E) to convert the Likert scale points into 
scores that ranged between 0 and a 100.   
The accuracy of the data entered into the SPSS was ensured by double checking 
of 25 completed questionnaires and comparing the data entered into the computer with 
the original data and examining. No errors related to data entry were found.  The 
researcher also checked that all data fell within the accurate range for each item. Running 
frequencies for all items revealed that there were not missing data as the researcher had 
reviewed each questionnaire while interviewing participants for missing data. None of the 
participants had refused to answer any item of the questionnaire.   
Data analysis procedures included basic descriptive statistics to describe the 
sample. Because the study was a descriptive study, the data were analyzed using 
descriptive statistics (mean, range, standard deviation, and percentage) and frequency 
distribution tables and occasionally t test. 
Normality of continuous variables distribution was assessed using skewness and 
kurtosis (i.e. Fisher measure of skewness). When the Fisher measure of skewness was 
calculated for the continuous variables, it was found that some results exceeded the ± 
1.96 (the critical value of significance at an alpha of 0.05). Fisher measure of skewness is 
calculated by “dividing the measure of skewness by the standard error for skewness” 
(Munro, 1997, p. 42). Examples for results of skewness that exceeded the critical value 
are the skewness for time elapsed after diagnosis (Table 4-7), skewness of scores for PCI 
QOL for participants who were receiving treatment (Table 4-15), and score of bodily pain 
and general health (Table 4-16 A).  
100 
Several authors, such as Tabachnick and Fidell (1997) mentioned that sample size 
may affect Fisher‟s measure of skewness and may result in large critical values with 
moderately large samples which have normal distributions. Field (1009, p.134) further 
added that “as our sample gets bigger then, we can be more confident that the sampling 
distribution is normally distributed” .Tabachnick and Fidell suggested that in a sample 
size of a 100 cases or more (such as in the case of this study) not to worry about the 
statistical significance of skewness. Although Tabachnick and Fidell did not provide 
guidelines about an acceptable degree of departure from the zero to be used in large 
studies, depending on the result of several computer simulation studies, Kline (1998) 
provided a rule of thumb of using an absolute skewness value of more than 3 to assume 
non-normality of data. In the case of this study, none of the variables that had a Fisher‟s 
measure of skewness was three or more.  
The qualitative part of the research question, particularly the part related to 
exploring the barriers to health care, was analyzed through careful reading of the 
responses provided by the respondents. Data analysis consisted of identifying, coding, 
and categorizing patterns found in data (Bryne, 2001). In this study the researcher used 
thematic analysis which is considered a way of seeing, as well as a process of coding 
qualitative information (Bryne, 2001). Throughout data coding, the researcher began with 
determining labels, defining the concern of each theme, describing how to know when 
each theme occurred, describing any qualifications or exclusions to identify themes, and 
determining some positive and negative examples to eliminate the possibility of 
confusion when looking to the themes (Bryne, 2001). Besides that, codes and categories 
were developed from the gathered information and the investigator did observe how 
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frequently these codes and categories appeared in the data base to establish the patterns of 
these categories and codes. Then the investigator identified the major themes and 
subthemes that came from the data. When appropriate, quotes were used. Finally, the 
identified themes were analyzed by using direct interpretation. 
 
Ethical Considerations 
 
 Prior to contacting the participants, all materials and procedures were submitted to 
the Internal Review Board (IRB) at the University of Akron and an approval to conduct 
the study was issued (Appendix H). Then after approval, a similar package was submitted 
to the Palestinian Ministry of Health and obtained their approval (Appendix I) for 
conducting this study, recruiting participants from the two government oncology centers, 
and seeking the cooperation of the employees in these two centers. A third approval was 
obtained from the Helsinki Committee (Appendix J) which is an independent committee 
in Gaza Strip that approves health related studies conducted in Gaza Strip. After getting 
the approvals to conduct the study from the IRB at the University of Akron, the 
Palestinian Ministry of Health, and Helsinki Committee; the investigator contacted the 
participants and a written consent (Appendix K) was obtained from each participant after 
explaining the purpose of the study. In case the participant was illiterate or interviewed 
over the phone, after consulting with the IRB at the University of Akron, a verbal consent 
was obtained to participate in the study. Prior to obtaining the verbal consent, the 
interviewer read the consent form to each participant and in case he had any question, the 
interviewer had answered those questions. The investigator explained to each participant 
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that his participation is voluntary and that he had the right to refuse to participate or to 
withdraw from the study at any time. All participants were assured of confidentiality and 
anonymity and were assured that no direct physiological, psychological, or 
socioeconomic risks or manipulations would be associated with this study. The 
investigator did secure the confidentiality of the participants and did not include their 
names on any documents or reports. Completed data sheets were entered into a 
computerized data file in the researcher‟s personal computer that was assigned a secured 
password. Data collection sheets and the computerized data entries were only accessible 
by the principle investigator and will be destroyed two years after the completion of the 
study.  
 
Summary 
 
 The design used for this study was a cross-sectional design that used both 
quantitative and qualitative approaches in data collection. All patients diagnosed with 
prostate cancer who live in Gaza Strip were asked to participate in the study. The 
instrument used to measure quality of life of prostate cancer men living in Gaza Strip was 
based on the UCLA-PCI instrument which is a valid and a reliable instrument. The part 
that measures the general health-related quality of life was translated into the Arabic 
Language by a group of researchers from Lebanon. After translating the PCI-related QOL 
part, a pilot testing for the instrument was done to ensure the easiness of its use by target 
population. Approvals from the IRB at the University of Akron and from the Palestinian 
Ministry of Health were obtained prior to conducting the study. After data were collected, 
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the SPSS package was used for data analysis. The data produced were mainly descriptive 
to fit the purpose of the study.    
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CHAPTER IV 
RESEARCH FINDINGS AND DISCUSSION 
 
This chapter outlines the results of data analysis performed to answer the research 
questions regarding quality of life of prostate cancer survivors living in Gaza Strip and 
the barriers to health care they faced during their treatment time. Quantitative approach 
was used to analyze data related to quality of life. Results were presented in tables and 
were related to relevant literature.  Qualitative approach was used to analyze data related 
to barriers to health care. A descriptive model was generated to depict barriers to health 
care reported by participants.  
 
Description of the Sample 
 
The target population for this study was all participants who were diagnosed with 
prostate cancer and live in Gaza Strip. The sample frame included prostate cancer 
patients who were receiving treatment and patients who had already finished their 
treatment at the time of data collection between August and November, 2009. Access to 
all patients diagnosed with prostate cancer in Gaza Strip at that time was not possible 
because cases diagnosed after 2007 were not registered at the Palestinian Cancer 
Registry. Further it proved impossible within the time parameters of this study to obtain a 
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list of prostate cancer patients from the Palestinian Cancer Registry. Therefore, data were 
obtained by going to the oncology outpatient clinics at the two centers providing 
oncology treatment at Gaza Strip (Shifa Hospital and Gaza European Hospital). In this 
way a list of 171 patients who were receiving treatment at the time of data collection or 
had previously received treatment was created.  
The process of identifying prostate cancer patients was much easier at Gaza 
European Hospital as the center has a computerized information system which helped the 
researcher in identifying patients who had been diagnosed with prostate cancer by 
entering the diagnosis into the system. The process was much more complicated at Shifa 
Hospital as all of the available medical records for all oncology patients that were 
available at the registrar‟s office had to be examined manually to identify patients who 
were diagnosed with prostate cancer.   
Of the 171 cases identified with prostate cancer, the addresses or the telephone 
numbers of six cases could not be identified.  In nine cases, the patients had died.  
Furthermore, 3 cases were out of the country, and one patient was hospitalized due to a 
serious illness. This reduced the sampling frame to a 152 cases. All of these participants 
were receiving treatment at the time of data collection except seven of them. When these 
patients were approached (either personally or by telephone), all of them agreed to 
participate in the study and completed the items of the questionnaire except one 
participant. Therefore, the respondents were 151 out of 152 participants with a response 
rate of 99.34% for this group of participants.  
To recruit more participants, especially of those who were not receiving treatment 
at the time of data collection, the snow ball technique was used. After interviewing 
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participants, they were asked to refer other patients who were diagnosed with prostate 
cancer that they knew. The result was identifying a new list of 54 patients. All of the new 
referred cases were from those prostate cancer survivors who were not receiving any 
treatment at the time of data collection. All participants were approached either 
personally or by telephone. Of the 54 new cases, six were found to be dead and one was 
outside the country. Of the remaining 47 cases, 44 agreed to participate in the study and 
the other three participants refused to be involved in the study. The final total number of 
participants was 195 (151 from the first group and 44 from the second group) out of 199 
with a final response rate of 97.98%.      
Such a response rate is considered a very high response rate. Similar studies that 
used the UCLA-PCI instrument to evaluate QOL of men who had prostate cancer 
reported response rates that ranged between 53.1 to 93% (Litwin et al.,1995; Litwin et al., 
1998; Litwin and McGuigan, 1999; Madalinska et al., 2001; Karakiewicz et al., 2003; Jo, 
Junichi, Tomohiro, Yoshinari, and Masato, 2005; Shikanov et al., 2008; Wakatsuki et al., 
2008; Inoue et al., 2009). The high response rate in this study could be related to the fact 
that participants were approached directly, either in person or by telephone, which 
provided participants with details about the purpose of the study and gave them a chance 
to answer their questions which encouraged hesitant participants to participants in the 
study. In fact, Litwin et al. (1998) contended that the high response to their study (79.4%) 
suggested that men with prostate cancer were interested to address issues related to their 
general QOL and prostate-specific QOL. This contention could be another reason that 
could contribute to the high response to this study. On the other hand, Babbie (2001) 
thinks that interview survey usually have a high response rate. He described a response 
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rate of 80-85% of interview survey as a “completion rate” (p. 258). Babbie added that 
another advantage of this method for data collection is decreasing the numbers of “don‟t 
knows” and “no answers” (p.258). 
 
Description of Study Measures 
 
 The study included several groups of measures such as demographic variables, 
general health-related variables, and variables describing the level of QOL. These are in 
addition to the answers for the open question related to barriers to health care. 
Demographic variables included age, level of education, whether the participant lives 
with his wife or not, and place of living. The general health-related measures included 
having a health insurance, having another cancer beside prostate cancer, when prostate 
cancer was diagnosed, whether he received treatment for prostate cancer or not, type of 
treatment, where he received or receiving treatment, and whether he had other 
comorbidities and/or health-related problems or not.  
 The other set of measures were used to assess QOL. One set included the 36 items 
(SF-36) that measure QOL related to general health. The SF-36 covers the following nine 
domains: physical functioning, role physical (role limitation due to physical health 
problems), bodily pain, general health, vitality (energy/fatigue), social functioning, role 
emotional (role limitation due to emotional problems), mental health (psychological 
distress and psychological well-being), and health transition. The other set of measures 
included 20 items that measure QOL specific to prostate cancer (Prostate-Cancer Index). 
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These items specifically measure urinary dysfunction and bother, bowel dysfunction and 
bother, and sexual dysfunction and bother.   
 
Demographic Variables 
 
 Demographic variable included the following variables: age, level of education, 
place of living, marital status, and whether a participant had a health insurance or not.  
 
Age  
 
The age of participants at the time of data collection ranged between 49 and 91 
years with a mean of 70.29 and a standard deviation of 8.81 (Table 4-1). The mean and 
standard deviation of age for the participants in this study were compatible with several 
studies that used the UCLA-PCI instrument which ranged between 67.7 and 72.7 years 
(Kakehi et al., 2002; Karakiewicz et al., 2003; Korfage et al., 2003; Ishihara et al., 2005; 
Namiki et al., 2006; Namiki et al., 2007; Inoue, et al.,2009). After calculating the mean 
and the standard deviation for the age of the participants, the age variable was 
categorized into the following categories: under 45, 46-50, 51-55, 56-60, 61-65, 66-70, 
71-75, and over 75. As table 4-2 shows, the highest prevalence of prostate cancer was 
among the participants who were over the age of 75 (65 participants who represented 
33.3% of the total population) while the lowest prevalence was among those who were 
between the ages of 45 and 49 (2 participants who represented 1% of the total sample).  
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Table 4-2: Age by Category 
 
Age of the participants at the time of diagnosis ranged between 46 and 85 with a 
mean of 65.99 years and a standard deviation of 8.27 (table 4-1). These results were 
relatively less than the means (68.1-69.5 years) reported in other studies (Lubeck, Litwin, 
Henning, and Carroll, 1997; Madalinska et al., 2001; Jayadevappa et al., 2006). The 
highest frequency of participants (n=42, 21.5%) were diagnosed at the age of 60-64,  
followed by the age category of 65-69 (n=40, 20.5%). The lowest frequency was noticed 
at the age younger than 50 years old as only 6 (3.1%) participants were diagnosed at that 
age group (Table 4-2). When examining the age at diagnosis carefully, it would be 
 
Age category 
Participants 
were receiving 
Treatment 
Participant were 
not receiving 
treatment 
 
All Participants 
Cumulative 
% for all 
participants 
Freq. % Freq. % Freq. %  
45-49  Now 2 1.4 0 0 2 1.0 1.0 
At diagnosis  
4 2.8 2 3.8 6 3.1 
3.1 
50-54  Now 
4 2.8 0 0 4 2.1 3.1 
At diagnosis  
5 3.5 2 3.8 7 3.6 6.7 
55-59  Now 
10 7.0 7 13.2 17 8.7 11.8 
At diagnosis  
21 14.8 11 20.8 32 16.4 23.1 
60-64  Now 
20 14.1 9 17.0 29 14.9 26.7 
At diagnosis  
28 19.7 14 26.4 42 21.5 44.6 
65-69  Now 
25 17.6 9 17.0 34 17.4 44.1 
At diagnosis  
28 19.7 12 22.6 40 20.5 65.1 
70-74  
Now 
33 23.2 11 20.8 44 22.6 66.7 
At diagnosis  
29 20.4 3 5.7 32 16.4 81.5 
75 or 
more 
Now 
48 33.8 17 32.1 65 33.3 100.0 
At diagnosis  
27 19.0 9 17.0 36 18.5 100.0 
Total  142 100.0 53 100.0 195 100.0  
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noticed that the majority of participants (n=108, 55.38%) were diagnosed with prostate 
cancer at the age of 65 years or older. Diagnosing prostate cancer at such age will put  
some clients at high risk to be treated by surgery and therefore, will eliminate the surgical 
option from their options‟ list to treat their cancer. On the other hand, such an old age at 
diagnosis would suggest the introduction of early screening for prostate cancer using 
digital rectal examination (DRE) and/or by testing for Prostate-Specific Antigen (PSA). 
  To compare the mean of age for the group that was receiving treatment to the 
group that was not receiving treatment, t test was used. The result showed that there was 
no statistically significant difference between the means of both groups (t= -.192, df=193, 
p= .848).  
 
Level of Education 
 
Table 4-3 depicts the level of education for participants. The table shows that 62 
participants (31.8%) did not receive any education at all, 28 (14.4%) received some 
education but did not complete the primary (sixth grade) level, 20 (10.3%) finished 
primary school, 18 (9.2%) completed the preparatory (9
th
 grade) school, 37 (19.0%) 
completed high school, and 30 (15.4%) had higher education. 
 
Place of Living 
 
Table 4-4 shows the place of living for participants. 37 participants (19%) live in 
the northern governorate, 82 (42.1%) live in the Gaza governorate, 29 (14.9%) live in the  
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Table 4-3: Level of Education of Participants.  
 
Level of education 
Participants 
were 
receiving 
Treatment 
Participant 
were not 
receiving 
treatment 
All 
Participants 
Cumulative 
% for all 
participants 
Freq. % Freq. % Freq. %  
No School 
 
42 29.6 20 37.7 62 31.8 31.8 
Some educating 
below Primary 
School 
23 16.2 5 9.4 28 14.4 46.2 
Finished Primary 
School 
13 9.2 7 13.2 20 10.3 56.4 
Finished 
Preparatory School 
15 10.6 3 5.7 18 9.2 65.6 
Finished High 
school 
 
29 20.4 8 15.1 37 19.0 84.6 
Higher Education 
 
20 14.1 10 18.9 30 15.4 100.0 
Total 
 
142 100.0 53 100.0 195 100.0  
 
Mid-Zone governorate, 26 (13.3%) live in Khanyounis governorate, and 21 (10.8%) live 
in Rafah governorate.  
As it was noticed from these results, the prevalence of prostate cancer was higher 
among men who lived in Gaza Governorate (42.1% of participants). When compared 
with the percentage of the male population who were living in Gaza governorate, which 
was 35.1% of all males living in Gaza Strip in the year 2007 (Palestinian Central Bureau 
of Statistics, 2009), it was noticed that men with prostate cancer in Gaza Governorate 
were over-represented (42.1% of participants live in Gaza Governorate while males 
represented 35.1% of male population in Gaza Strip), while men with prostate cancer 
were under represented in the Southern governorates (Khanyounis and Rafah  
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Table 4-4: Place of Living for Participants 
 
 
Place of living 
Participants 
were 
receiving 
Treatment 
Participant 
were not 
receiving 
treatment 
 
All 
Participants 
Cumulative 
Percent for 
all 
participants 
Freq. % Freq. % Freq. %  
Northern Governorate 27 19.0 10 18.9 37 19.0 19.0 
Gaza Governorate 67 47.2 15 28.3 82 42.1 61.0 
Mid zone 
Governorate 
25 17.6 4 7.5 29 14.9 75.9 
Khanyounis 
Governorate 
13 9.2 13 24.5 26 13.3 89.2 
Rafah Governorate 10 7.0 11 20.8 21 10.8 100.0 
Total 142 100.0 53 100.0 195 100.0  
 
Governorates) (comparison presented in Table 4-5). On the other hand, the percentages of 
men with prostate cancer living in the Northern and Mid Zone Governorates were 
representative to the male population in both governorates.  
Such a difference between Gaza Governorate and the southern Governorates 
could be related to the difference in the socioeconomic status. Gaza is the main city and 
the capital of Gaza Strip and has a better economical status than both Khanyounis and 
Rafah. Therefore, it is expected that men who lived in Gaza Governorate consume more 
red meat than their counterparts who lived in the Southern Governorates. Munden (2007) 
and Held-Warmkessel (2007) included that the incidence of prostate cancer increases 
with diet high in saturated fats, high-calorie diet, and high consumption of red meat. This 
is besides their ability to buy and smoke cigarettes as 37.28% of participants who were  
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Table 4-5: Comparison between Male Population and Prostate Cancer Survivors 
According to Their Place of Living.   
 
 
Place of living 
Male population in Gaza 
Strip 2007  
Participants (men diagnosed 
with Prostate cancer) 
Frequency Percent Frequency Percent 
Northern Governorate 137,596 19.2 37 19.0 
Gaza Governorate 252,465 35.1 82 42.1 
Mid zone Governorate 103,608 14.4 29 14.9 
Khanyounis Governorate 137,577 19.1 26 13.3 
Rafah Governorate 87,465 12.2 21 10.8 
Total 718,711 100.0 195 100.0 
 
smoking at the time of data collection or had a history of smoking lived in Gaza  
Governorate while men represented 35.1% of the male population in Gaza Strip. 
According to Held-Warmkessel (2007), a long history of tobacco smoking may increase 
the risk for prostate cancer.  
 
Health Insurance Possession and Marital Status 
 
The results of the study showed that 194 (99.5%) participants had a health 
insurance and only one participant (0.5%) did not have a health insurance. Results also 
showed that 155 participants (79.5%) were married and lived with their wives. The rest of 
participants (n=40, 20.5%) were either divorced, widowed, or not married (Table 4-6).   
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Table 4-6: Marital Status of Participants.  
 
 
Participants were 
receiving 
Treatment 
Participant were 
not receiving 
treatment 
 
All Participants 
Cumulative 
Percent for 
all 
participants 
frequency percent frequency percent frequency percent  
Living with 
wife 
114 80.3 41 77.4 155 79.5 79.5 
Has no wife 28 19.7 12 22.6 40 20.5 100.0 
Total 142 100.0 53 100.0 195 100.0  
 
 
Prostate Cancer-Related Variables 
 
Most of the participants (175=89.7%) had only prostate cancer and had no other 
cancers. Among those who had other cancers (20 participants =10.3%), in 15 cases 
(75%), prostate cancer was diagnosed before the other cancer, which may reflect that 
prostate cancer was the primary cancer and had metastasized to other organs later on. In 
the other 5 cases (25%), other cancers were diagnosed before prostate cancer which may 
indicate that prostate cancer was secondary and was metastasized from the other primary 
cancers. It also could be interpreted that prostate cancer was there but was not discovered 
until it was metastasized to the other organs as men may live and die with prostate cancer 
without discovering it. According to the American Cancer Society (2008), autopsy 
studies showed that many older men and some younger men who died due to other 
diseases also had prostate cancer that never caused a problem for them while they were 
alive. 
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The time elapsed after being diagnosed with prostate cancer at the time of data 
collection ranged between 3 months and 17 years with a mean of 48.90 months and a 
standard deviation of 34.14 (Table 4-7). After calculating the mean and the standard 
deviation for the elapsed time of diagnoses, this variable was categorized into the 
following categories: zero to 3 months, more than 3 moths up to 6 months, more than 6 
moths up to 9 months, more than 9 moths up to 1 year, more than 1 year up to 1.5 year, 
more than 1.5 year up to 2 years, and more than 2 years (Table 4-8). The results showed 
that the majority of cases (n=122, 62.2%) were diagnosed more than 2 years ago.  
When t test was done to check if there is any statistical difference between the 
means of time elapsed after diagnosis with prostate cancer between the group of 
participants who were receiving treatment at the time of data collection and the group of 
participants who were not receiving treatment at that time, the result showed that there 
was a statistically significant difference between the two means (t=-44.7, df=173, p < 
.001).  
 
Table 4-7: Descriptive Statistics for Time Elapsed after Diagnosis (by month) 
 
 
Group 
Median  Mode  Mean 
Std. 
Dev. Minimum Maximum 
 
Skewness 
All 
Participants 
36 18 48.90 43.14 3 204 8.43 
Participants 
receiving 
treatment 
30 24 40.85 36.83 3 156 7.45 
Participants 
receiving no 
treatment 
60.0 60.0 70.49 51.12 6 204 3.41 
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Table 4-8: Time Elapsed after Diagnosis by Category 
 
 
 
Time category 
 Participants 
received 
treatment 
Participant 
received no 
treatment 
 
All 
participants 
Cumulative 
percent for all 
participants 
Freq. % Freq. % Freq. % 
Zero to 3 months  5 3.5 0 0 5 2.6 2.6 
More than 3 months 
up to 6 months 
12 8.5 0 0 12 6.2 8.7 
More than 6 months 
up to 9 months 
6 4.2 0 0 6 3.1 11.8 
More than 9 months 
up to1 year 
13 9.2 1 1.9 14 7.2 19.0 
More than 1 year 
up to 1.5 year 
14 9.9 6 11.3 20 10.3 29.2 
More than 1.5 year 
up to 2 years 
13 9.2 3 5.7 16 8.2 37.4 
More than 2 years 79 55.6 43 81.1 122 62.6 100.0 
Total 142 100 53 100 195 100  
 
Of the total number of participants, 142 participants (72.8%) were receiving 
treatment at the time of data collection, while the rest of them (n=53, 27%) were not 
receiving any treatment at that time (Table 4-9).  
 
Table 4-9: Frequency of Patients Who Were Receiving or Not Receiving Treatment  
Group of participants Frequency Percent Valid Percent 
Receiving treatment  142 72.8 72.8 
Not receiving treatment  53 27.2 27.2 
Total 195 100.0 100.0 
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Table 4-10 shows that the most common type of treatment used by participants 
was hormonal therapy (n=62, 31.8%) followed by prostatectomy (n=41, 21%) and 
combined therapy of prostatectomy and hormonal therapy (n=35, 17.9%). The least 
common methods used for treatment were radiation therapy and combination of 
hormonal, radiation, and chemotherapy as only one participant (0.5%) used each type of 
these treatment options. 
In spite that most of the literature (Turini et al. 2003, Heidenreich et al. 2008, and 
Fourcade et al. 2009) cited that prostatectomy and radiation therapy are the two most 
common modalities used in treating prostate cancer, the case in Gaza Strip was different. 
The most common method used to treat prostate cancer among participants in this study 
was hormonal therapy. About 31.8% of participants used hormonal therapy as a solo 
method of treatment compared to 21% who were treated by prostatectomy (Table 4-10). 
The overuse of hormonal therapy to treat prostate cancer could be due to the relatively 
old age of participants at the time of diagnosis of prostate cancer. The majority of 
participants (n=108, 55.38%) were diagnosed with prostate cancer at the age of 65 years 
or older. At such age, with the limited facilities available in Gaza Strip, performing the 
surgery will be risky and, in the absence of radiation therapy option, the use of hormonal 
therapy will be safer.   
Although the literature showed that patients treated with radiation therapy 
reported higher QOL in several domains of QOL, i.e. urinary and sexual dysfunction 
domains, than those treated with either prostatectomy or hormonal therapy (Jonler, 1994; 
Nguyen, Pollack, and Zagars, 1998; Sommers and Ramsey, 1999;  Potosky et al. 2004),  
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Table 4-10: Types of Treatment Provided to Participants.  
 Participants 
receiving 
Treatment  
Participant 
receiving no 
treatment  
All 
Participants 
Cumulative 
%t for all 
participants 
Freq. % Freq. % Freq. % 
Prostatectomy 14 9.9 27 50.9 41 21.0 21.0 
Hormonal therapy 60 42.3 2 3.8 62 31.8 52.8 
Radiation therapy 0 0 1 1.9 1 .5 53.3 
Prostatectomy & 
hormonal therapy 
23 16.2 12 22.6 35 17.9 71.3 
Prostatectomy & 
chemotherapy 
11 7.7 7 13.2 18 9.2 80.5 
Hormonal & 
chemotherapy 
15 10.6 1 1.9 16 8.2 88.7 
Prostatectomy, hormonal, 
& chemotherapy 
6 4.2 3 5.7 9 4.6 93.3 
Prostatectomy, hormonal, 
& radiation therapy 
2 1.4 0 0 2 1.0 94.4 
Hormonal & Radiation 
therapy 
8 5.6 0 0 8 4.1 98.5 
Hormonal therapy & 
Orchiodectomy 
2 1.4 0 0 2 1.0 99.5 
Prostatectomy, hormonal,  
radiation & chemotherapy 
1 .7 0 0 1 .5 100.0 
Total 142 100.0 53 100.0 195 100.0  
 
only one participant used radiation therapy as a solo treatment for his prostate cancer and 
another 11 participants (5.64%) used radiation along with other modalities for treating  
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their prostate cancer. Such limited use of radiation therapy was due to the unavailability 
of this option for men living in Gaza Strip which did not have the facility to offer 
radiation therapy. Patients who would need to be treated with radiation therapy were 
usually referred to receive treatment outside Gaza Strip (mostly to Egyptian or Israeli 
Hospitals). With the inability to move outside Gaza Strip due to the blockade imposed 
against Gaza since June, 2006, a very few number of patients could travel outside Gaza 
Strip to receive such a treatment.   
According to Table 4-11, the major center for providing treatment to prostate 
cancer survivors in Gaza was Shifa Hospital. The majority of participants, 118 (60.5%), 
received or were receiving treatment at Shifa Hospital.  Forty-one participants (21%) 
received treatment at Gaza European Hospital, 8 participants (4.1%) received treatment 
abroad, 22 participants (11.2%) received treatment abroad and in one of the local medical 
centers and only three participant (1.5 %) were receiving or had received their treatment 
at Gaza European Hospital and abroad (Table 4-11).   
In a total, 141 participants (72.31%) had received treatment at Shifa Hospital at 
some point while 44 participants (22.56%) only had received treatment at Gaza European 
Hospital. The rest of participants (n=10, 5.14%) had received their treatment at other 
facilities or abroad. Shifa Hospital serves the population of Northern, Gaza, and Mid-
zone governorates which contains 68.7% of the male population in Gaza Strip 
(Palestinian Central Bureau of Statistics, 2010) and 76% of the participants (men 
diagnosed with prostate cancer) while Gaza European Hospital serves Khanyouns and 
Rafah Governorates which contains 31.3% of the male population in Gaza Strip and 24% 
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Table 4-11: Place of Treatment 
 
 
Place of treatment Frequency Percent Valid Percent 
Cumulative 
Percent 
Shifa Hospital 118 60.5 60.5 60.5 
Gaza European 
Hospital 
41 21.0 21.0 81.5 
Received treatment 
abroad 
8 4.1 4.1 85.6 
Others 2 1.0 1.0 86.7 
Shifa and others 4 2.1 2.1 88.7 
Shifa and abroad 19 9.7 9.7 98.5 
European and 
abroad 
3 1.5 1.5 100.0 
Total 195 100.0 100.0  
 
 
of the participants. Such results reflect that Gaza European hospital is providing services 
to less proportional percentage of the participants. These findings could be normal 
knowing that Shifa Hospital has the major oncology center at Gaza Strip and has more 
experienced physicians. Besides that, several participants are referred from Gaza 
European Hospital to Shifa Hospital.  
 
Comorbidities and other Related Medical Conditions 
 
Participants reported that they had several comorbidities and other related health 
conditions. Table 4-12 shows that a large number of participants (n=74, 37.9%) had two 
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comorbidities, followed by 48 (24.8%) participants who had only one comorbidity, and 
32 (16.4%) participants had three comorbidities or health-related issues. Only 25 
participants (12.8%) had no comorbidities or health-related issues. The rest of the 
participants (n=16, 8.2%) had four or more comorbidities. The most common reported 
comorbidity/ health-related issue was current or previous cigarette smoking as 110 
participants reported that they were smokers or previous smokers. The second more 
common comorbidity was diabetes mellitus (n=72) followed by heart attack and 
complaining of chest pain (n=47). The least common reported comorbidities were seizure 
(n=1) and major depressions (n=0) (Table 4-13).  
 
 
Table 4-12: Total Number of Comorbidities and Health-Related Problems Reported by a 
Single Participant 
 
Number of total 
comorbidities  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
0 25 12.8 12.8 12.8 
1 48 24.6 24.6 37.4 
2 74 37.9 37.9 75.4 
3 32 16.4 16.4 91.8 
4 10 5.1 5.1 96.9 
5 5 2.6 2.6 99.5 
6 1 .5 .5 100.0 
Total 195 100.0 100.0  
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Table 4-13: Most Common Comorbidities and Health-Related Problems Reported by 
Participants. 
 
 
Quality of Life Variables 
 
Prostate cancer is the second most common type of cancer among males in the 
world (American Cancer Society, 2007a) and in Palestine (MoH, 2006). The new medical 
technology along with the use of screening techniques involving the use of digital rectal 
examination (DRE) and testing for prostate-specific antigen (PSA) had helped to 
diagnose those patients who did not show any signs or symptoms of prostate cancer and 
helped to diagnose prostate cancer at the early stages of its occurrence (Hoedemaeker et 
al., 2001; Hugosson et al., 2004; Makinen et al., 2004; Gorin et al., 2008). According to 
Tewari et al. (2004), about 57% of new prostate cancers are diagnosed while the 
carcinoma is localized which will help in improving the survival rate of those men and 
improve their prognosis especially with the presence of several treatment modalities; 
such as surgical removal of the prostate, radiation therapy, hormonal therapy, and 
watchful waiting to treat prostate cancer. The use of prostatectomy, radiation, and  
Comorbidity  No.  Comorbidity  No.  
Diabetes mallets  72 Stroke  14 
Heart attack, chest pain 47 Amputation  4 
Circulation problems in your legs 
or feet 
7 Kidney disease 25 
Asthma, emphysema, breathing 
problems 
30 Major depression 0 
Stomach ulcer, irritable bowel 19 Seizer  1 
Current or past cigarette smoker 110 Other health problems  
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hormonal therapies helped to increase the survival rate of men with prostate cancer, 
which is the primary goal of treatment for any patient diagnosed with prostate cancer 
(Middleton et al., 1995). Furthermore, according to Ramos, Carvalhal, Smith, Mager, and 
Catalona (1999) and Martinez et al. (2000), the survival rates of the available different 
treatment options are usually similar. On the other hand, all of these treatment modalities 
will cause life-lasting side effects that mostly affect urinary, bowel, and sexual functions 
(Sommers and Ramsey, 1999; Wei et al., 2002; Penson and Litwin, 2003;  Potosky et al., 
2002; Clark et al., 2003; Turini et al., 2003;  Albaugh, and Hacker, 2005). Therefore, in 
recent years, more attention is paid to the issues of health-related quality of life as they 
play a major role in the decision-making process of the treatment option that the patient 
and his physician will make about which method to use to treat prostate cancer. 
Assessing health-related QOL can provide men diagnosed with localized prostate cancer 
with valuable knowledge about the potential risks, benefits, and changes in their health-
related QOL that they may experience after initiating treatment (Litwin, 1994, Moul, 
1998; Clark, Rieker, Propert, and Talcott, 1999; Saigal, Gornbein, Reid, and Litwin, 
2002; Ishihara et al., 2004; Kakehi et al., 2006; Arredondo, 2007;  Inoue et al., 2009).      
Several studies had assessed the level of QOL for men with prostate cancer using 
different tools. One of the most commonly used tools to assess QOL for men with 
prostate cancer is the UCLA-PCI instrument. This instrument has the advantage to assess 
general health QOL and prostate-specific QOL including; urinary, bowel, and sexual 
functions and bothers. The UCLA-PCI instrument was used in this study to measure QOL 
of prostate cancer survivors in Gaza Strip. To compare the result of this study with the  
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literature, several studies that used the UCLA-PCI were reviewed. Unfortunately, none of 
the studies gave a total score for QOL but they reported on the scores of each individual 
sub-domain of the general QOL (SF36) and/or those related directly to prostate cancer. 
The scores of the QOL sub-domains reported in the reviewed studies are summarized in 
Table 4-14.  
Table 4-15 depicts the scores of the quality of life for participants of this study. 
Quality of life was described in three categories: a) General quality of life (SF 36), b) 
Prostate-Specific QOL (PCI-QOL), and c) total quality of life (both general QOL and 
PCI-QOL).  
 
General Quality of Life (SF 36) 
 
The general QOL scale (SF36) includes 9 domains:  physical function, role 
limitation due to health problems, role limitation due to emotional problems, vitality, 
mental health, social functioning, bodily pain, general health, and health transition 
(Litwin et al., 1998). The mean score of the general quality of life for all participants was 
52.53. The mean of score for general quality of life (SF-36) for the participants who were 
receiving treatment at the time of data collection was 51.31 while the mean of the general 
QOL scores for the participants who were not receiving treatment at the time of data 
collection were 55.81 (Table 4-15). The results of t test showed that there were no 
statistically significant differences between the means of the general QOL scores of the 
two groups (t= -1.26, df=193, p= 0.211).  
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Tables 4-16, 4-17, and 4-18 summarizes the scores of QOL for each of the 9 
domains of the general health QOL (SF-36).  In general, participants who were not 
receiving treatment at the time of data collection reported higher scores than those who 
were receiving treatment at that time in all domains except the domains of social 
functioning, bodily pain, and health transition. The lower scores reported by participants 
who were receiving treatment could be related to impact of the side effects of the 
treatment they were receiving at that time.  
To compare if there were any statistically significant differences between the 
means of the sub-domains of the general QOL among participants who were receiving 
treatment and those who were not receiving treatment at the time of data collection, t test 
was done. The results (Table 4-19) showed that there were statistically significant 
differences between the means of the participants in the two groups only in the areas of 
vitality (t=-2.17, df=193, p=0.033) and health transition (t=3.40, df= 193, p=0.001). 
By examining the scores of the general health QOL (SF-36) reported by 
participants of this study and comparing them to those reported in the literature and 
summarized in Table 4-14, it can be noticed that the scores of QOL reported by men 
diagnosed with prostate cancer and living in Gaza Strip were less than those reported in 
the literature with the exception of three sub-domains; role limitation due to physical 
function, social functioning, and bodily pain. The mean of scores reported in this study 
for role limitation due to physical function was 42.69 while the least reported score in the 
literature for this sub-domain was 42 (Schapira et al., 2001) followed by a score of 53.4 
(Albertsen et al., 1997) and a score of 61.3 (Litwin et al., 1998). The score of 42 reported  
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Table 4-19:  Independent Samples Test for the Domains of the SF36. 
 
Domain Group Mean SD t df p 
 Physical 
Function 
Treatment 50.07 31.42 
-1.798 193 .074 No 
Treatment 
58.77 26.07 
Role 
Limitation 
Physical 
Treatment 40.98 35.38 
-1.131 193 .259 No 
Treatment 47.29 32.60 
Role 
Limitation  
Emotional  
Treatment 39.91 34.93 
-1.272 193 .205 No 
Treatment 46.86 31.10 
Vitality Treatment 48.64 24.77 
-2.172 193 .031 No 
Treatment 
57.31 24.93 
Mental 
Health 
 
Treatment 57.46 20.47 
-.898 193 .370 No 
Treatment 60.28 16.57 
Social 
Functioning 
Treatment 61.44 31.42 
.801 193 .424 No 
Treatment 
57.55 26.67 
Bodily Pain Treatment 70.03 29.39 
1.152 193 .251 No 
Treatment 
64.38 33.13 
General 
Health  
Treatment 52.54 27.019 
-.785 193 .433 No 
Treatment 
56.13 32.06 
Health 
Transition 
Treatment 55.28 34.70 
3.398 193 .001 No 
Treatment 
36.79 31.24 
 
by Schapira et al. was for patients who were treated with radiation therapy. Knowing that 
only one participant of the current study was treated with radiation therapy as a 
monotherapy, would make it more appropriate to compare the score results of this study 
with those reported by Albertsen et al. (1997) for patients treated with radical 
prostatectomy, which was 53.4. The same thing can be said about the domain of social 
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functioning. The reported score in this study was 60.38, which was only higher than the 
score of 58.9 reported by Schapira et al. for patients who were treated with radiation 
therapy. The second least score for the social function domain was reported by Litwin et 
al. (1997) which was 80 for patients who were treated with radical prostatectomy. The 
scores of bodily pain are of no difference. It was only the scores reported by Schapira et 
al. for patients who were treated with radiation therapy lower than those scores reported 
in this study. In general, it can be inferred that all the scores reported for the sub-domains 
of the SF-36 were less than those reported in the literature for patients who were treated 
with radical prostatectomy.  
Though, one cannot infer that the scores are actually different and that this 
difference among scores could be merely due to chance or sample fluctuation. To 
examine if these differences were not due to chance or sampling errors, the t test using 
the following formula was calculated for all studies that reported needed information 
(mean, standard deviation, and number of participants) to calculate the t test (Munro, 
1997): 
 
 
 
The results of the comparison of t tests are presented on table 4-20. As the sample 
of this study was 195, the degree of freedom (df) for this study and any other study will 
be more than a 120, therefore, the critical value of 1.98 at an alpha of 0.05. is the value to  
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be used to infer the significance of the differences between the means reported in this 
study and the means reported in the studies reviewed in the literature. By examining the 
results of means for SF36 quality of life scores and t tests, it is noticed that the means 
reported in this study are less than all of those reported in table 4-20 and the t values were 
more than the critical value of 1.98 which reflect that all of these differences were 
statistically significant.  
Such low scores can be interpreted in two different ways. First, the low scores 
reported in this study compared to those reported in the literature could be related to the 
fact that this study was conducted in a developing country, while those reviewed in the 
literature were conducted in developed countries including USA, Canada, Germany, 
Italy, and Japan. Developed countries have more facilities that will help men to discover 
prostate cancer earlier than their counterparts living in developing countries and they 
have more advanced medical technology and more experienced physicians than 
developing countries. Therefore, it is expected that patients living in developed countries 
to have a better level of QOL than those living in a developing country such as Gaza 
Strip. 
Second, the low scores reported in this study could be related to the unique 
situation that surrounds Gaza Strip. Blockade and economical sanctions had been 
imposed against Gaza since June 2006 and were tightened on May 2007. Blockade and 
economical sanctions affected the medical supply incluging medications that are needed 
for patients living in Gaza. Furthermore, they limited the number of patients who would 
travel to receive treatment outside Gaza Strip (Association of International Development 
Agencies, 2010 and World Health Organization: West bank & Gaza, 2010). Such 
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shortage in medical supplies and limited chances for patients to travel to receive 
treatment outside Gaza might attributed to the low scores reported by men participated in 
this study. Finally, those low scores reported in this study could be related to both 
blockade and living in a developing country.  
 
Prostate-Specific QOL (Prostate-Specific Index) 
 
The Prostate-Specific QOL variable contains 6 domains; urinary function (UF), 
urinary bother (UB), bowel function (BF), bowel bother (BB), sexual function (SF), and 
sexual bother (SB) (Litwin et al. 1998). The mean for prostate specific quality of life 
scores for the entire sample was 51.29. It was 46.74 for the group that were receiving 
treatment at the time of data collection while it was 63.49 for the group that were not 
receiving treatment (Table 4-15). The result of the t test showed that there was a 
statistically significant difference (p less than 0.001) between the means of the prostate 
specific QOL scores of the two groups. Such lower scores for the group of participants 
who were receiving treatment at the time of data collection could be attributed to the 
consequences and side effects of the treatment that they were receiving.  
Table 4-21 summarizes the mean scores of QOL for the 6 domains included in the 
prostate-specific index for the total sample and for the group of participants who were 
receiving treatment and who were not receiving treatment at the time of data collection. 
The highest scores were those for BB and BF domains and the lowest scores were for the 
SF and UB (22.23 & 46.31 respectively). In general, participants who were not receiving 
treatment at the time of data collection reported higher scores than those who were 
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Table 4-21: Descriptive Statistics of Means of QOL for PCI-QOL Domains. 
 
 All participants Participants were 
receiving treatment  
Participants were not 
receiving treatment  
Mean Std. Div Mean Std. Div Mean Std. Div 
Urinary function 62.32 31.00 59.95 31.87 68.65 27.88 
Urinary bother 46.28 38.44 41.55 37.29 58.96 38.94 
Bowel function 86.71 16.97 86.00 16.12 88.61 19.09 
Bowel bother 90.26 21.57 90.32 21.23 90.09 22.65 
Sexual function 22.24 29.39 13.63 24.30 45.30 29.61 
Sexual bother 53.08 29.22 50.18 29.55 60.85 27.08 
 
receiving treatment at that time in all domains except the BB domain as the scores were 
almost equal.  
To compare if there were any statistically significant differences between the 
mean scores of QOL of these six domains between both groups, t test was done and 
results showed (Table 4-22) that there were statistically significant differences between 
the mean scores of participants in the two groups in the areas of UB (p = 0.005), SF (P < 
0.001), and SB (p = 0.023).  
To the contrary of the scores reported by participants of this study for the SF-36 
sub-domains, all the scores of the sub-domains of the PCI-QOL fell within the range of 
the reported scores in the literature with the exception of urinary bother which was much 
less than the least reported score in the literature (Table 4-14). The scores reported by 
participants for the urinary bother sub-domain were 42.8 compared to the least score of 
69.5 reported in the literature by Lubeck et al. (1997).  
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When the t test was calculated to compare the means of PCI QOL reported by 
participants of this study and those reported in the literature (that reported the needed 
information to calculate the t tests), it was found that the scores of urinary function and 
urinary bother were less than the means reported in the literature(Table 4-20). The results 
of the t test showed that these differences were statistically significant (result of t tests 
exceeded the critical value of 1.98).  The difference was larger in the urinary bother 
domain. The mean of score for urinary bother reported by participants of this study was 
46.28 while the lowest score was 74.30 reported by Karakiewicz et al. (2003). This huge 
difference in the urinary bother scores could be related to the fact that being clean of 
urine and stool is one of the requirements for any Muslim for praying. When Muslims  
 
Table 4-22:  Independent Samples Test for Means of QOL for PCI-QOL Domains.  
 
Domain Group Mean SD t df p 
Urinary 
Function 
Treatment 59.95 31.87 
-1.750 
 
-1.750 
 
-1.750 
 No Treatment 68.65 27.88 
Urinary 
Bother 
Treatment 41.55 37.29 
-2.866 -2.866 -2.866 
No Treatment 58.96 38.94 
Bowel 
Function 
Treatment 86.00 16.12 
-1.750 
 
-1.750 
 
-1.750 
 No Treatment 88.61 19.09 
Bowel 
Bother 
Treatment 90.32 21.23 
-2.866 -2.866 -2.866 
No Treatment 90.09 22.65 
Sexual 
Function 
Treatment 13.63 24.30 
-1.750 
 
-1.750 
 
-1.750 
 No Treatment 45.30 29.61 
Sexual 
Bother 
Treatment 50.18 29.55 
-2.866 -2.866 -2.866 
No Treatment 29.55 60.85 
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prepare themselves for their prayers, they clean themselves from residuals of urine and 
stool by toilet paper and water before they proceed to purification which includes 
washing several body parts with water. Although the laws of Islam give a special 
permission for patients who cannot control their urination and/or defecation; people, 
especially the elderly, are very hesitant and feel inferior and stressed to use such 
permissions and they prefer and act to be clean as their counter partners who are not 
suffering from their disease conditions.     
The relatively high scores for bowel function and bowel bother were due to the 
fact that not so many patients used radiation therapy as a monotherapy or along with 
other adjunct treatment modalities. Side effects that affect bowel function and leads to 
bowel bother are most likely due to radiation therapy. When t tests were calculated to 
examine the significance between the reported scores by participants of this study and the 
scores reported in the literature for bowel function and bowel bother, the majority of the t 
test values showed that there were statistically significant difference between the results 
(Table 4-20). 
Although the scores reported by participants about sexual function was low 
(22.24), the scores reported about sexual bother were much higher (53.08). The same 
huge difference between scores of sexual function and sexual bother was noticed in the 
reviewed studies that were summarized in Table 4-14. Such differences could be related 
to the fact that these men whose mean age was 70.29 (± 8.80) had accepted changes in 
their sexuality and related these changes to the process of aging and not to the impact of 
the disease or its treatment on their sexual functioning. In fact, Gacci et al. (2005) found 
that there was no correlation between sexual function and sexual bother domains and  
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suggested the each domain to be treated as a discrete construct and to be considered 
separately. When t tests were calculated to examine the significance between the reported 
scores by participants of this study and the scores reported in the literature for sexual 
function and sexual bother, all the t test values showed that there were statistically 
significant differences between the results except for the Karakiewicz et al. (2003) study 
for the sexual function and the Gacci et al. (2005) for the sexual bother domain as the t 
results did not reach to the critical value of 1.98 (Table 4-20). 
 
Total Quality of Life 
 
Total quality of life includes the mean of all variables related to quality of life 
(those related to general health QOL and to prostate-specific QOL). The total QOL for all 
participants was 52.09. The mean of the total QOL for participants who were receiving 
treatment was 49.67 while it was 58.56 for those participants who were not receiving 
treatment.  The results of t test showed that there was a statistically significant difference 
between the means of the total quality of life (t=291, df=193, & p= 0.004) of the scores 
of participants who were receiving treatment and the scores of participants who were not 
receiving treatment at the time of data collection. Unfortunately, none of the studies 
reviewed in the literature reported on the total score for QOL but they reported on the 
scores of each individual sub-domain of the general QOL (SF36) and/or those related 
directly to prostate cancer.  
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Relationship between Quality of Life and Treatment Modalities 
 
Analysis of variance (ANOVA) test was run to examine if there were any 
statistically significant differences in the level of general QOL, prostate specific QOL, 
and total QOL among participants using various treatment methods. Results (Table 4-23) 
showed that there were no statistically significant differences among the mean scores of 
general QOL (p=0.272) and total QOL (p=.090) and the use of different treatment 
modalities, while there was a statistically significant difference of the mean scores of 
prostate specific QOL (p=0.008). The statistical difference among the means of PCI QOL 
was due to the difference between the means of PCI QOL for patients used prostatectomy 
(mean=59.47)and patients who used hormonal therapy options (mean=46.22) as the p 
value was 0.015. 
 
Table 4-23: Results of Analysis of Variance to Examine Impact of the Use of Different 
Treatment of Prostate Cancer on Total QOL, General QOL, and Prostate-Specific 
QOL. 
  Sum of 
Squares df 
Mean 
Square F Sig. 
General 
quality of life 
 
Between Groups 
Within Groups 
Total 
4276.183 
88627.095 
92903.279 
7 
183 
190 
610.883 
484.301 1.261 .272 
Prostate 
Specific Index 
QOL 
 
Between Groups 
Within Groups 
Total 
7148.938 
66257.513 
73406.451 
7 
183 
190 
1021.277 
362.063 2.821 .008 
Total QOL  
Between Groups 
Within Groups 
Total 
4488.961 
65214.374 
69703.335 
7 
183 
190 
641.280 
356.363 1.800 .090 
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 ANOVA test was repeated to examine if there were any statistical differences 
between the QOL of participants who used different treatment modalities in the group 
was receiving treatment at the time of data collection and the group which was not 
receiving treatment at the same time. Results showed that there were no statistical 
differences in QOL related to treatment modalities in both group in all three domains 
(total QOL, PCI QOL, and SF36QOL). The p values were ≥ 0.210 in all results. These 
results reflected that patients who were treated with prostatectomy (mean=59.47) enjoyed 
better QOL in the domains included in prostate-specific QOL (UF, UB, BF, BB, SF, and 
SB) than those treated with hormonal therapy (mean=46.22). The difference between the 
two means was found to be statistically significant (p=0.018). In fact, this was expected 
as usually prostatectomy is used as a curative option to treat localized prostate cancer 
(Turini et al., 2003) while hormonal therapy is usually used (alone or along with other 
treatment options) as a palliative option to treat advanced prostate cancer (Albaugh and 
Hacker, 2005). It can be also given for patients with localized tumor who are unfit for 
curative treatment (Fourcade et al., 2009).   
Unfortunately, not so many studies reported about the quality of life for prostate 
cancer men treated with hormonal therapy. Only one study was found to compare 
between QOL of patients received different treatment options including the use of 
hormonal therapy (Namiki et al, 2007). The scores of the prostate-specific QOL reported 
in this study and by Namiki et al. are summarized in Table 4-24. The comparison 
presented in Table 4-24 shows that participants of this study had much lower scores than 
the scores reported by Namiki et al for Japanese men in all domains with few exception. 
Participants of this study treated with prostatectomy showed higher scores in the bowel  
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Table 4-24: Comparison of Prostate-Specific QOL Scores Reported in this Study and by 
Namiki et al. (2007) 
 
 
PCI Domain 
This study Namiki et al. (2007) 
Prostatectomy Hormonal Prostatectomy Hormonal 
Urinary Function 70.57 58.06 74 94 
Urinary Bother 56.71 41.94 78 86 
Bowel Function 89.66 89.08 90 87 
Bowel Bother 92.07 92.74 92 90 
Sexual Function 34.29 12.20 14 14 
Sexual Bother 54.88 45.56 59 74 
 
bother and sexual function domains, while those treated with hormonal therapy showed a 
slightly higher scores in the domains of bowel bother and bowel function than those 
reported by Namiki et al.   
The literature reported that the use of prostatectomy don‟t cause bowel 
dysfunction as much as radiation therapy (Potosky et al., 2000) and patients treated with 
prostatectomy reported higher scores in the bowel dysfunction and bowel bother 
domains. On the other hand, compared to prostatectomy, radiation therapy causes fewer 
sexual side effects (D‟Amico et al., 1997), but it still cause some erectile problems for 
men (Potosky et al., 2004) and other urinary complications such as urinary incontinence 
and irritation (Brandeis et al., 2000). On another study by Potosky et al. (2000), patients 
treated with radiation therapy reported less experience of urinary incontinence (3.5%) 
than those treated with radical prostatectomy (9.6%), less leakage of urine (2.3% 
compared to 13.8%), and less urinary frequency and bother than those treated with 
radical prostatectomy. Potosky‟s et al. (2000) study further added that impotence was less 
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common among patients treated with radiation than with prostatectomy (61.5% compared 
to 79.6%) and sexual bother was less common among younger patients who were 55-59 
years old (25.3% compared to 59.4%). Unfortunately, the results of this study could not 
provide any comparison between QOL of men treated with prostatectomy and radiation 
therapy as only one participant reported that he was treated with radiation as a 
monotherapy.   
 
Barriers to Health Care 
 
 After examining the scripts of the participants‟ responses, emerging themes were 
identified and coded into the following major concepts: barriers due to unavailability, 
organizational barriers, geographical barriers, socioeconomic barriers, and barriers 
related directly to the blockage imposed on Gaza Strip. Under the umbrella of each 
concept, there were several sub-concepts that had emerged (Figure 4-1).  
In general, it was noticed that the percentage of patients who reported having at 
least one barrier was much higher among participants who were still receiving treatment 
at the time of data collection than those who were not receiving any treatment at that 
time. In total, 119 participants (61.02) reported facing some barriers at a certain point of 
their treatment time. From the 142 participant who were receiving treatment, 107 
participants (75.35%) reported having at least one barrier to health care. From the group 
was not receiving treatment (n=53), only 12 participants (22.64%) reported having some 
barriers to health care at a certain point. The barriers reported by participants of this study 
were compatible with the barriers reported in the literature with the exception of 
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those barriers related directly to the impact of the blockade imposed against Gaza Strip 
(McKinlay, 1972; McCullock-Melnyk, 1988; Estrada et al., 1990, Trevino, and Ray 
1990; Margolis, et al., 1995; Battista, Williams, and MacFarlane, 1996; Weinick et al., 
1997; Demark-Wahnefried, 1995; Bennett, 1999; Beckman, et al. 2000; Weinrich, 
Reynolds, Tingen, and Starr 2000; Chin, et al., 2001; Rutten, Nelson, and Meissner, 
2004; the American Medical Student Association, 2009). 
 
Barriers Related to Unavailability 
 
 Participants reported that several items and services were not available at the 
health care system in Gaza. These items included drugs, equipments, reagents for some 
diagnostic procedures, and the absence of the radiation therapy option. The most 
commonly reported missing item was drugs. Many participant (n= 86) reported that drugs 
were not available at some point at the governmental health system during their treatment 
time. In case needed drugs were available at the drug stores outside the governmental 
health system, those who could afford to buy them had to pay for it from their own 
money. And in case drugs would not be available at other drug stores or if participants 
could not afford to buy them, they would stay without their drugs until they would 
become available at the pharmacies of the medical centers at the governmental health 
care system. In response to lack of certain drugs, doctors had to prescribe other available 
drugs that were not as effective as the needed drugs. One participant mentioned: 
Drugs are not available at most of the times; therefore, the doctors had to change 
me to another drug. The problem was that the first drug was very expensive as I 
need about 2000 New Israel Shekel (NIS) each month, which I can‟t afford. 
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 For this participant, he could not afford to buy his medication because it would 
cost him too much to get his monthly supply of the drug as he needed about 2,000 NIS 
(1$= 3.8 NIS). This amount of money is more than the monthly income for a new 
graduate nurse. Even for those participants who could afford to buy the drug from private 
drug stores, they, sometimes, faced the same problem that the drug was not available. 
Twenty seven participants mentioned that when they looked for the drugs at the private 
drug stores, they were not available. Therefore some participants had to find their own 
way to get their drug supply. For some participants, as one mentioned, they asked friends 
or relatives in Egypt to buy the drug for them and pass it to Gaza from one the tunnels 
used to smuggle goods and food from Egypt to Gaza:  
The drugs are not available at the government pharmacies. They are not available 
at outside drug stores too. Therefore, we have to call our friends and relatives who 
live in Egypt and ask them to buy these drugs and we smuggle them from the 
tunnels under the border between Egypt and Gaza Strip. 
 
 Others who had some friends or relatives living in West Bank or in Israel, they 
asked them to buy the drugs for them and they had to wait until any person would pass 
into Gaza and send the drug with him/her. For those who couldn‟t manage to get their 
drugs from Egypt or any other place and those who could not afford to buy their drug 
supply from private drug stores, they had to spend the time without taking their drugs 
until it becomes available again at the governmental health system. This could take 
several weeks or several months, and it would affect their level of health and their QOL. 
One participant summarized his suffering as follow: 
Drugs were not available sometimes at the hospital pharmacy. I used to take my 
drug (from the pharmacy at the governmental health care system) every 15 days. 
Sometimes I come to the hospital to get my drug and it was not available. I looked 
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at the outside drug stores; it was not available there too. What shall I do? I had to 
spend the time without treatment until the drug becomes available at the hospital. 
 
To overcome the problem of unavailability of their drugs in neither the 
governmental health care system or at the private drug stores, some participants 
mentioned that they sometimes had to buy drugs that had passed its expiration date by 
several months, as expressed by one participant:  
One time, the drug I used to take, was not available neither at the hospital nor at 
the outside drug stores. I and my children looked for it in all the drug stores that 
we know until we found it at one store, but it was expired for about 6 moths. I 
decided to buy it and to take it. I thought it was better than staying without taking 
any drug. 
 
Other participants expressed that the lack of drugs had affected negatively their 
health status and this was reflected on the level of their Prostate-Specific Antigen (PSA) 
results.  
After I had a bone scanning done to me in Egypt, the treating physician prescribed 
to me a hormonal therapy called „Cadex,‟ or its substitute. The doctor wrote a 
report about this issue and gave it to me. But when I came back to Gaza, I gave 
the report to the doctors at the hospital. The doctors told me that neither the drug 
nor its substitute was available at the pharmacy at the governmental hospital at 
that time. I spent several weeks without the drug.  This resulted in the elevation of 
my tests levels (means the PSA level), which negatively affected my health. 
  
Other items that were reported as “unavailable” by other participants were the 
lack of some equipments and chemical reagents for some diagnostic procedure. Nine 
patients mentioned that at some point some equipment were not available for either their 
treatment or their diagnoses. The result then would be waiting for the equipment to 
become available or waiting for a referral to be treated outside Gaza Strip then waiting 
again for either a permission to pass Israel to receive treatment either in West Bank or in 
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an Israeli hospital or waiting for the border to open so that they can travel to Egypt to 
receive treatment. One participant summarized his concerns: 
The machine needed for bone scanning is not available in Gaza, therefore, we 
have to wait until we get a referral either to Egypt or to Ramallah (in West Bank) 
to do this. Only Allah (God) knows if we will get the referral and if will be able to 
travel. 
 
Other participants (n=13) expressed their frustration about the lack of the 
diagnostic equipments and some chemical reagents that needed for diagnostic procedures. 
Such lack would delay the diagnoses for their cases which will result in physical and 
emotional distress. One of them mentioned: 
The lack of the diagnostic equipments is one of the big barriers. It‟s true that they 
took a biopsy from me, but they sent it to outside laboratories (laboratories 
outside the governmental health care system) and the result took so much time to 
appear. You can imagine how my emotional and psychological conditions were at 
that time while I was waiting for the result. 
 
Besides the direct impact of restricting patients to travel outside Gaza Strip to 
receive treatment, the blockade affected several domains of quality of life of people 
living in Gaza Strip. The impact of the blockade on quality of life in general and on 
health-related quality of life in particular was well recognized by international 
organizations including the United Nations (UN) and the World Health Organization 
(WHO). For example, on the  20
th
 of January 2010, Max Gaylard, the Resident 
Humanitarian Coordinator for the occupied Palestinian territories (oPt), said:  
The continuing closure of the Gaza Strip is undermining the functioning of the 
health care system and putting at risk the health of 1.4 million people in Gaza. It 
is causing on-going deterioration in the social, economic and environmental 
determinants of health. It is hampering the provision of medical supplies and the 
training of health staff and it is preventing patients with serious medical 
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conditions getting timely specialised treatment outside Gaza (Association of 
International Development Agencies, 2010, p. 1).  
 
Many participants of this study reported that so many items were not available at 
the health care system in Gaza including drugs, equipment, chemical reagents needed for 
diagnostic procedures and the lack of the radiation treatment option. Lack of drugs at 
some point was reported by participants as the most missing item from the health care 
system in Gaza. Usually, drugs, equipments, and other medical supplies are provided to 
Gaza from Rammallah stores in the West Bank or could be provided directly to Gaza 
when some humanitarian organizations succeed to challenge the siege and enter Gaza 
through the Mediterranean Sea or from the Egyptian borders. At either case, the 
importation of the supplies is contingent on the permission of the Israelis to let the 
supplies provided from Rammallah to enter into Gaza and the permission of the 
Egyptians to open the borders between Gaza and Egypt which used to be opened for 
limited hours per day for two to three days every one to three months.  
According to the reports of the Association of International Development 
Agencies (2010) and the World Health Organization: West bank & Gaza (2010), 
disposables and drug supplies were generally allowed into Gaza, but there were usually a 
shortage of some items on the ground. For example Table 4-25 shows that between 
March and December, 2009, shortage in drug supplies ranged between 14-30% while 
shortage of medical disposables ranged between 10-20%. The list for essential drug 
supply includes 480 drugs while the list for essential medical disposables includes 700 
items (World Health Organization: West bank & Gaza, 2010). 
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Table 4-25: Percentages of missing drugs and medical disposables in the stores of 
ministry of health in Gaza Strip. Source: World Health Organization: West bank & Gaza 
(2010). 
 
Store  
 
Mar.  Apr.  May  Jun.  Jul.  Aug. Sept. Oct.  Nov.  Dec.  
Drugs 30%  14% 17% 15% 16% 22%  29%  16%  26%   
Disposables  10%  13% 14% 16% 20% 15%  14%  17%  17%  18%  
 
At the same time, both reports recognized that certain types of medical 
equipments including those needed for x-ray and other electronic devices were very 
difficult to be brought into Gaza. Furthermore, the reports added that in many times, 
provided equipments were either broken or out of date and spare parts were not available 
(Association of International Development Agencies, 2010 and World Health  
Organization: West bank & Gaza, 2010). For example, the computerized tomography 
scanning (CT scan) machine at Gaza European Hospital, which is one of the two medical 
centers that provide oncology care in Gaza Strip, was broken for more than a year. Parts 
were not allowed, so far, to be supplied to MoH to repair it. Such lack of equipment and 
drug supply will hamper the quality of provided health care to patients living in Gaza 
Strip and therefore their QOL. 
The issue of lacking some medical supplies or drugs was not mentioned 
extensively in the literature. A few studies had reported about this issue. For example, 
based upon the data from the Medical Expenditure Panel Survey Household Component, 
Weinick et al., (1997) found that inability to afford health care services was reported by 
about 60% of families as the major barrier for family members to receive the needed 
health care. Other literature (McKinlay (1972, McCullock-Melnyk, 1988) reported about 
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the refusal of health insurance to cover the expenses of the services or the cost of the 
drugs not on the lack of the services or drugs themselves.  
   Gaza Strip has a unique situation due to the pertaining political situation that 
prevails in the area. Such a situation contributed to the lack of several drugs, equipments 
and supplies to be available at the medical centers that provide oncology care. Besides 
that, Abed (2007) included that there is a lack of several services at the MoH and he 
attributed this lack to the inability of the MoH to finance such services which depends on 
donating countries which covers about 50% of the budget of the MoH. Such constraints 
on the health care system can impede the delivery of care for beneficiaries (Mandelblatt, 
Yabroff, and Kerner, 1999) and alter the quality of care that is provided to people living 
in Gaza Strip.  
Not so much literature addressed the availability of drugs, equipments, and 
offering other services in the health care system. For example Battista, Williams, and 
MacFarlane (1996) reported that the lack of radiation therapy was one of the barriers to 
health care reported by adult cancer patients. Weinick et al. (1997) reported that lack of 
appropriate equipments was a barrier for health care utilization and Estrada et al. (1990) 
reported that care was not available when needed.   
 
Organizational Barriers  
 
 Several barriers were reported under the concept of organizational barriers. The 
sub-concepts emerged under the organizational barriers included: long waiting time, 
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incompetent physicians, physicians are not available at their offices, complicated referral 
process for treatment abroad, and long time to hear about the results of their diagnosis. 
The oncology outpatient clinics opens between 8:00 am to 1:00 pm. Usually, 
patients do not have exact appointments for follow up. Therefore, they are served on the 
basis of “first comes, first served.” After the patient is seen by the treating physician, he 
will go to the pharmacy to collect his medication. If he needs a drug, such as an injection 
or a chemotherapeutic agent, he will go to the oncology nurse to receive his treatment 
then he will go home. Depending on how much busy is the clinic at that day, the process 
may take between 30 minutes and up to more than four hours. Usually, the clinic gets 
busy at the beginning of the month, the time the drugs are delivered to the pharmacy.   
Fifty one patients had expressed their feelings that the waiting time was too long 
to them. The reported waiting time varied between two and four hours. One participant 
reflected his frustration about the long waiting time by saying: 
Waiting time is too long. It is really long. Sometimes it takes me about 4 hours to 
wait in order to be seen by the doctor. It is very boring. I have to bring my wife 
with me each time I come to the clinic so that I can find someone to talk to. 
 
 Some times the rule of “who comes first served first” is violated by health care 
personnel who sometimes allow their family members, friends, and acquaintances to be 
seen by the doctors without following the order they came to the clinic. This usually leads 
to prolonging the waiting time for other patients and occasionally leads to verbal or 
physical violence among waiting patients and personnel. One participant expressed his 
feelings:  
Employees in the health care system do not follow the order for seeing the 
patients. Some patients come late, but because they know someone in the hospital, 
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they will be seen by the doctor before the patients who have been waiting for 
hours. Some doctors too allow the patients who come to their private clinics to be 
seen before us who were waiting for hours outside. 
 
 The process even becomes more complicated and the waiting time becomes even 
longer, according to some participants, as some physicians leave their offices for long 
periods of time which leads to frustration among the waiting patients. Physicians are 
employed by the MoH and they are supposed to stay in their offices during the working 
hours to see their patients. But because the system doesn‟t enforce a disciplinary action 
policy, some physicians leave their offices to chat with other colleagues or go home 
early.  
 Seven participants expressed lack of confidence in their physicians and described 
them as being incompetent. This is in fact a general feeling in Gaza Strip about the 
competency of physicians, especially about young physicians who graduated from the 
former Soviet Union counties and Romania. The reputation of graduates from these 
countries is not good as people heard so many stories about how these graduates pass 
their exams by paying money or buying presents to their professors. One participant 
described his concerns as: 
The doctors here (in Gaza Strip) are not good. They don‟t understand anything in 
medicine. For example, one doctor told me that my treatment is by passing a tube 
into my urethra and take small chips of the prostate (Trans-Urethral Resection of 
Prostate). Another doctor told me that the prostate should be removed by a 
surgical operation. A third one treated me for urinary tract infection. The issue is 
that there are no doctors who are competent in the area of urology. When I went 
to Palestine Hospital in Cairo, the doctor there asked to do some tests for prostate 
cancer, but here, none of the doctors; I went to, asked for this test. 
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 Fifteen participants expressed that the process of getting a referral to be treated 
abroad (outside Gaza Strip) was very complicated. Usually the process is time consuming 
and has to be signed by several doctors and other personnel from the Ministry of Health. 
With the presence of blockade, the process even became more complicated. This is 
related to the blockade itself, therefore, the MoH work to limit the number of the referred 
patients to the lowest possible number, so that when the borders open, it will be much 
easier to manage the process for a smaller number of patients.  
 Five more participants reported that the results for the diagnostic tests and 
procedures took too much time and that such a long time of waiting for them is very 
difficult. One participant expressed his feelings as: 
The result of the diagnostic tests takes so much time. One time, the result of the 
PSA took about a month and a half as the material (reagent) was not available 
because of the blockade. You can‟t imagine how my condition was while I was 
waiting to hear about the results. I was living in sever distress for that period of 
time. 
  
Organizational barriers reported by participants of this study are not unique. The 
reported barriers are consistent with what had been reported in the literature. For 
example, Weinrich, et al. (2000) mentioned that participants in their study reported that 
doctors‟ hours were not convenient. The long waiting time, in spite of having a previous 
appointment, was reported as a barrier to heath care by McCullock-Melnyk (1988), 
Estrada et al. (1990), Weinick et al. (1997), Bennett, 1999, Beckman et al. (2000), Chin 
et al. (2001), and the American Medical Student Association (2009). Long waiting time 
was not the only time-related barrier reported in the literature. Some studies also reported 
that participants complained about waiting too long to get an appointment or that there 
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was a long time between appointments themselves (Estrada et al., 1990; Weinick et al., 
1997; Chin et al., 2001; the American Medical Student Association, 2009). 
Because sometimes some physicians were not available at their offices, patients 
had to wait for them until they come back or in some instances, they would see another 
physician. Seeing a different physician may lead to interruption and inconsistency in the 
treatment plan. Demark-Wahnefried (1995) reported that not having a regular physician 
was reported by both blacks and whites as a barrier for prostate cancer screening. 
Margolis et al. (1995) identified limited availability of health care providers as a barrier 
to health care while Rutten, Nelson, and Meissner (2004) reported that having „no 
physician‟ was a barrier for pap smear and mammography which are used to screen for 
cervix and breast cancers. 
The participants of this study were not unique in mistrusting their physicians. 
Others had reported that mistrust of health care recipients in their physicians was one of 
the barriers that impeded the utilization of health care services (Powell, Gelfland, 
Parzuchowski, Heilbrun, and Franklin, 1995; Robinson, Ashley, and Haynes, 1996). 
Although barriers to referring patients to be treated in a different country was not 
reported in the literature, but participants in the Weinick et al., (1997) study reported that 
in some instances, referrals required by the insurance companies were not obtainable. 
Other organizational barriers that were reported in the literature included the lack of 
support personnel (Drass et al., 1998).   
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Communication Barriers 
 
 Some of the participants (n=24) complained that the treating physicians and other 
health care professionals were not considering their emotional status when they talked to 
them and felt that they were humiliated by the way the physicians talked to them. They 
thought that they need and deserve special treatment and communication methods when 
they communicate with them as they felt that being diagnosed with cancer is a big issue. 
One participant described the way his doctor talked to him: 
Some of the doctors don‟t think that we are human beings. We are like them, flesh 
and blood and have feelings like they have. Some of them (the doctors) are 
inconsiderate to what we feel. It is enough to be diagnosed with cancer. They 
should put this into their consideration and know how to deal with us.” 
 
 Another participant confirmed: 
I don‟t know how these doctors deal with us. They think that we are less 
than animals and have no feelings. For example, one of the physicians told me 
that whether I take the medication or not, the disease (cancer) will spread all over 
my body. Even if this is a true, he should give me more information about my 
condition and instruct me about what to do to prevent or limit the spread of cancer 
to other parts of my body. 
 
Six participants complained about the medical jargon that some doctors used 
when they communicated with them. They expressed that sometimes they were nodding 
their heads to convey to those doctors that they understood what they were saying while 
they did not understand anything. They even complained that if they (the participants) 
will go to the private clinic of the same doctor, they will be treated much better and that 
the doctor will spend more time to explain for them about their health condition and to 
discuss with them what to do and what not to do. 
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 The reported communication barriers by participants are consistent with the 
literature. For example, the participants in Estrada‟s et al. (1990) study reported that 
health care staff was disrespectful. Weinick et al. (1996) and Chin et al. (2001) added that 
communication problems were one of the most common reported barriers to health care. 
Furthermore, Mandelblatt et al. (1999) mentioned that health care providers are usually 
not prepared well to communicate with patients diagnosed with cancer especially when 
communicating the complexities related to cancer care, treatment, and its complications 
to their clients. On the other hand, the Center for Universal Design and The North 
Carolina Office on Disability and Health (2009) added that communication skills and the 
pattern of communication between providers and clients, especially those who are 
disabled, is a major barrier to health care that could lead to frustration among that 
vulnerable group of clients.  
McCullock-Melnyk, 1988; Mandelblatt et al. (1999); and Chin et al. (2001) 
reported that some of the major barriers to health care and health education were related 
to language and cultural differences among health care providers and health care 
recipients. Such differences in language and culture may alter the process of 
communication between providers and recipients of health care services. The good thing 
about Gaza Strip is that all people are speaking the same language and have the same 
cultural backgrounds; therefore, neither culture nor language by itself were reported as 
barrier to health care.  
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Socioeconomic Barriers 
 
Under the socioeconomic barriers, several sub-concepts emerged. These sub-
concepts related to the high cost of drugs, diagnostic procedures, and private doctor 
visits. Many participants reported that they could not afford to buy these expensive drugs 
or to go to the private clinics of their physicians. A few number of participants reported 
that they even could not afford to pay for their transportation to go to the medical centers.  
Since the siege was imposed on Gaza Strip on June 2006, living in Gaza became 
very hard. A large number of people who used to work in Israel lost their jobs and 
therefore, their income. Besides that, the expenses of living became very high as the 
quantity of so many goods became limited in the market because of the blockade. As a 
consequence, poverty level increased among Gaza inhabitants and several families 
became unable to afford providing their basic physical needs. Such hardship affected 
prostate cancer survivors and several participants reported that when the drugs became 
unavailable at the governmental health care system and in case it was available at private 
drug stores, they could not afford to buy these drugs and they had to wait without drugs 
for several days, weeks, or months until the drug becomes available at the governmental 
health care system. 35 participants complained that the cost of the drugs were very 
expensive. One participant expressed his concerns:  
When the drug becomes unavailable at the hospital, my children look for it at the 
private drug stores. If they found it, it is usually very expensive. In one time, I 
bought 50 capsules of my drug. The cost was very, very expensive as it was 5,000 
NIS (About $1300). I could afford to buy the drug this time, but if it becomes 
unavailable one more time, I will not be able to buy it. Where shall I get the 
money to buy it? It is very expensive as you see. For me I could buy the drug at 
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that time, but most of other patients are not able to buy the drug at such an 
expensive cost. What shall they do? Shall they wait and die slowly? 
 
 For this participant, he could manage to buy his drug, but many other participants 
reported that they could not afford to buy theirs. One participant concluded: 
Sometimes my drug is not available. It is very expensive to buy from outside drug 
stores. I can‟t afford to buy it. Therefore, I have to wait without medication until 
the drug becomes available again at the hospital. I need to come back to the 
cancer clinic every few days to ask if the drug became available. What shall I do? 
Life became very difficult in this country after the blockade. This is our fate and 
we have no other choice. 
 
 Inability to afford to cover the cost of drug supply was not the only 
socioeconomic barriers. Few participants complained that they could not afford to cover 
for the cost of transportation to the medical health centers to see their doctors and obtain 
their drug supply.  
Because doctors show more interest and spend more time with patients when they 
go to visit them in their private clinics, some patients prefer to be seen at the private 
clinics of their doctors and they will come only to the governmental health centers to 
collect their drug supply. But not all participants can afford to cover the expenses to see 
their doctors at their private clinics. Some of them expressed their concerns about the 
high cost of seeing their doctors at their private clinics (visit cost between $10-15 for 
specialized physicians).  
 The high cost of services also applied to some diagnostic procedures. As 
mentioned previously, sometimes some diagnostic procedures or some chemical reagents 
are not available at the health care system; therefore, patients needed to do these 
procedures or tests at clinics or laboratories outside the health care system and cover for 
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their cost from their pocket money. Usually, the expenses for such procedures and tests 
are expensive and several participants expressed that they were not able to cover for their 
costs. One participant put it straight forward and said: 
The cost of treatment at the outside clinics (private clinics) and the outside 
diagnostic centers is very expensive. I can‟t afford to pay for seeing the doctors at 
their clinics or to do exams outside (means outside the health care system). I 
hardly can cover the cost of the basic issues for me and my family to live. 
Since the siege was imposed on Gaza Strip on June 2006, living in Gaza became 
very hard and the cost of living increased so high to become intolerable for many 
people.  
 
A large number of people who used to work in Israel lost their jobs and therefore 
their income. According to the Palestinian Central Bureau of Statistics (2009), over than 
140,000 citizens (constituting 41.5% of work force in Gaza) living in Gaza were 
unemployed in the first quarter of 2009. As a result, poverty level increased. According 
to a household survey conducted by ICRC (2009) in May 2008, over than 70% of Gaza 
families had less than one US dollar per day per person with about 40% of surveyed 
families were living on income of less than 0.5 US dollar per person per day.  
Besides that, the expenses of living became very high as the quantity of so many 
goods became limited or unavailable in the market because of the blockade. As a 
consequence, poverty level increased among Gaza inhabitants and several families 
became unable to afford providing their basic physical needs. Such hardship affected 
quality of life of most people living in Gaza including prostate cancer survivors. Due to 
their inability to afford buying their drug supplies, several participants reported that when 
the drugs were not available at the governmental health care system they could not afford 
to buy these drugs and they had to wait with no drugs for several days, weeks, or months 
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until the drug became available at the governmental health care system. Such a delay of 
drug would affect the health-related QOL of these patients.  
The literature had reported about issues related to cost and inability of patients to 
afford the expenses of health care. Weinrich et al. (2000) reported that participants with 
total family income of less than $59,000 per year were less likely to perform screening 
for prostate cancer than men who had higher family income. Chin et al. (2001) reported 
that diabetic patients and health care providers reported inability to afford buying devices 
to monitor their blood glucose at home as one of the major barriers to health care. Based 
upon the data from the Medical Expenditure Panel Survey Household Component, 
Weinick et al. (1997) found that inability to afford health care services was reported by 
about 60% of families as the major barrier for family members to receive the needed 
health care. 
On the other hand, Blazer, Landerman, Fillenbaum, and Homer (1995) reported 
that cost was a major reason for patients to delay seeking health care especially for those 
living in rural counties. Many others had also reported that the cost of health services, 
cost of transportation, and other financial issues were major barriers to health care 
(Estrada et al., 1990, McCullock-Melnyk, 1988, Weinick et al., 1996, Bennett, 1999, 
Mandelblatt. et al., 1999, Beckman et al, 2000, American Medical Student Association, 
2009, and Choice Regional Health Network, 2009).  
Other sociodemographic barriers reported in the literature such as barriers related 
to gender, social class, culture, race, and ethnicity were not reported by participant in this 
study. This could be due to the fact that all participants were males and all of their 
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doctors were males too. This is besides that people living in Gaza Strip had the same 
racial and cultural backgrounds and speak the same language. 
 
Geographical Barriers 
 
 Geographical barriers reported by the participants of this study included few sub-
concepts; distance, physical accessibility, and availability of public transportation. 
Physical accessibility was a very major barrier to health care utilization before September 
2005 (the time the Israelis pulled out from Gaza Strip). At that time, Israelis used to have 
checkpoints at the main roads between the major cities in Gaza Strip. One could spend a 
few minutes or several hours to pass from these check points. Sometimes, the Israelis 
used to block the major roads between cities up to several days that could extend to more 
than a week in rare occasions. As a result, several participants could not physically access 
either one of the two medical centers that provide oncology care at that time. In fact, most 
of the participants who mentioned physical accessibility as a barrier were from 
participants who had been diagnosed with prostate cancer before September 2005 and 
most of them had finished their treatment. After September 2005, physical accessibility 
became not a major concern as only a few number of participants reported that distance 
and availability of public transportation were a major barrier to health care at the current 
time. This is because the two oncology centers are located in strategic geographical 
positions to be accessible by patients (Figure 4-2). For example, Shifa Hospital is located 
at Gaza city which located in the middle of Gaza governorate and between the Northern 
Governorate and the Mid-zone Governorate. It serves participants from these three  
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Figure 4-2: Geographical Location of Shifa Hospital and Gaza European Hospital. 
 
166 
governorates. On the other hand, Gaza European Hospital is located between Rafah and 
Khanyounis Governorates and it is easily accessible by participants who live there. In 
general, the location of the two hospitals was accessible by most of the participants and 
public transportation was usually available and relatively the cost was not expensive. 
Only a few number of patients who lived away from major roads had reported 
geographical-related barriers. 
 Geographical and transportation-related barriers were reported in many studies. 
For example, Guidry, Aday, Zhang, and Winn (1997) reported that transportation was 
one of the major barriers for African Americans to cancer treatment. In another study, 
Blazer, et al. (1995) reported that transportation was a barrier to access health care 
services for those who live in the rural areas. McCullock-Melnyk, 1988; Weinick, et al. 
(1996); Guidry, et al., (1997) reported that physical proximity and distance between place 
of living and health care facilities was a barrier to health care. Other related barriers that 
were reported in the literature included not having transportation (Estrada et al., 1990), 
not having a car, inability to drive, lack of public transportation (Weinick, et al., 1996), 
lack of access to automobile and unavailability of someone to drive patients to health care 
facilities (Guidry et al., 1997). 
 
Blockade 
 
Blockade as a barrier is related directly to the barriers labeled under the titles of 
“unavailability” and “socioeconomic barriers.” In fact, most of the items that were not 
available within the health care system and the low socioeconomic status were due to 
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blockade. Usually, drug supplies, equipments, diagnostic reagents, and other stocks are 
supplied to Gaza either from the major stores located in Ramallah in the West Bank, or 
donated directly from donor countries or organizations to the health care system in Gaza.  
After the election which took place in Palestine in January 2006, Hamas, an 
Islamic political party that is not accepted by Israel and the Western countries, won the 
election and formed the government in April 2006.  Sanctions were imposed against Gaza 
Strip started at that time and were tightened after imprisoning an Israeli soldier by 
Palestinian military groups in Gaza Strip in June, 2006. Since that time, Israel limited the 
number and quantity of items that enter Gaza including food, fuel, and medical supplies. 
Besides that, Israel restricted the movement of people living in Gaza to leave Gaza Strip. 
As a result, the majority of patients who can‟t find treatment in Gaza Strip and used to be 
referred for treatment in hospitals in West bank, Egypt, Jordan, and Israel were prohibited 
to travel. The most affected categories of patients affected by the blockade were those 
who had cardiology and oncology problems (Association of International Development 
Agencies, 2010 and World Health Organization: West bank & Gaza, 2010).  
The process to travel outside Gaza for medical purposes is very complicated. 
After the patient gets a referral from the governmental health system (which is a 
complicated process as mentioned earlier), if they want to travel to West Bank or to 
Israel, they need to apply to the Israelis to get a permission to travel through the Gaza-
Israeli border. Israelis give a little number of permissions to patients. According to the 
fact sheet issues by World Health Organization: West bank & Gaza (2010), many patients 
were denied permission to cross Israeli borders to receive treatment. For example, in 
December 2009, 1103 patients applied to get a permission to cross the borders to travel 
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for treatment in an Israeli hospital or a Palestinian hospital at the West Bank. Out of 
them, 21% were denied these permissions or the permissions were delayed so patients 
had lost their appointment and had to start over to set a new appointment and start a new 
process to get a new permission to cross the Israeli borders (Figure 4-3 depicts the 
number of patients who were issued or denied a permission to cross the borders). Several 
patients died while waiting to get permission or because they were denied permissions to 
travel to receive treatment outside Gaza Strip. Figure 4-4 depicts the number of people 
from Gaza Strip who died while waiting for a permit to cross the Israel border to receive 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3: Result of Patients Application for Permit to Cross Israeli Borders. Source: 
World Health Organization: West bank & Gaza (2010, p.2).   
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Figure 4-4: Number of People Who Died While Waiting for a Permit to Cross the Israel 
Border to Receive Treatment between October 2007 up to December 2009. Source: 
World Health Organization: West bank & Gaza (2010.p.2).   
 
 
treatment between October, 2007 up to December, 2009 (World Health Organization: 
West bank & Gaza, 2010). According to the ministry of health (2010), up to March, 9th, 
368 patients from Gaza strip died because of the blockade.  
Indeed, many patients were denied such permissions under the excuse of “security 
reasons” which may apply to any person live in Gaza who himself or one of his 
immediate or extended family members were in prison, were injured, or killed due to the 
Israeli Palestinian conflict. On the other hand, patients who are referred to receive 
treatment in Egypt need to wait until the borders open and they will be lucky to pass at 
the first attempt as a few hundreds of travelers are allowed to pass at each occasion when 
the border opens. One participant summarized his agony about his inability to travel 
freely to Egypt by saying: 
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My treatment is in Egypt. The biggest barrier to me is the blockade. When I 
traveled to Egypt last time, I had to wait for three months in order to be able to get 
to Egypt. Now, I am scheduled for a follow up visit in Egypt and I am very worry 
that the borders will not be open in the near future and I will not be able to go to 
Egypt for my follow up appointment. 
 
 
Summary  
 
 The results of this study reflected that prostate cancer survivors living in Gaza 
Strip had reported lower scores of general quality of life than those reported in the 
literature for patients treated with prostatectomy and radiation therapy and used the 
UCLA-PCI instrument. Prostate-specific quality of life scores reported by participants of 
this study were congruent with those reported in the literature with the exception of the 
scores reported for urinary bother which were lower than those reported in the literature. 
Participants who were treated with prostatectomy reported higher PCI QOL scores than 
those treated with hormonal therapy. In general, scores of quality of life reported by 
participants who were not receiving treatment at the time of data collection were higher 
than those who were receiving treatment at that time which could reflect the impact of 
treatment on quality of life.  
 Results revealed that participants had faced many barriers to health care. These 
barriers were categorized into five major concepts: barriers due to unavailability, 
organizational barriers, geographical barriers, socioeconomic barriers, and barriers 
related directly to the blockage imposed on Gaza Strip. Under each concept, several sub-
concepts were identified. It was found that participants who were receiving treatment had 
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reported more barriers to health care than those who were not receiving treatment at that 
time. Lack of drug at the governmental health care facilities was the most reported 
missing item from the system. So many participants could not afford to buy these drugs 
when they were not available which had a negative impact on their health.  
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
This chapter summarizes the results of the study findings. Where appropriate, 
conclusions are derived. Then, implications and recommendations for the practice of 
health policy are discussed. In addition, recommendations for future areas of study are 
also outlined. Finally, limitation are discussed.  
 
Summary of Study 
 
Prostate cancer is one of the most common cancers among male population and it 
was the second most common cancer and the second cancer-related leading cause of 
death among Palestinian males (Ministry of Health, 2006). The incidence of diagnosing 
new prostate cancer cases is increasing as the Palestinian population is aging. In 
developed countries, the incidence of diagnosing new prostate cancer is increasing due to 
the use of digital rectal examination and prostate-specific antigen in screening for new 
cases (American Cancer Society, 2007a). The rate of cure of localized prostate cancer is 
very high (Turini et al., 2003). The use of different treatment modalities such as 
prostatectomy, radiation therapy, and hormonal therapy helped many prostate cancer 
survivors to live for longer periods of time than they used to live few decades ago.  
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Managing cancer itself and the consequences of its treatment became of 
paramount importance recently as patients now live longer and have to bear with the 
burdens of cancer itself and the consequences of its treatment (American Cancer Society, 
2007b). Such problems, if not taken into consideration, will result in longer or incomplete 
recovery, higher stress, and long-term impact on QOL (Gotay & Muraoka, 1998; Green 
et al. 2000).  Because the use of prostatectomy and radiation in treating localized prostate 
cancer provide similar curative results, issues related to QOL that accompany each 
treatment option become more important in the decision making about which treatment 
option to use (Turini et al., 2003). The use of radiation therapy produces bowel 
dysfunction and bowel bother while prostatectomy doesn‟t. Both options result in urinary 
dysfunction and bother and sexual dysfunction and bother. Though, radiation therapy 
produces less urinary and sexual symptoms (Potosky et al, 2000).   
As explained in chapter one nearly all of the studies related to QOL of prostate 
cancer survivors were conducted in developed countries and none was found to be 
conducted in a developing country. Further, no study addressed barriers to health care as 
perceived by prostate cancer survivors. For example, Lubeck et al. (1997); Albertsen et 
al. (1997); Litwin et al. (1998); Potosky et al. (1999); Stanford et al. (2000); Potosky et 
al. (2000); Schapira et al. (2001); Penson et al. (2003); Reis et al. (2004);  Jayadevappa et 
al. (2006); Arredondo et al. (2007); and Shikanov et al. (2008) examined QOL of prostate 
cancer survivors in the USA .Karakiewicz et al. (2003) examined QOL of prostate cancer 
survivors in Canada. Korfage et al. (2003) examined QOL of prostate cancer survivors in 
Germany. Gacci et al. (2005) examined QOL of prostate cancer survivors in Italy. 
Chapple and Ziebland (2002) examined QOL of prostate cancer survivors in United 
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Kingdom. Hedesting et al. (2005) examined QOL of prostate cancer survivors in Sweden. 
Ishihara et al. (2006); Namiki et al. (2007); and Wakatsuki et al. (2008) examined QOL 
of prostate cancer survivors in Japan. Oliffe (2005) examined QOL of prostate cancer 
survivors in Australia. Navon and Morag (2003) examined QOL of prostate cancer 
survivors in Israel.  Further, no study addressed barriers to health care as perceived by 
prostate cancer survivors. The purpose for this study was to evaluate the level of QOL 
and to assess the barriers to health care as perceived by prostate cancer survivors who 
live in Gaza Strip in an attempt to fill part of the gap in the literature related to QOL of 
prostate cancer survivors and barriers to health care in the developing countries. 
 In order to evaluate the level of QOL, the UCLA-PCI including the RAND 36-
Item Health Survey v2 (SF-36 v2) Health-Related Quality of life was used to evaluate the 
level of QOL for prostate cancer men living in Gaza Strip. Barriers to health care were 
assessed by using a semi-structured interview. The design for the study used both 
qualitative and quantitative approaches in data collection. 199 patients were recruited 
from the two medical centers that provide oncology care in Gaza Strip. 195 patients 
agreed to participate in the study with a response rate of 97.98%.  
 The findings of this study revealed that the mean age of participants was 72 years 
(± 8.81) and the mean of their age at time of diagnosis was 65.99 years (± 8.27). More 
than 55% of prostate cancer cases were diagnosed after the age of 65 years. Gaza 
governorate had a relatively higher percentage of men diagnosed with prostate cancer 
than the percentage of its male population. The majority of participants (72.8%) were 
receiving treatment at the time of data collection and most of them (60.5%) were treated 
at Shifa Hospital which has the major oncology center in Gaza Strip. The most common 
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method of treatment used as a monotherapy was hormonal therapy (31.8% of 
participants) followed by prostatectomy (21.0% of participants). Only one patient used 
radiation therapy as a monotherapy. The rest of participants used a combination of the 
different treatment options including chemotherapy. Most of the participants (87.2%) 
had, at least, one comorbidity with a current or a past history of smoking being the most 
common comorbidity followed by diabetes mellitus.          
 The findings of this study revealed that the scores of the general quality of life 
(SF-36 QOL) of prostate cancer men living in Gaza Strip was less than those reported in 
the literature in all domains of SF-36 with the exclusion of the scores reported by 
Schapira et al., (2001) for patients who used radiation therapy. The scores of all domains 
of Prostate-Specific Index fell within the range of scores reported in the literature with 
the exception of the scores of urinary bother. Participants‟ score for urinary bother was 
42.8 while the least score reported in the literature was 69.5 (Lubeck et al., (1997). This 
big difference in the urinary bother score could be related to the fact that being clean of 
urine and stool is one of the conditions any Muslim should have before praying. Further, 
participants who were treated with prostatectomy (59.47) had reported higher scores of 
PCI QOL than those treated with hormonal therapy (46.22). This difference was proved 
to be statistically significant (p=0.018).  
  Participants had reported several barriers to health care. These barriers were 
categorized under five major categories. These categories included barriers due to 
unavailability, organizational barriers, geographical barriers, socioeconomic barriers, and 
barriers related directly to the blockage imposed on Gaza Strip. Under the umbrella of 
each category, there were several subcategories that had emerged (figure 4-1). In general, 
176 
most of the barriers reported by participants were compatible with barriers reported in the 
literature with the exception of those barriers related directly to the impact of the 
blockade imposed against Gaza Strip. 
 
Answers to Research Questions 
 
 It was noticed that the available literature about quality of life of prostate cancer 
survivors addressed this topic in developed countries. None of the available studies 
addressed QOL of prostate cancer survivors in any of the developing countries. The topic 
of barriers to health care was addressed in general in the literature, but no studies 
addressed the topic of barriers to health care as perceived by prostate cancer survivors. 
This study was designed to evaluate the level of quality of life of prostate cancer 
survivors and to assess barriers to health care for prostate cancer survivors living in Gaza 
Strip.  
 
Research Question #1: What is the Level of the Perceived Quality of Life 
of Prostate Cancer Survivors Who Live in Gaza Strip? 
 
Quality of life of prostate cancer survivors living in Gaza Strip was described in 
three categories: a) General quality of life (SF-36), b) Prostate-Specific QOL (PCI-QOL), 
and c) total quality of life (both general QOL and PCI-QOL).  The UCLA-PCI including 
the RAND 36-Item Health Survey v2 (SF-36 v2) Health-Related Quality of life was used 
to assess QOL of prostate men survivors in Gaza.  
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General Health Quality of Life 
 
The general QOL scale (SF36) includes 9 domains:  physical function, role 
limitation due to health problems, role limitation due to emotional problems, vitality, 
mental health, social functioning, bodily pain, general health, and health transition 
(Litwin et al., 1998). The mean score of the general quality of life for participants was 
52.53. Scores for each domain of the general health QOL was presented in Table 4-15. In 
general, participants who were not receiving treatment at the time of data collection 
reported higher scores than those who were receiving treatment at that time in all 
domains except the domains of social functioning, bodily pain, and health transition. 
The general health QOL scores reported by participants of this study were less 
than those reported in the literature with the exception of three sub-domains; role 
limitation due to physical function, social functioning, and bodily pain. In fact those 
lower scores were reported by Schapira et al. (2001) for patients who were treated with 
radiation therapy. Since only one participant of this study used radiation therapy as a 
monotherapy, scores of participants would be less than other scores reported in the 
literature for patients treated with prostatectomy or hormonal therapy.  
 
Prostate-Specific QOL (Prostate-Specific Index) 
 
The Prostate-Specific QOL variable contains 6 domains; urinary function, urinary 
bother, bowel function, bowel bother, sexual function, and sexual bother (Litwin et al., 
1998). The mean score for prostate specific quality of life scores reported by participants 
178 
was 51.29. The highest scores reported by participants were those for bowel function and 
bowel bother domains and the lowest scores were for the sexual function and urinary 
bother domains (22.23 & 46.31 respectively). The results (Table 4-15) showed that 
participants who were not receiving treatment at the time of data collection reported 
higher scores (mean score = 63.49) than participants who were receiving treatment at that 
time (mean score = 46.74). This difference was found to be statistically significant (p less 
than 0.001). 
To the contrary of the scores reported by participants of this study for the general 
health sub-domains, all the scores of the sub-domains of the PCI-QOL fell within the 
range of the reported scores in the literature with the exception of urinary bother which 
was much less than the least reported score in the literature. The scores reported by 
participants for the urinary bother sub-domain was 42.8 compared to the least score of 
69.5 reported in the literature by Lubeck et al. (1997). This big difference in the urinary 
bother score could be related to the fact that being clean of urine and stool is one of the 
conditions any Muslim should have before praying. Such inability to control their urinary 
function could have a negative impact on participants‟ feelings. In spite that the laws of 
Islam give a special permission for patients who cannot control their urination, usually, 
elderly Palestinian people are very hesitant and feel inferior and stressed to use such 
permission and they prefer and act to be clean as their counter partners who are not 
suffering from their disease conditions.     
The relatively high scores for bowel function and bowel bother reported in this 
study are due to the fact that only a few number of patients used radiation therapy as a 
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monotherapy or along with other adjunct treatment modalities. Side effects that affect 
bowel function and leads to bowel bother are most likely due to radiation therapy.  
Although the scores reported by participants about sexual function were low 
(22.24), the scores reported about sexual bother were much higher (53.08). The same 
relatively huge difference between scores of sexual function and sexual bother was 
noticed in the reviewed studies that were summarized in Table 4-14. Such differences 
could be related to the fact that participants had accepted changes in their sexuality and 
related these changes in their sexuality to the process of aging and not to the impact of 
the disease or treatment on their sexual functioning.  
 
Total Quality of Life 
 
Total quality of life variable includes the mean of all variables related to quality 
of life (those related to general health QOL and to prostate-specific QOL). The total score 
of QOL for participants was 52.09. The mean of the total QOL for participants who were 
not receiving treatment (58.56 ) was higher than those were not (49.67). The difference 
between the two scores was found to be statistically significant (p= .004). Unfortunately, 
none of the studies reported in the literature reported on the total scores of QOL, rather 
they reported on the scores of each individual sub-domain of the general QOL (SF36) 
and/or those related directly to prostate cancer.  
 
 
 
180 
Impact of Treatment Options on Quality of Life 
 
The results of this study showed that the use of different treatment options had no 
effect on the level of general quality of life while it had a significant impact on the 
prostate-specific QOL (p=0.008). Participants who were treated with prostatectomy had 
reported higher mean scores (59.47) than those who were treated with hormonal therapy 
(46.22). The difference between the two means was found to be statistically significant 
(p= 0.015). Such differences in QOL scores are expected. Usually prostatectomy is used 
as a curative option to treat localized prostate cancer (Turini et al., 2003) while hormonal 
therapy is usually used (alone or along with other treatment options) as a palliat ive option 
to treat advanced prostate cancer (Albaugh & Hacker, 2005). It can be also given for 
patients with localized tumor and unfit for curative treatment (Fourcade et al., 2009).   
 
Research Question #2: Are there any Differences of the Perceived Quality of Life Issues 
Reported by Prostate Cancer Survivors Who Live in Gaza Strip and Currently Receiving 
Treatment and Those who Had Finished their Treatment? 
 
Quality of life of prostate cancer survivors living in Gaza Strip was described in 
three main categories: a) General quality of life (SF-36), b) Prostate-Specific QOL (PCI-
QOL), and c) Total quality of life (both general QOL and PCI-QOL).  The UCLA-PCI 
including the RAND 36-Item Health Survey v2 (SF-36 v2) Health-Related Quality of life 
was used to assess QOL for prostate cancer survivors in Gaza Strip. After evaluating the 
level of QOL in the three main categories of QOL mentioned earlier, a comparison 
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between levels of QOL between the group of participants who were receiving treatment 
at the time of data collection and the group of participants who were not receiving 
treatment at that time was performed.  
The score of the general quality of life (SF36) for the participants who were 
receiving treatment was 51.30 while it was 55.81 for participants who were not receiving 
treatment (Table 4-19). The result of the t test (Table 4-20) showed that there was no 
statistically significant difference (p=0 .211) between the scores reported by participants 
of each group. The SF36 consists of nine sub-domains. The mean scores of the sub-
domains of the general quality of life (SF36) for participants of each group were 
presented in table 4-21. Results showed that participants who were receiving treatment at 
the time of data collection had lower scores in all sub-domains of the general QOL than 
participants who were not receiving treatment at that time with the exception of the 
domains of social functioning, bodily pain, and health transition as they reported higher 
scores. To compare if there were any statistically significant differences between the 
means of the sub-domains of the general QOL among participants of both groups, t test 
was done. The results showed (Table 4-22) that there were statistically significant 
differences between the means of the participants in the two groups only in the areas of 
vitality (p=.033) and health transition (p=.001). 
The score for prostate specific index (PCI) quality of life for the entire sample 
was 51.29. It was 46.74 for participants who were receiving treatment at the time of data 
collection while it was 63.49 for participants who were not receiving treatment at that 
time (Table 4-19). The result of the t test showed that there was a statistically significant 
difference (p less than 0.001) between the reported scores of the two groups. Such lower 
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scores for the group of participants who were receiving treatment at the time so data 
collection could be attributed to the sequel and side effects of the treatment that they were 
receiving.  
Table 4-23 summarizes the scores of QOL for the six sub-domains included in the 
PCI for the total sample and for participants who were receiving treatment and 
participants who were not receiving treatment at the time of data collection. The highest 
scores reported by participants were those for bowel bother and bowel function sub-
domains and the lowest scores were for the sexual function and urinary bother (22.23 & 
46.31 respectively). In general, participants who were not receiving treatment at the time 
of data collection reported higher scores than those who were receiving treatment at that 
time in all domains except the bowel bother domain as the scores were almost equal. 
Although scores of sexual function were the lowest scores in both groups, but it is noticed 
that there was a relatively huge difference between the scores reported by participants in 
each group (score of sexual function reported by participants who were receiving 
treatment was 13.62 compared to 45.29 for participants who were not receiving 
treatment). The results of the t test (Table 4-24) showed that there were a statistically 
significant differences between the mean scores of participants in the two groups in the 
areas of urinary bother (p = 0.005), sexual function (P < 0.001), and sexual bother (p = 
0.023).  
Total quality of life includes the scores of all variables related to quality of life 
(all the sub-domains of the SF36 and the PCI scores). The score of the total QOL for 
participants who were receiving treatment was 49.67 while it was 58.56 for those 
participants who were not receiving treatment (Table 4-19). The result of t test showed 
183 
that there was a statistically significant difference between the means of the total quality 
of life (p= 0.004) between the scores reported by participants of the two groups. 
 
Research Question # 3: What are the Barriers to Health Care Faced by Prostate 
Cancer Survivors Living in Gaza Strip during their Treatment Period? 
 
Many barriers to health care were reported by the participants of this study. 119 
participants (61.02%) reported facing at least one barrier to health care at a certain point 
of their treatment time. In general, it was noticed that barriers to health care were 
reported by more participants who were receiving treatment at the time of data collection 
(n=107) than those who were not receiving any treatment at that time (N=12).  
After examining the scripts of the participants‟ responses, emerging themes were 
identified and coded into the following major concepts: barriers due to unavailability, 
organizational barriers, geographical barriers, socioeconomic barriers, and barriers 
related directly to the blockage imposed on Gaza. Under the umbrella of each concept, 
there were several sub-concepts that had emerged (figure 4-1).  
 
Barriers related to Unavailability 
 
Participants reported that several items or services were not available at the health 
care system in Gaza. These items included drugs, equipments, reagents for some 
diagnostic procedures, and the absence of the radiation therapy option. The most 
commonly reported missing item was drugs as many participants (N= 86) reported that 
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drugs were not available at some point at the governmental health system during their 
treatment time. Some participants could afford to buy drugs from other drug stores in 
case they were available, but many others could not. For those who could not afford 
purchasing drugs from outside drug stores or if the drugs were not also available at 
outside drug stores, participants had to wait without drugs until these drugs were 
delivered to the pharmacy of the governmental health care centers, which could 
negatively impact the status of their health and quality of life.    
Usually, drugs, equipments, and other medical supplies are provided to Gaza from 
Rammallah stores in the West Bank or by some humanitarian organizations that succeed 
to challenge the siege and enter Gaza through the Mediterranean Sea or from the 
Egyptian borders. Therefore, the importation of the supplies is contingent on the 
permission of the Israelis to let the supplies provided from Rammallah to enter into Gaza 
and the permission of the Egyptians to open the borders between Gaza and Egypt which 
used to be opened for limited hours per day for two to three days every one to three 
months. In general, reports from World Health Organization: West bank & Gaza (2010) 
and the Association of International Development Agencies (2010) showed that between 
March and December, 2009, shortage in drug supplies ranged between 14-30% while 
shortage in medical disposables ranged between 10-20% and that certain types of medical 
equipments including those needed for x-ray and other electronic devices were very 
difficult to get them into Gaza. Furthermore, the reports added that in many times, 
provided equipments were either broken or out of date and spare parts were not available. 
Such lack of equipment and drug supply will hamper the quality of provided health care 
to patients living in Gaza Strip and therefore their QOL. 
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The issue of lacking some medical supplies or drugs was not mentioned 
extensively in the literature. A few studies had reported about this issue. For example, 
Weinick et al., (1997) found that inability to afford health care services was reported by 
about 60% of families as the major barrier for family members to receive the needed 
health care.  
 
Organizational Barriers 
 
 Several barriers were reported under the concept of organizational barriers. The 
sub-concepts emerged under the organizational barriers included: long waiting time, 
incompetent physicians, physicians are not available at their offices, complicated referral 
process for treatment abroad, and long time to hear about the results of their diagnoses. 
These barriers were congruent with what was reported in the literature. Some examples 
reported in the literature included inconvenient doctors‟ hours (Weinrich et al., 2000), 
long waiting time in spite of having a previous appointment (McCullock-Melnyk, 1988; 
Estrada et al., 1990; Weinick et al., 1997; Bennett, 1999; Beckman et al., 2000; Chin et 
al., 2001), waiting too long to get an appointment or long time between appointments 
themselves (Estrada et al., 1990; Weinick et al., 1997; Chin et al., 2001), limited 
availability of health care providers (Margolis et al., 1995), having no physicians (Rutten 
et al., 2004), and mistrust in physicians (Powell, et al., 1995; Robinson et al., 1996).  
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Communication Barriers 
 
 Some of the participants (N=24) complained that the treating physicians and other 
health care professionals were not considering their emotional status when they talked to 
them and felt that they were humiliated by the way the physicians talked to them. 
Complaining participants thought that they needed special treatment and communication 
methods when they communicate with them as they felt that being diagnosed with cancer 
is a big issue that should be considered. Other participant reported that the use of some 
medical terminologies by their physicians impeded the process of communication and 
they did not understand the instructions or the explanations made by their physicians.  
 Several studies reported that communication problems were one of the reported 
barriers to health care (Weinick et al., 1996; Chin et al., 2001). Further, participants in 
Estrada‟s et al., (1990) study reported that staff being disrespectful as one of the barriers 
to health care. According to Mandelblatt et al., (1999), health care providers are usually 
not prepared well to communicate with patients diagnosed with cancer especially when 
communicating the complexities related to cancer care, treatment, and complication to 
their clients.  
 
Socioeconomic Barriers 
 
Under the socioeconomic barriers, sub-concepts related to the high cost of drugs, 
diagnostic procedures, and doctor visits emerged. Many participants reported that they 
could not afford to buy these expensive drugs or to go to the private clinics of their 
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physicians. A small number of participants reported that they even could not afford to 
pay for their transportation to go to the medical centers.  
After the blockade was imposed against Gaza Strip, the level of unemployment 
reached 41.5% (Palestinian Central Bureau of Statistics, 2009) and poverty markedly 
increased (ICRC, 2009). The cost of living in Gaza also increased as several basic goods 
became unavailable in the market or smuggled from Egypt through the tunnels. Such 
hardship affected prostate cancer survivors and several participants reported that when 
drugs were unavailable at the governmental health care system, they could not afford to 
buy them and they had to wait without drugs for several days, weeks, or months until the 
drug became available at the governmental health care system which may have negative 
impact of their health and QOL.  
Cost and inability of clients to afford the expenses of health care or the cost of 
transportation loomed as a major barrier to health care in several studies (Estrada et al., 
1990; Landerman et al, 1995; McCullock-Melnyk, 1988; Weinick et al., 1996; Bennett, 
1999; Mandelblatt. et al., 1999; Beckman et al, 2000; Weinrich et al., 2000; Chin et al., 
2001). 
  
Geographical Barriers 
 
 Geographical barriers reported by the participants of this study included few sub-
concepts; distance, physical accessibility, and availability of public transportation. 
Physical accessibility was a very major barrier before September 2005 before the Israelis 
pulled out from Gaza Strip. At that time, Israelis used to have checkpoints at the main 
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roads between the major cities in Gaza which impeded or prevented physical accessibility 
to health care facilities. After September 2005, physical accessibility became not a major 
concern since the two oncology centers are located in geographical locations that allows 
easy accessibility without traveling for long distances (Figure 4-2) and have public 
transportation that are relatively not expensive to reach them. Geographical and 
transportation-related issues were reported as barriers to health care in several studies 
(Estrada et al., 1990; McCullock-Melnyk, 1988; Blazer, et al., 1995; Weinick, et al., 
1996; Guidry, et al., 1997).  
 
Blockade 
 
 Beside that blockade was associates with the absence of many items at the health 
care system and inability of participants to cover the cost of needed drugs and other 
health care services, it was also involved as a barrier of inability of participants to travel 
to receive treatment outside Gaza Strip. After the elections took place in 2006, sanctions 
were imposed against Gaza Strip. Sanctions included the prohibition of people, including 
patients, to leave Gaza Strip. Since that time, the process to travel outside Gaza for 
medical purposes became very complicated as patients need to get special permissions 
from the Israelis to leave Gaza for treatment in West bank or in an Israeli hospital or to 
wait for the borders between Gaza and Egypt which opens occasionally for few day and 
relatively, a very few number of people is allowed to pass.   
 Israelis deny issuing permissions to many patients to cross Israeli borders to 
receive treatment. For example, in December 2009, 1103 patients applied to get  
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permissions to cross the borders to travel for treatment in an Israeli hospital or a 
Palestinian hospital at the West Bank (World Health Organization: West bank & Gaza 
(2010). Out of them, 21% were denied these permissions or the permissions were delayed 
so patients had lost their appointments and had to start over to set a new appointment and 
start a new process to get a new permission to cross the Israeli borders (figure 4-3). In 
fact, several patients died while waiting to get permissions or because they were denied 
permissions to travel to receive treatment outside Gaza Strip (Figure 4-4). Inability of 
people to travel freely in and out of Gaza deprived several prostate cancer patients to 
receive radiation therapy which could be necessary if the patient was diagnosed with 
localized prostate cancer and was not fit for surgery.  
 
Implications for Health Policy Change 
 
Prostate cancer is one of the most common cancers that affect men. It was the 
second most common type of cancer and the second leading cancer-related cause of death 
among Palestinian males (Ministry of Health, 2006). The incidence of prostate cancer and 
the probability of developing invasive cancer increase with age (American Cancer 
Society, 2007b; Held-Warmkessel; 2007; Munden, 2007). In spite of that, when 
discovered while localized, prostate cancer is curable (Tewari et al., 2004) and the 
survival rate had improved a lot in recent years. The five-year relative survival rates for 
prostate cancer in the United States (the chance of living 5 years after being diagnosed 
with prostate cancer) was 99.9% at all stages of cancer and 100% if the cancer was local 
between 1996 and 2002 (American Cancer Society, 2007b). The five-year survival rate 
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decreases to 94% for patients diagnosed with regional prostate cancer and to 31% for 
patients with distant metastasis (Parker, Tong, Bolden, and Wingo, 1997). Tewari et al., 
(2004) added that about 57% of prostate cancers are diagnosed while still localized with a 
ten-year survival rate of 93% and a crude survival rate of 67%.  
With the high incidence of prostate cancer, high survival rates, and with the 
several potential morbidities associated with the different treatment methods, more focus 
on quality of life issues was observed in the relevant literature (Sommers, and Ramsey, 
1999; Kakehi et al, 2002; Gacci et al, 2005; Ishihara et al, 2006; Inoue et al, 2009). 
Secchi and Strepparava (2001) added that QOL is now considered one of the most 
important parameters in evaluating clinical trials. Furthermore, the American Cancer 
Association (2007b) added that managing the consequences of cancer itself and 
treatment-related consequences become more important because patients live longer with 
the burdens of treatment consequences. Not understanding or not considering these issues 
can contribute to poorer recovery, higher level of stress, and disturbances in their QOL 
(Gotay & Muraoka, 1998; Green et al., 2000). Therefore, this group of patients deserves 
more attention from health policy decision-makers to improve the quality of their lives 
and to eliminate barriers to health care which would improve the quality of provided care 
which might be reflected on their QOL. Several implications for policy health policy 
came out from this study. The suggested health policy areas include requesting 
physicians to inform patients about the pros and cons of the different treatment 
modalities, set a plan to introduce a prostate cancer screening policy, reconsider the 
referral policy to increase radiation therapy, and set polices designated to eliminate 
barriers to health care. 
191 
Requesting Physicians to Inform Patients about the Pros and Cons of the 
Different Treatment Modalities 
 
There are several treatment options available for prostate cancer that include 
prostatectomy, radiation therapy, hormonal therapy, and watchful waiting (Albaugh, & 
Hacker, 2005; Turini, Redaelli, Gramegna, & Radice, 2003). For localized prostate 
cancer, treatment is usually curative. Prostatectomy and radiation therapy, either external 
beam radiation or internal radiation, are the most commonly options used to treat 
localized prostate cancer and they usually provide prolonged survival rate (Turini et al., 
2003). Since both options may result in several long-term complications, some men 
prefer the watchful approach (Turini et al., 2003). In Europe, radical prostatectomy is 
recommended for younger patients with ≥ 10 years of life-expectancy who are willing to 
accept its complications (Heidenreich et al., 2008). Radiation therapy is used for patients 
who are expected to live for a long time or who are unfit for surgical procedure and 
willing to accept treatment-related complications (Fourcade et al., 2009). 
While hormonal therapy is not curative but it is usually used as a palliative option 
in advanced prostate cancer, where cancer have spread to involve lymph nodes and other 
organs such as bone. It is used to suppress testosterone production which will diminish 
the growth rate of the hormone-dependent tumor and to limit the complications resulting 
from this growth (Albaugh & Hacker, 2005). It can be also given for patients with 
localized tumor and unfit for curative treatment (Fourcade et al., 2009). Other 
combination modalities such as prostatectomy, radiation, or chemotherapy could be used 
along with hormonal therapy to limit disease complications and relieve symptoms (Turini 
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et al., 2003; Fourcade et al., 2009). On the other hand, according to Van Erps, van den 
Weyngaert, and Denis (1998), the best treatment option for localized prostate cancer still 
controversial as there is no proven evidence about the superiority of one over the others. 
But Fleming et al. (1993) concluded from the results of decision analysis study that 
younger patients were the ones who clearly benefited from prostatectomy and radiation 
therapy. Turini et al (2003) added that prostatectomy is usually the treatment of choice 
used in the United States but in case of presence of concurrent medical conditions, 
radiation therapy is used.  
 Each of the available treatment modalities has several long-lasting complications 
that may negatively impact the quality of life (Albaugh & Hacker, 2005). For example, 
radical prostatectomy may lead to several urinary problems such as incontinence, 
nocturia (frequent urination during the night time), dribbling, and incomplete bladder 
emptying; sexual dysfunction including impotence, lack of ejaculation, changes in 
orgasm, and penile shortening; psychological concerns, and rarely death (Woolf, 1995; 
Clark et al., 2003; Turini et al., 2003; Albaugh & Hacker, 2005). Sommers and Ramsey 
(1999) reviewed the literature about post-prostatectomy complications and reported that 
the incidence of some degree of urinary incontinence reported in the literature they 
reviewed ranged between 4 to 74%, between 6 to 34% reported significant bother related 
to incontinence, and between 85 to 100% experienced some degree of sexual dysfunction. 
Sexual problems that lasted for 2-4 years affected 69-89% of patients in the literature 
reviewed by Sommers and Ramsey. 
 Radiation therapy has its own complications that include changes in bowel 
function, urinary function, and sexual function (Clark et al., 2003).  The urinary 
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dysfunction is usually related to bladder irritation, incontinence, and obstructive 
symptoms that include urgency, frequency, burning pain during voiding, and incomplete 
emptying of the bladder (Wei et al., 2002; Albaugh & Hacker, 2005). In their extensive 
review of the literature, Sommers and Ramsey (1999) found that 21 to 36% of patients 
used radiation therapy reported that they had experienced moderate to major changes in 
their bowel function. Bowel dysfunction includes frequency, urgency, diarrhea, fecal 
incontinence, pain during bowel movement, proctatitis, and blood in stool. This is besides 
other complications such as erectile dysfunction, lymphadema, and feeling tired during 
the treatment course (Sommers & Ramsey, 1999; Albaugh & Hacker, 2005).  
Hormonal therapy commonly leads to sexual problems such as impotence, 
decreased libido, and erectile dysfunction; gynacomastia (increase breast size in men); 
weight gain, hot flashes, sleep disturbances, fatigue, altered mood and depression; and 
osteoporosis (Sommers & Ramsey, 1999; Potosky et al., 2002; Penson & Litwin, 2003;  
Turini et al., 2003; Albaugh & Hacker, 2005). Melmed, Kwan, Reid, and Litwin ( 2002) 
further added that hormonal therapy is associated with diminished QOL because of 
subsequent deterioration in physical function and pain domains in the SF-36 health 
assessment tool.  
One more option for treating prostate cancer is watchful waiting. It involves 
carefully monitoring the prognosis of the disease which includes regular PSA testing and 
periodical prostate biopsy to determine the need and/or time of introducing treatment. 
Usually, this approach is used with elderly men or with those who have limited life span 
due to other comorbidities as they might not be good candidates for surgical intervention 
or might not be able to tolerate the complications of the other available treatment options 
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(Albaugh & Hacker, 2005). In spite of introducing no treatment, watchful waiting has its 
own psychological consequences. These consequences include stress, anxiety, and fear of 
the unknown (Chodak & Warren, 2006). On the other hand, men who choose watchful 
waiting may report some bladder problems such as frequency, urgency, and incomplete 
bladder emptying as the growing tumor will lead to obstruction of bladder neck. Others 
may complain of severe bone pain and fractures if the cancer is metastasized to bone, 
which will negatively impact their QOL (Chodak & Warren, 2006; Albaugh & Hacker, 
2005).   
As it had been noticed by Van Erps et al., (1998), the best treatment option for 
localized prostate cancer is still controversial because there is no proven evidence about 
the superiority of one option over the others. It will be a hard decision to be made by the 
patients and the treating physicians about which treatment option to choose. In general, 
younger patients usually get more benefits from prostatectomy and radiation therapy 
(Fleming et al, 1993). Although patients treated with prostatectomy reported higher 
(87%) confidence than patient treated with radiation therapy (73%) that prostate cancer 
was eliminated (Fowler et al., 1996), there is no evidence that prostatectomy has a better 
survival rate than the use of radiation (Turini et al., 2003). On the other hand, patients 
treated with radiation therapy reported high level of satisfaction (81-97%) about their 
treatment (Jonler, 1994; Nguyen, Pollack, Zagars, 1998).  
With all of the reported complications and side effects of each treatment option 
and their impact on quality of life, Litwin et al. (1998) noticed that patients diagnosed 
with prostate cancer rated QOL in a different manner than their treating physicians. In 
another study, Crawford et al., (1997) found that the goals of patients with prostate 
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cancer are completely different from the goals of their treating physician. The most 
important goal for patients was preserving QOL (45%) followed by extending life (29%) 
while the goals of their physicians were related to treatment efficacy (86%), followed by 
side effect (43%) and cost (29%). Albaugh, and Hacker, (2005) suggested that the 
potential cure from prostate cancer must be weighed with the predicted impact of 
different treatment options on quality of life. Since each individual is a unique, that 
individual is the best person to report about his own level of QOL. Therefore, a clear 
policy should be made that physicians should inform their patients and fully discus with 
them about all available treatment options, their physical and psychological 
consequences, and their impact on quality of life. Patients with prostate cancer should be 
fully aware of potential outcomes of their treatment option and should feel confident 
about their decision (Albaugh, and Hacker, 2005).   
 
Prostate Cancer Screening Policy 
 
As the Palestinian male population is aging, prevalence of prostate cancer is 
expected to increase and its cost will have a significant burden on the health care system 
in the next few decades. In the developed countries, the increased incidence of prostate 
cancer was linked to the policy of early screening for prostate cancer (American Cancer 
Society, 2007b and Kvåle et al., 2007). Therefore, Palestinian health policy decision 
makers need to give attention to early detection of prostate cancer in Palestine.  
Early detection through screening for several cancers such as breast and colorectal 
cancers showed to reduce cancer-related mortality among elderly 65 years and older 
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(Gorin, Gauthier, Hay, Miles, & Wardle, 2008). As cancer will be diagnosed at earlier 
stages, survival rates will be improved and morbidity will decrease (Rutten et al., 2004; 
Albaugh & Hacker, 2005). Rutten et al. (2004) added that screening for many types of 
cancer may reduce their devastating effects and the complications associated with cancer 
treatment.  
Although there are controversial opinions about prostate cancer screening, several 
organizations recommend for screening. For example, The American Urological 
Association, the American Cancer Society, the American College of Radiology, and 
German Urology Association recommend yearly prostate cancer screening for men over 
50 years and have a ten year life expectancy. On the other hand, the Swedish Council on 
Technology Assessment in Health Care and the National Cancer Institute don‟t 
recommend screening as scientific support for large-scale screening is not available 
(Holmberg, Carlsson, Löfman, & Varenhorst, 1998). The controversy about prostate 
cancer stems because prostate cancer has a relatively low biological risk and it is difficult 
to predict whether a newly diagnosed cancer will remain latent and localized or will 
progress into more advanced stages (Turini et al, 2003). Fourcade et al. (2009) added that 
the link between PSA screening and improvement in survival rate is less clear than that 
between prostate cancer incidence and PSA screening and some hypothesized that the 
increase in survival rate was related to the availability of radiation and hormonal 
therapies. Nevertheless, Schröder (2008) thinks that introducing a screening policy for 
prostate cancer in the health care is desirable as it will be effective in decreasing 
mortality and morbidity related to prostate cancer at an acceptable price in terms of cost 
and quality of life.  
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While several authors think that the results of Prostate, Lung, Colorectal and 
Ovary (PLCO) Cancer Screening Trial in the USA and the European Randomized 
Screening for Prostate Cancer (ERSPC) trial will provide more information about the 
impact of PSA screening on mortality and morbidity of prostate cancer (Sommers and 
Scott, 1999; Gorin et al., 2008), the good news is that some evidence about the efficacy 
of prostate cancer screening is emerging (Gorin et al., 2008). For example, several studies 
reported an important reduction of grade and stage of prostate cancer between first and 
second rounds of screening in several ERSPC centers (Hoedemaeker et al., 2001; 
Hugosson et al., 2004; Makinen et al., 2004). In a study that involved a control group, 
Holmberg et al. (1998) reported that the screening group generated more than twice the 
number of localized prostate cancer than in the non-screening group. The cancers 
detected in the control group were usually more advanced. Identified cases in the 
screening group with the potential cure were triple those in the non-screening group. 
Holmberg et al. concluded that the chance is higher for cure in the screening group and 
that screening can “be performed at a reasonable cost per detected localized cancer and 
probably at an acceptable cost per curative treated cancer” (p.146).  
To prove their economical conclusion regarding cost effectiveness of prostate 
cancer screening, Holmberg et al. (1998) had estimated that the total accumulated cost 
(from time of diagnosis to death) for treating advanced prostate cancer was 294.100 
Swedish Koruna, compared with 203.400 for treating localized cases. In a similar study, 
Senfalt, Sandblom, Carlsson, and Varenhorst (2004) contended that screening for prostate 
cancer would be probably cost effective if patients with curable cancers gained at least a 
survival of one year. In another study, Wilson et al. (2007) found that it was costly to 
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treat elderly patients diagnosed with advanced stages of prostate cancer as they would 
usually need a combination of treatment options including hormonal therapy which was 
found to be much more expensive than other treatment options. This conclusion enhances 
the view point that supports screening as it will help to discover prostate cancer before it 
becomes advanced and therefore, its treatment will be less costly and produce better 
QOL.  
Based upon the previous discussion, adoption of a prostate cancer screening 
policy is recommended. While the available policy options include the options to screen 
or not to screen, the option „to screen‟ is recommended because of the following reasons. 
First, there are several emerging evidences that screening for prostate cancer helps to 
discover prostate cancer at early stages which will provide a higher chance for cure and 
the cost for treating prostate cancer while it is localized will be much cheaper than its cost 
when it becomes advanced. Unfortunately, there is no data about the number of prostate 
cancer cases diagnosed at early stages (localized) and at late stages (advanced) in 
Palestine. But one can read from the treatment modalities presented by Najjar et al. 
(2002) that many cases were diagnosed with prostate cancer at an advanced stage since 
28.6% of prostate cancer patients living in Gaza received chemotherapy and 66.7% 
received hormonal therapy. The high percentage of using hormonal therapy (either as a 
monotherapy or adjuvant therapy) and relatively high percentage of using chemotherapy 
reveals that there were a high percentage of men diagnosed with prostate cancer at 
advanced stages which are usually non-curable. This is besides the economic burden 
comes from using such expensive drugs since the yearly cost for hormonal therapy were 
reported to be the most expensive method for prostate treatment (Wilson et al., (2007). 
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This recommendation of screening for prostate cancer is not expected to be costly 
to the ministry of health. The population pyramid in Palestine has a flat bottom and a 
very narrow top (Figure 5-1). According to the Palestinian Central Bureau of Statistics 
(2010), the male population falls within the target population for screening (between the 
ages 50 and 69 years) is expected to be 42,232 men in the year 2010. The cost of 
screening this relatively small number of male population will be relatively small if 
compared with the cost burden related to diagnosing several prostate cancer cases in the 
advanced stages if screening policy is not performed as the use of hormonal therapy 
which is used along with other treatment options including chemotherapy for advanced 
prostate cancer is proved to be very expensive. This is besides that if the ministry of 
health adopts a screening policy, it would be expected that if they require from the 
donating countries to finance such a program, that the donating courtiers, which show 
lots of interest in measures targeting health promotion and preventive measure to cover 
the cost of this program.  
 
 
Figure 5-1: Population Pyramid in Gaza. Source, Palestinian Central Bureau of Statistics 
(2010) 
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Referral Policy to Increase Radiation Therapy 
 
 Although prostatectomy and radiation therapy are the main curative methods used 
to treat prostate cancer (Turini et al., 2003), the use of radiation therapy to treat men with 
prostate cancer in Gaza is very rare. According to Najjar et al., (2002), prostatectomy was 
the most common method used for treating prostate cancer in Gaza Strip. About 62.5% of 
total prostate cancer patients were treated surgically, 28.6% received chemotherapy, and 
66.7% received hormonal therapy. The use of radiation therapy was not included as one 
of the methods used in treating prostate cancer patients in Gaza Strip. The results of this 
study support the report of Najjar et al. Only one participant was treated with radiation 
therapy as a monotherapy. Another 11 participants were treated with radiation therapy as 
adjuvant therapy.  The minimal use of radiation therapy in Gaza is related to the fact that 
radiation therapy is not available in Gaza Strip and in sometimes, patients are referred to 
be treated abroad (in Egypt, Israel, or Jordan) to get radiation therapy. 
Radiation therapy is used to treat localized prostate cancer and it can be used with 
other treatment modalities to treat advanced cases. It is used for patients who are 
expected to live for a long time or who are unfit for surgical procedure and willing to 
accept treatment-related complications (Fourcade et al., 2009). Although there is no 
evidence about the superiority of using radiation therapy or prostatectomy to treat 
localized prostate cancer (Van Erps et al., 1998), patients treated with radiation therapy 
reported high level of satisfaction (81-97%) about their treatment (Jonler, 1994 and 
Nguyen, Pollack,and Zagars, 1998). While prostatectomy don‟t cause bowel dysfunction 
as much as radiation (Potosky et al., 2000), Sommers and Ramsey (1999) found that 21 to 
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36% of patients used radiation therapy reported that they had experienced moderate to 
major changes in their bowel function. On the other hand, compared to prostatectomy, 
radiation therapy causes fewer sexual side effects (D‟Amico et al., 1997), but it still 
causes some erectile problems for men (Potosky et al., 2004) and other urinary 
complications such as urinary incontinence and irritation (Brandeis et al., 2000). On 
another study by Potosky et al., (2000), patients treated with radiation reported less 
experience of urinary incontinence (3.5%) than those treated with radical prostatectomy 
(9.6%), less leakage of urine (2.3% compared to 13.8%), and had less urinary frequency 
and bother than those treated with radical prostatectomy. Potosky‟s et al. (2000) study 
further added that impotence was less common among patients treated with radiation than 
with prostatectomy (61.5% compared to 79.6%) and sexual bother was less common 
among younger patients who were 55-59 years old (25.3% compared to 59.4%).  
Based upon that, it is recommended that health policy decision makers to 
reconsider the referral policy for treatment abroad and provide more referrals for prostate 
cancer patients to be treated with radiation therapy especially for younger patients who 
would be more concerned about their sexuality and those diagnosed with prostate cancer 
and unfit for surgery. At the long run, it is recommended to establish a radiation therapy 
center in Gaza Strip. Such a center will provide radiation treatment not only for prostate 
cancer patients, but also for patients diagnosed with other cancers. Having such a center 
will help in decreasing the cost of referring cancer patients to receive radiation therapy 
abroad as the total cost of treatment abroad consumed about 45.9% of the actual health 
expenditure in 2004 (Ministry of Health, 2005).  
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Eliminating Barriers to Health Care 
 
Several barriers to health care were reported in this study by men diagnosed with 
prostate cancer that were categorized into five major categories; barriers due to 
unavailability, organizational barriers, geographical barriers, socioeconomic barriers, and 
barriers related directly to the blockade imposed on Gaza Strip. Under the umbrella of 
each category, there were several subcategories that had emerged (Figure 4-1). Such 
barriers may influence negatively the quality of provided care and limit the utilization of 
health care services by recipients. According to the Health Promotion Model, “situational 
influences in the external environment can increase or decrease commitment to or 
participation in health-promoting behavior” (Pender et al., 2002, p. 63-64). Therefore, 
eliminating barriers to health care in Gaza is expected to increase utilization of health 
care services which will be reflected on the health-promoting behaviors.  
The health policy makers then are required to eliminate these barriers by taking 
some actions to “control the system, to help solve problems within it or caused by it, or to 
help obtain benefits from it” (Walker (2000, p. 13). Of course not all reported barriers are 
removable as there are many barriers that are not directly related to the system but they 
were imposed on the system. Barriers related directly or indirectly to the effect of 
blockade are almost non-removable. On the other hand, almost all barriers reported under 
the concepts of organizational and communication barriers could be eliminated.  
For example, workshops can be arranged to train health professionals about how 
to communicate with patients in general and how to communicate with patients with 
sensitive diagnosis such as prostate cancer. Especially the literature reported that health 
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care providers are usually not prepared well to communicate with patients diagnosed with 
cancer especially when communicating the complexities related to cancer care, treatment, 
and complications to their clients (Mandelblatt et al., 1999). Such workshops also may 
address the importance of communication and stress the avoidance of using medical 
jargon while communicating with patients and stress the use of simple terms that are 
understandable by their clients. Improving health professionals‟ communication skills is 
expected to help them to achieve the goals and benefits of communicating with their 
patients.  
Establishing and enforcing a disciplinary policy for those professionals who leave 
their offices for hours is recommended so that they can abide to their working hours. 
Long waiting times could be solved by establishing an appointment system so that a 
certain number of patients will be given appointments for certain dates. Such policy may 
reduce waiting time and crowdedness at the outpatient oncology clinics. 
To resolve the barriers related to unavailability of drugs, equipments, and some 
diagnostic reagents, MoH is encouraged to be opportunistic and ask for extra supply 
when the Israelis will allow the entrance of medical supply from the main stores in the 
West Bank and request donating countries and organizations to supply them with the 
needed equipment and provide them with a list of needed drugs to bring with when the 
crossing borders with Egypt will open. Finally, it might be wise at this time that the 
government exercises its regulatory role and observe and control the prices of drugs and 
other services provided outside the governmental system.  
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Findings and the Health Promotion Model 
 
The Health Promotion Model (Pender, et al., 2002) was used as the conceptual 
framework for this study. The model involves explaining the complex biopsychosocial 
process and how it motivates humans to practice activities that are directed toward 
enhancing their health and well-being. According to the revised Health Promotion Model 
(HPM), there are many factors that are involved in the patient‟s decision making process 
about treatment options for prostate cancer which include psychological, socio-cultural, 
biological factors, environmental factors, other‟s experience, barriers to health care, as 
well as prior related behavior that will make the patients think about and evaluate the 
benefits, obstacles, and complications of the different treatment options which will 
influence their decisions about making the right choice of the available treatment options.  
The results of this study showed that patients who were treated with surgical 
intervention to treat prostate cancer (prostatectomy) reported higher scores of QOL than 
those who were treated with hormonal therapy. The experience of others (in this case, the 
participants of this study), can serve as an impetus for newly diagnosed patients to prefer 
the surgical intervention (Pender, et al., 2002). Therefore, establishing a health policy that 
requires treating physicians to fully inform newly diagnosed patients about the 
advantages and disadvantages of each treatment option is very important in providing 
these patients with the necessary information before making the decision about the 
treatment option.    
Such information will help newly diagnosed patients to assess the perceived 
benefits, perceived barriers, and the perceived-self efficacy of each treatment option and 
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how it will affect their quality of life. Keeping in mind that one of the assumptions of the 
HPM is that “health professionals constitute a part of the interpersonal environment, 
which exerts influence on persons throughout their lifespan” (p. 63) and that “health care 
providers are important sources of interpersonal influence that can increase or decrease 
commitment to and engagement in health-promoting behavior” (p. 64) is a very important 
aspect that will help in the decision making process. Because the treating physicians 
know more about the available treatment options, their opinions will be highly 
appreciated and mostly will be considered by patients in the decision making process. 
Other factors that may intervene in their decision making include interpersonal 
influences and situational influences. In this case, interpersonal influences include the 
effect of other men who received different treatment modalities and health care 
professionals. Situational influences include the ability to pursue the chosen treatment 
modality especially that such a decision is contingent and depends completely on the 
political situation in the area. For example, if a patient chooses to receive radiation 
therapy, which is not available in Gaza Strip, and needs a referral to be treated outside 
Gaza Strip, he may not be able to have such a treatment for several months because of the 
limited number of referrals made for treatment abroad and the Israeli closure for the 
borders of Gaza Strip. Even other choices for treatment will be affected by the closure 
imposed on Gaza Strip since it affects the availability of hormonal and chemotherapy 
choices and affects the availability of instruments and anesthetic agents that are required 
for the surgical choice and equipments and chemical reagents that are necessary for the 
diagnosis of prostate cancer.  
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Because some patients will not be fit for surgical intervention, it may be wise to 
manipulate the referral policy to allow those patients to be treated abroad outside Gaza 
Strip. The referral policy and inability to travel outside Gaza were some of the reported 
barriers by men in Gaza who have prostate cancer. According to the HPM (Pender, et al., 
2006), barriers can constrain commitment to an action plan and will discourage 
individuals to participate in health promoting activities which in this case may have a 
negative impact on their QOL. Here comes the importance of the proposed policy 
focusing on eliminating barriers to health care reported by participants of this study.   
Barriers to health care may negatively influence the quality of care provided to 
men in Gaza Strip diagnosed with prostate cancer and limit their utilization of the 
available health care services. According to the Health Promotion Model, “situational 
influences in the external environment can increase or decrease commitment to or 
participation in health-promoting behavior” (Pender et al., 2002, p. 63-64). Therefore, 
eliminating barriers to health care in Gaza is expected to increase the utilization of the 
available health care services which will be reflected on the health-promoting behaviors 
and the level of QOL.  
Since the Health Promotion Model depicts that health promotion involves 
activities directed toward developing means that enhance or maintain an individual‟s 
well-being, individual will adopt behaviors that promote their health (Pender, et al, 2002). 
Further, the HPM assumes that “persons commit to engaging in behaviors from which 
they anticipate deriving personally valued benefits (p. 63). Based on that, the proposed 
policy related to prostate cancer screening will serve to meet the needs of the male 
population in Gaza Strip to promote their health. Screening is considered one of the 
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primary prevention tools for prostate cancer (Harris & Lohr, 2002) and early detection of 
cancer through screening was described by Brawer (1995) as the only feasible possibility 
to reduce cancer-related mortality. Early detection of prostate cancer will help in identify 
men who are asymptomatic. When the disease is detected at the early stages, treatment 
will be more effective and complications will be less (Harris & Lohr, 2002; Frankel, 
Smith, Donovan, & Neal, 2003; American Urological Association, 2009). Rutten et al. 
(2004) added that screening for many types of cancer may reduce their devastating 
effects and the complications associated with their treatment. Therefore, these patients 
are expected to have better diagnosis and better levels of their QOL.    
 
Limitations 
 
 Like all other studies, this study has its own limitations. These limitations are 
discussed in the following paragraphs.  
Many studies had addressed the issue of quality of life for cancer patients 
including quality of life for prostate cancer survivors. As discussed earlier, all of these 
studies were conducted in developed courtiers and none was found addressing the quality 
of life for prostate cancer survivors in any developing country including Palestine. 
Although barriers to health were addressed in several studies, most of these studies had 
addressed barriers to health care in general. Some had addressed barriers related to 
socioeconomic status, language, immigrants, and for some categories of patients such as 
prenatal care, mentally ill, and so. Some studies had addressed barriers to prostate cancer 
screening, but none had addressed barriers to health care faced by prostate cancer 
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patients. Because Gaza Strip has a unique situation as there is a blockade imposed against 
it since June 2006, which possibly had affected the results of the study. Therefore, results 
can‟t be generalized to patients diagnosed with prostate cancer who live in the West 
bank, the other part of Palestine, nor to other patients with prostate cancer living in other 
developing countries. 
One of the limitations was that all new prostate cancer cases that were diagnosed 
after the year of 2007 were not registered by the Palestinian Cancer Registry due to the 
political chaos that prevails in the region. To identify patients diagnosed with prostate 
cancer at Shifa Hospital, all medical records available at the oncology department at 
Shifa Hospital were examined manually to identify those patients. The process was much 
easier at Gaza European Hospital which has a computerized system that helped in 
identifying patients diagnosed with prostate cancer in a short time. Such thing took too 
much time and efforts from the researcher and it could be possible that some prostate 
cancer patients who were receiving treatment at Shifa Hospital had been missed and were 
not included in the study.   
One of the expected limitations and experienced limitations for this study was 
identifying participants contact information. Some of the participants had incomplete or 
no contact information on their medical record. Telephone directory was used in an 
attempt to find contact information for those participants. For a few patients, it was not 
possible to find any contact information and therefore they were not included in the 
study. Even after identifying some participants‟ addresses, because most of the streets in 
Gaza Strip has no names and houses have no numbers, so much time and efforts were 
spent to reach to these participants.   
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Another limitation of this study was that there was only one participant who used 
radiation as monotherapy and another 11 participants used radiation therapy along with 
other treatment modalities. The lack of representation of patients who received radiation 
therapy did not allow the researcher to compare between QOL of patients receiving 
different treatment options especially that the literature usually reported more commonly 
about the QOL of prostate cancer patients receiving radiation therapy and prostatectomy 
and to a less extent, patients receiving hormonal therapy. Therefore, the results of this 
study can‟t be generalized to patients treated with radiation as a monotherapy.  
Finally, the high level of bureaucracy that prevails in the governmental health 
care system was a major limitation. As a result of that bureaucracy, it was not possible to 
get information about prostate cancer patients from the Palestinian Cancer Registry, 
especially those who were diagnosed with prostate cancer before the year of 2007. As a 
result, the number of participants who were diagnosed with prostate cancer and were not 
receiving treatment at the time of data collection was under represented. Having an 
access to a higher number of these patients would definitely add to the quality of the 
findings produced by this study.  
 
General Recommendations 
 
 Several recommendations came from this study. The recommendations made 
pertain to the following areas: hospital administration, practice, public health policy, and 
public administration. 
 
210 
Implication for Hospital Administration 
 
The process of identifying patients diagnosed with prostate cancer was much 
easier at Gaza European Hospital than at Shifa Hospital as they had a computerized 
system that helped to identify prostate cancer patients by punching the diagnosis of 
prostate cancer into the system. Within a few seconds, a list of all patients who were 
treated for prostate cancer was displayed. On the contrary, at Shifa Hospital, they don‟t 
have such a system. To identify patients diagnosed with prostate cancer at Shifa Hospital, 
all patients‟ records that were available at the oncology clinic were examined manually to 
identify patients who had prostate cancer, which took a lot of time and efforts. Therefore, 
it is recommended that a computerized system to be established at Shifa Hospital similar 
to the one available at Gaza European Hospital. Such a system will help in providing 
appointments for oncology patients which will help in resolving one of the barriers 
reported by the participants of this study. On the other hand, it will help in future 
researches as it will help future researchers to identify their clients and will save their 
times in looking for their contact information. Such thing will encourage researchers to 
conduct more research in the area of oncology which hopefully will contribute to 
improving and promoting the health of people living in Gaza Strip and their QOL.  
Further, it is recommended that patients to be questioned if they mind to release 
their names for possible research in the future or not. Providing such information, either 
in a computerized system or on the current paper work files, will help researchers in 
identifying their clients who are willing to participate in their studies and relieve any 
ethical dilemmas of looking at their files without their permissions. 
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Several participants in this study reported that in several cases it took a long time 
for them to hear about the results of their diagnoses. Because the diagnosis of cancer 
leads to feelings of anxiety and fear of the unknown, it will be good that some measures 
to be taken into consideration by the hospital management to work on decreasing the time 
between taking the sample from the patient and disclosing the results. This will help to 
decrease the amount of anxiety experienced by the patient and his family while waiting to 
hear about the results of the diagnosis.   
 
Implications for Practice 
 
Usually, the diagnosis of cancer leads to stress, anxiety, and feelings of fear of 
death and fear of the unknown. When a man is diagnosed with prostate cancer, he may 
experience additional fears and stress about becoming impotent and/or infertile. When a 
health care provider will tell a patient about his diagnosis, he needs to consider the 
patient‟s feelings while communicating with him. He needs to use his communication 
skills to introduce the diagnosis for the patient and accept the reaction of the patient to the 
diagnosis. It might be wise to communicate the diagnosis and related treatment to the 
patient on a step-wise progression. Crightom suggested the following steps when 
communicating the diagnosis of cancer to the clients (p. 124): 
provide the diagnosis with compassion, allow time for patients to process the 
meaning, listen to their interpretation of the diagnosis, provide patient-friendly 
information, give them additional information resources, provide a list of 
questions they should ask, and instill in them that they are part of the health care 
team. 
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To help health care providers to improve their communication skills, it is 
recommended that some workshops to be organized where some experts in 
communication guide health care providers involved in the oncology care to improve 
their communication skills. 
Several participants of this study reported that the treating physicians were not 
competent. This is a general feeling among people in Gaza Strip especially toward young 
physicians who graduated from Romania and former Soviet Union countries. Therefore, 
it is recommended that the MoH in Gaza Strip to arrange for continual education 
programs and provide seminar sessions for these doctors to improve their competency. It 
is also highly recommended to supply the libraries in the hospitals with recent books and 
periodicals that pertain to prostate cancer and providing an access to some related 
electronic data base. 
 
Implications for Public Health Policy 
 
In this research endeavor, the researcher faced many obstacles related to high 
bureaucracy that prevails in the governmental health care system. An example was 
inability to get information about prostate cancer patients from the Palestinian Cancer 
Registry. Presence of high bureaucracy within the system may discourage and impede 
future research. Therefore, it is recommended that a new approach to be adopted to allow 
access for researchers to public information. Hopefully, in the near future such data will 
be available on the internet for public use. Easy accessibility for information or having it 
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available on line will encourage researchers to conduct more studies that meet their 
interests and the needs of their clients. 
The Palestinian Cancer Registry is a health information system that is designated 
to register all cancer cases in Palestine. There is a branch in Gaza Strip and another 
branch in West Bank. New cancer cases that were diagnosed after 2007 were not entered 
into the system. This is due to the political chaos that prevails in the region after the 
fighting between Hamas and Fateh in May 2007 since the employees who receive their 
salaries from West Bank were asked not to work in all governmental systems 
administered by Hamas. It would be highly appreciated if both parties work for the good 
of the nation and keep their political conflicts away from public organizations. But at the 
time being, it would be highly recommended to employ new staff by Gaza government so 
that they can work on entering cases that were discovered earlier and not entered into the 
system along with new cancer cases that will be discovered in the coming future.   
Prostate cancer is one of the most common cancers that affect men. If diagnosed 
early while at the localized stage, the cure rate is very high. Therefore, it is recommended 
that health education programs to be established. The target of these programs is to be 
directed about prevention of prostate cancer and the importance of screening for prostate. 
This could be accomplished through teaching people about the risk factors for prostate 
cancers that were addressed in the literature review chapter and how to avoid them. 
Teaching men living in Gaza Strip about the importance of screening for prostate cancer 
will encourage men to participate in prostate cancer screening programs.  
Diagnosis of cancer by itself leads to several feelings of anxiety and fear of death 
and the unknown. The diagnosis of prostate cancer adds the fears of becoming impotent 
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or infertile. Therefore, it is recommended that a health club for patients diagnosed with 
prostate cancer to be established. Usually, patients who had the same diagnosis will 
provide newly diagnosed patients with the best emotional support. Meeting with other 
men who had suffered the same diagnosis, treated with same treatment, and suffered from 
the consequences of treatment options will help those patients to mutually provide 
support to each other and alleviate their anxiety.  
One of the major criticism to the health care system in Palestine mentioned in the 
literature review chapter was the fragmentation of the health policy process between 
Gaza Strip and West Bank, and between the governmental health care system, the 
NGO‟s, UNRWA, and the private sector. It is highly recommended to unify the health 
policy process and policy making between Gaza Strip and West Bank and among the four 
health care providers. Workshops that include the different stakeholders could be 
arranged to discuss health policy issues and different health polices then can be made that 
meet the interests of all or most of the interests of the stakeholders.  
 
Implications for Public Administration 
 
One of the challenges for this study was identifying participants‟ locations. Some 
of the participants had incomplete or no contact information on their medical record. 
Therefore, the telephone directory was used to find contact information for those 
participants. After identifying some participants‟ addresses, because most of the streets in 
Gaza Strip have no names and houses have no numbers, the researcher spent so much 
time and effort to reach to these participants. Therefore, it is recommended for the 
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municipalities of Gaza Strip to give all or at least the major streets names and give 
numbers to the houses. This will make it easy for future researchers and for the public to 
identify the needed address and reach it without wasting so much time looking for that 
address. 
When the data collected for this research study, it was collected via personal 
interview and questionnaires were not mailed to participants at their mailing addresses. 
Though sending questionnaires to participants through mail could save time, efforts, and 
money, it was impossible to do so because, as mentioned earlier, most of the streets in 
Gaza Strip have no names and houses have no numbers. This is besides that there are no 
postal code areas or postal zip codes. Therefore, it is highly recommended that the 
municipalities and the post office in Gaza Strip to establish a post code or zip code 
system. Such a system will benefit all people living in Gaza Strip in mail delivery and 
will save their time, efforts, and money.  
 
Future Research 
 
This dissertation study was meant to shed further light on barriers to health care 
and the level of quality of life of prostate cancer men living in Gaza Strip in an attempt to 
manipulate health policies to improve the quality of provided care to prostate cancer 
patients and to improve their quality of life. Conducting more related studies would add 
to the depth of this study. Therefore, the following recommendations were made for 
future research:  
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To have more information about barriers to health care and QOL of prostate 
cancer survivors in Palestine, it is recommended that a new study that involves 
participants from Gaza Strip and West Bank to be conducted to assess barriers to health 
care and evaluate QOL. Conducting such a study will provide information to compare 
barriers to health care and level of QOL reported by participants living in Gaza and 
participants living in West Bank and it may help to detect if the low scores concerning 
general QOL (SF-36) reported by participants of this study would be repeated by 
participants from West Bank, or there were some other factors, such as the impact of the 
blockade imposed against Gaza Strip since June 2006, that contributed to these low 
scores. Reported results in both parts of the country will contribute to motivate both 
health policy makers in Gaza Strip and West Bank to work together on elaborating on 
new health policies to improve quality of provided care, eliminate barriers to health care, 
and improve quality of life of prostate cancer survivors.    
The design for this study was a cross-sectional design that evaluated quality of 
life of prostate cancer survivors living in Gaza Strip at a certain point of time (August to 
December, 2009). Therefore, an important recommendation for future research is to 
conduct a longitudinal study that evaluates QOL at different time intervals, i.e. before 
treatment, at 3, 6, 12, and 24 months intervals. Because treatment options will have 
several long-lasting consequences that will affect quality of life, conducting such a study 
will provide more in depth information about QOL at different points of time before and 
after the initiation of treatment and will provide patients with an idea about the lengths of 
different treatment options, the complications of each option, and their impact on QOL at 
different time intervals. Having such information will help physicians and patients in 
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their decision making process regarding what type of treatment to choose for their 
prostate cancer.  
Participants in this study had reported several barriers to health care and low 
scores for the general health QOL domain (SF-36). To explore if these barriers and low 
scores of SF-36 QOL were unique to prostate cancer survivors living in Gaza Strip, it is 
recommended to conduct several studies in Gaza and West Bank that involve participants 
who have other types of cancers. Further, it would be recommended to use the same 
instrument (SF-36 v2) that was used in this study to evaluate the level of general quality 
of life.     
To build a body of literature about quality of life and barriers to health care for 
prostate cancer survivors in the developing countries, it is recommended that similar 
studies to be conducted in other developing countries. Conducting such studies will help 
to bridge the gap in the literature and hopefully will contribute to improving the QOL of 
prostate cancer survivors in the developing world.     
This research endeavor examined quality of life of prostate cancer survivors using 
the quantitative approach. It can be noticed from the provided definitions in the literature 
review section that the concept of QOL has a subjective nature since it reflects one‟s 
individual own feelings toward his/her own life depending upon the unique experiences 
of each individual (Ferrans, l996). Such a way to look at QOL is definitely applies to 
survivors of prostate cancer as the whole experience of cancer is very personal. 
Therefore, it is recommended that quality of life for prostate cancer survivors living in 
Gaza Strip to be repeated using a qualitative approach. Using a qualitative research 
method to evaluate QOL of prostate cancer survivors will provide more richness and 
218 
texture to the findings because its inductive approach emphasizes developing insights out 
of the data collected (Neuman, 2006).  
 
Summary  
 
Prostate cancer is the second most common cancer among Palestinian males and 
the second leading cause of cancer-related deaths in Palestine. The incidence of 
diagnosing new prostate cancer cases is expected to increase as the Palestinian population 
is aging. The rate of cure of localized prostate cancer is very high. The use of different 
treatment modalities such as prostatectomy, radiation therapy, and hormonal therapy 
helped many prostate cancer survivors to live for longer periods of times than they used 
to live a few decades ago. Managing cancer itself and the consequences of its treatment 
became of a paramount importance as patients now live longer and have to bear with the 
burdens of cancer itself and the consequences of its treatment (American Cancer Society, 
2007b). Because the use of prostatectomy and radiation in treating localized prostate 
cancer provide similar curative results, issues related to QOL that accompany each 
treatment option became more important in the decision making about which treatment 
option to use.  
All available studies in the literature evaluated QOL of prostate cancer survivors 
were conducted in developed countries and none was conducted in a developing country. 
Further, no study addressed barriers to health care as perceived by prostate cancer 
survivors. The purpose for this study was to evaluate the level of QOL and to assess the 
barriers to health care as perceived by prostate cancer survivors who live in Gaza Strip in 
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an attempt to fill part of the gap in the literature related to QOL of prostate cancer 
survivors and barriers to health care in the developing countries. 
 The UCLA-PCI including the RAND 36-Item Health Survey v2 (SF-36 v2) 
Health-Related Quality of life was used to evaluate the level of QOL for prostate cancer 
men living in Gaza Strip. Barriers to health care were assessed by using a semi-structured 
interview. The design for the study used both qualitative and quantitative approaches in 
data collection. 199 patients were recruited from the two medical centers that provide 
oncology care in Gaza Strip. 195 agreed to participate in the study with a response rate of 
97.98%.  
 The findings of this study revealed that the scores of the general quality of life 
(Sf-36 QOL) of prostate cancer men living in Gaza Strip were less than those reported in 
the literature in all domains of SF-36 for patients treated with prostatectomy and 
hormonal therapy. The scores of all domains of Prostate-Specific Index fell within the 
range of scores reported in the literature with the exception of the scores of urinary 
bother, which was much less than those reported in the literature. Further, participants 
who were treated with prostatectomy had reported higher scores of PCI QOL (59.47) than 
who were treated with hormonal therapy (46.22). This difference was proved to be 
statistically significant (p=0.018). The use of hormonal therapy and prostatectomy were 
reported to be the most common treatment modalities used for treatment of prostate 
cancer in Gaza. Although radiation therapy is one of the most common methods used to 
treat prostate cancer, only one participant reported to be treated by radiation therapy as a 
monotherapy and 11 participants used radiation as adjuvant therapy.  
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  Participants had reported several barriers to health care. These barriers were 
categorized under five major categories. These categories included barriers due to 
unavailability, organizational barriers, geographical barriers, socioeconomic barriers, and 
barriers related directly to the blockage imposed on Gaza. Under the umbrella of each 
category, there were several subcategories that had emerged. While lack of continuous 
drug supply was reported as the most important barrier to health care, most of the 
reported barriers were directly or indirectly linked to the impact of the blockade imposed 
against Gaza Strip since June, 2006. In general, most of the barriers reported by 
participants were compatible with barriers reported in the literature with the exception of 
those barriers related directly to the impact of the blockade imposed against Gaza Strip. 
 Because managing the consequences of cancer by itself and treatment-related 
consequences became more important since patients live longer with the burden of 
treatment consequences, not understanding or not considering these issues can contribute 
to poorer recovery, higher level of stress, and disturbances in their QOL. Therefore, this 
group of patients deserves more attention from health policy decision-makers to improve 
the quality of their lives and to eliminate barriers to health care which would improve the 
quality of provided care which might be reflected on their QOL. The suggested health 
policy areas include: 
1. Requesting physicians to inform patients about the pros and cons of different 
treatment modalities. Since most of treatment options available for localized 
prostate cancer yield similar results, discussing the pros and cons of each 
treatment option with prostate cancer patients will help them to choose the option 
that they think it will give them a better quality of life.  
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2. Set a plan to introduce a prostate cancer screening policy. Cancer screening 
contributed to the high incidence reported in the last few decades in the Western 
Countries. Some emerging evidence shows that discovering prostate cancer at 
early stages, where it will be curable, will be cost effective and improve QOL.  
3. Reconsider the referral policy to increase radiation therapy. Although the use of 
prostatectomy and radiation therapy is controversial, radiation therapy produces 
more bowel-related symptoms while producing less urinary and sexual 
dysfunction symptoms. Increasing the number of referrals for younger patients 
will preserve their sexual functioning and it will help in treating patients who 
have localized cancer but are unfit for surgical interventions.   
4. Set policies designated to eliminate barriers to health care. Eliminating removable 
barriers from the health care system will improve the quality of provided care for 
prostate cancer patients and will contribute to improving their quality of life.  
222 
BIBLIOGRAPHY 
 
 
Aaronson, N. K. (1990). Quality of life assessment in cancer clinical trials. In J. C. 
Holland & R. ZiHoun (Ed.), Psychological aspects of oncology (pp. 97-113). New 
Yourk: Springer-Velag. 
 
Abed, Y. (2007). Health sector review:  A summary report 2007. Retrieved February, 27, 
2009 from the World Health Organization website at: 
http://www.emro.who.int/palestine/reports/health_policy_planning/Health_Sector
_Review_Report_2007.pdf. 
Albaugh, J. & Hacker, E. D. (2005). Measurement of quality of life in men with prostate 
cancer. Clinical Journal of Oncology Nursing, 12(1), 81-86. 
Albertsen, P. C., Aaronson, N. K., Muller, M. J., Keller, S., D. & Ware, J. D. (1997). 
Health-related quality of life among patients with metastatic prostate cancer. 
Urology, 2, 207-217. 
 
American Cancer Society (2007a). Global cancer facts & figures: 2007. Retrieved June, 
11, 2008 from the American Cancer Society web site: 
http://www.cancer.org/downloads/STT/Global_Cancer_Facts_and_Figures_2007
_rev.pdf. 
 
American Cancer Society (2007b). Cancer facts & figure:2007. Atlanta: American 
Cancer Society. Retrieved June, 11, 2008 from the American Cancer Society web 
site: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf.  
 
American Cancer Society (2008). Overview: Prostate Cancer. Retrieved June, 11, 2008 
from the American Cancer Society web site: 
http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_What_is_prostate_canc
er_36.asp.  
 
American Cancer Society (2009). Cancer facts & figure: 2009. Atlanta: American 
Cancer Society. Retrieved April, 15, 2010 from the American Cancer Society web 
site: http://www.cancer.org/downloads/STT/500809web.pdf.  
 
 
 
 
223 
American Cancer Society. (2010). Overview: Prostate Cancer: How Many Men Get 
Prostate Cancer? Retrieved April, 17, 2010 from the American Cancer Society 
web site: 
http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_men_get_
prostate_cancer_36.asp?sitearea=. 
 
American Medical Student Association. (2009). Breaking barriers. Retrieved May 02, 
2009 from the American Medical students website: 
http://www.amsa.org/programs/barriers/barriers.html.  
 
American Urological Association. (2009). Prostate cancer awareness for men: A 
doctors’ guide for patients developed by the American Urological Association, 
Inc., Based on the PSA best practice policy. Retrieved March, 11, 2009 from the 
American Urological Association website at: 
http://www.auanet.org/content/guidelines-and-quality-care/clinical-
guidelines/patient-guides/prostate_awareness.pdf.  
 
Andel, G. v., & Kurth, K. H. (2003). The impact of androgen deprivation therapy on 
health related quality of life in asymptomatic men with lymph node positive 
prostate cancer. European Urology, 44, 209-214.  
 
Anderson, R. (1995). Revisiting the Behavioral Model and access to medical care: Does 
it matter? Journal of Health and Social Behavior, 36(1), 1-10.  
 
Anderson, R. and Newman, J. F. (2005). Societal and individual determinants of medical 
care utilization in the United States. Milbank Memorial Fund Quarterly: Health 
and Society, 83(4), 1-28. 
Arredondo, S. A., Latini, D. M., Sadetsky, N., Kawakami, J., Pasta, D. J., DuChane, J., et 
al. (2007). Quality of life for men receiving a second treatment for prostate 
cancer. The journal of urology, 177, 273-279. 
Association of International Development Agencies (AIDA). (2010). UN Humanitarian 
Coordinator and Association of International Development Agencies (AIDA): 
―The closure of the Gaza Strip puts at risk the health of people in Gaza and 
undermines the functioning of the health care system." Retrieve February, 11 
from the World Health Organization: Regional office for the Eastern 
Mediterranean website: 
http://www.emro.who.int/eha/pdf/GAZA_PR_Jan2010.pdf. 
 
Aus, G.,  Abbou, C. C., Bolla, M.,  Heidenreich, A. Schmid, H., van Poppel, H., et al. 
(2005). Editorial and EAUGuideline: EAUGuidelines on Prostate Cancer. 
European Urology 48, 546-551.  
 
224 
Bacon, C. G., Giovannucci, E., Testa, M., Glass, T. A., & Kawachi, I. (2002). The 
Association of treatment-related symptoms with quality-of-life symptoms for 
localized prostate carcinoma patients. Cancer, 94(3), 862-871. 
 
Bamberger, M., Rugh, J. & Marby, L. (2006). Realworld Evaluation: Working under 
budget, time, data, and political constraints. Thousand Oaks: Sage Publications. 
 
Bandura, A. (1986). Social foundations of thought and action: A social cognitive theory. 
Englewood Cliffs, NJ: Prentice- Hall, Inc. 
  
Barghouti, M. and Diabes, I. (1996). Infrastructure and health services in the Gaza Strip. 
Health Development Information Project in cooperation with the World Health 
Organization. Ramallh: Palestine.  
 
Barghouti, M. and Lennock, J. (1997). Health in Palestine. Potential and challenges. 
MAS Discussion Papers, Ramallah, Palestine.  
 
Bartsch, G., Horninger, W., Klocker, H., Eissigl, A., Oberaigner, W., Nitzer, D. S., et al. 
(2001). Prostate cancer mortality after introduction of Prostate-Specific Antigen 
mass screening in the Federal State of Tyrol, Austria. Urology, 58(3), 417–424.  
Battista, R. N., Williams, J. I., MacFarlane, L. A. (1986). Determinants of primary 
medical practice in adult cancer prevention. Med Care, 24, 216-224. 
Beckman, C. A., Buford, T. A., and Witt, J. B. (2000). Perceived barriers to prenatal care 
services. The American Journal of Maternal/Child Nursing, 25(1), 43-46. 
Benjamin-Coleman, R, Alexy, B. (1999). Use of the SF-36 to identify community 
dwelling rural elderly at risk for hospitalization. Public Health Nursing, 16(3), 
223-227. 
Blazer, D. G., Landerman, L. R., Fillenbaum, G., & Homer, R. (1995). Health services 
access and use among older adults in North Carolina: Urban vs. rural residents. 
American Journal of Public Health, 85(10), 1384-1390.  
Bottomley, A. (2002). The cancer patient and quality of life. The Oncologist, 7, 120-125. 
 
Brandeis, J. M., Litwin, M. S., Burnison, C. M., & Reiter, R. E. (2000). Quality of life 
outcomes after brachytherapy for early stage prostate cancer. Journal of Urology, 
163(3), 851-857. 
 
Brawer, M. K. 91995).  How to Use Prostate-Specific Antigen in the Early Detection or 
Screening for Prostatic Carcinoma. Cancer Journal for Clinicians,45, 148 - 164.  
 
225 
Brazier, J. E., Harper, R., Jones, N. M., O'Cathain, A., Thomas, K. J., Usherwood, T., et 
al. (1992). Validating the SF-36 health survey questionnaire: new outcome 
measure for primary care. British Medical Journal, 305 (6846), 194-2164. 
 
Bryne, Michelle, (2001). Data analysis strategies for qualitative research-Research 
Corner. AORN Journal, 74(3), 401-403.  
 
Calman, K. C. (1984). Quality of life in cancer patients- an hypothesis. Journal of 
Medical Ethics, 10, 124-127. 
 
Campbell, A. (1976). Subjective measures of well-being. American Psychology, 31(2), 
117-124. 
 
Carr, A. J., Gibson, B., & Robinson, P. G. (2001). Is quality of life determined by 
expectations or experience? British Medical Journal, 322(7296), 1240-1243. 
 
Cella, D. F. (1994). Quality of life: Concepts and definitions. Journal of Pain and 
symptoms, 9, 186-192. 
 
Cella, D. F. & Cherin, E.A. (1988). Quality of life during and after cancer treatment. 
Comprehensive Therapy, 14, 69–75. 
 
Cella, D. F., & Tulsky, D. S. (1990). Measuring quality of life today: methodological 
aspects. Oncology, 4(5), 29-38.  
 
Central Intelligence Agency (2009). The world factbook: Gaza Strip. Retrieved January, 
22, 2009 from Central Intelligence Agency web site: 
https://www.cia.gov/library/publications/the-world-factbook/print/gz.html.  
 
Chapple, A., & Ziebland, S. (2002). Prostate cancer: Embodied experience and 
perceptions of masculinity. Sociology of Health & Illness, 24(6), 820-841. 
Chin, M. H., Cook, S., Jin, L., Drum, M. L., Harrison, J. F.,  Koppert, J., et al. (2001). 
Barriers to providing diabetes care in community health centers. Diabetes Care, 
24, 268-274. 
 
Choice Regional Health Network. (2009). Barriers to health care services. Retrieved 
May, 2, 2009 from the Choice Regional Health Network website: 
http://crhn.org/reports/Barriers.htm.  
Clark, J. A., Inui, T. S., Silliman, R. A., Bokhour, B. G., Krasnow, S. H., Robinson, R. 
A., et al. (2003). Patients‟ perceptions of quality of life after treatment for early 
prostate cancer. Journal of Clinical Oncology, 21(20), 3777–3784. 
 
226 
Clark, J. A., Rieker, P., Propert, K. J., & Talcott, J. A. (1999). Changes in quality of life 
following treatment for early prostate cancer. Urology, 53, 161-168. 
Crawford, E. D., Benett, C. L., Stone, N. N., Knight, S. J., DeAntoni, E., Sharp, L., et al. 
(1997). Comparison of perspectives on prostate cancer: Analysis of survey data. 
Urology, 50 (3), 366-372.  
Crightom, F. I. (2002). The experience and self-care of men treated for prostate cancer. 
Unpublished doctoral dissertation, University of Kansas-Kansas.   
D'Amico, A. V., Whittington, R., Kaplan, L, Beard, C., Jiroutek, M., Malkowicz, S. B., 
et al. (1997). Equivalent biochemical failure-free survival after external beam 
radiation therapy or radical prostatectomy in patients with a pretreatment prostate 
specific antigen of > 4-22 ng/ml. International Journal of Radiation Oncolology 
Biolology Physics, 37(5), 1053-1058. 
Demark-Wahnefried, W., Strigo, T., Catoe, K., Conaway, M., Brunetti, M., Rimer, B. et 
al. (1995). Knowledge, beliefs, and prior screening behaviors among blacks and 
whites reporting for prostate cancer screening. Urology, 46,346–351.  
DeVellis, R.F. (1991). Scale development: Theory and application. Applied social 
research method theories serried v. 26. Newbury Park. CA: Sage.   
Drass, J., Kell, S., Osborn, M., Bausell, B., Corcoran, J., Moskowitz, A., et al. (1998). 
Diabetes care for Medicare beneficiaries: Attitudes and behaviors of primary care 
physicians. Diabetes Care, 21, 1282-1287. 
Dunn J., Lynch B., Rinaldis M., Pakenham K., McPherson L., Owen N., et al. (2006) 
Dimensions of quality of life and psychosocial variables most salient to colorectal 
cancer patients. Psycho-Oncology 15, 20–30. 
Estrada, A. L., Trevino, F. M., & Ray, L. A. (1990). Health care utilization barriers 
among Mexican Americans: Evidence from HHANES 1982-84. American 
Journal of Public Health, 80(Suppl), 27–31. 
 
Fairclough, D. L. (2002). Design and analysis of quality of life in clinical trials. New 
York: Chapman & hall/CRC. 
 
Fang, J. & Hao, Y. (2003). Quality of life: Issues concerning assessment and analysis. In 
Y. Lu & J. Fang (Ed.), Advanced medical statistics. (pp.195-231). London: World 
Scientific. 
 
Feather, N. T. (Ed.). (1982). Expectations and actions: Expectancy-value models in 
psychology. Hillsdale, NJ: Lawrence Erlbaum Associates. 
 
 
227 
Ferrans, C. E. (1990). Development of a quality of life index for patients with cancer. 
Oncology Nursing Forum, 17(3), 15-19. 
 
Ferrans, C.E. (1996). Development of a conceptual model of quality of life. Scholarly 
Inquiry for Nursing Practice, 10(3), 293-304. 
 
Ferrans, C. E. (2005). Quality of life as an outcome of cancer care. In C. H. Yarbro, M. 
H. Frogge, & M. G. Goodman (Eds.) Cancer nursing: Principles and practice 
(pp. 183-200). Boston: Jones and Bartlett Publishers.  
 
Field, A. (2009). Discovering statistics using SPSS (and sex and drugs and rock ‘n’ roll). 
London: Sage.  
 
Fleming, C., Wasson, J. H., Albertsen, Barry, P. C, & Wennberg, J. E. (1993). A decision 
analysis of alternative treatment strategies for clinically localized prostate cancer. 
Prostate Patient Outcomes Research Team. The Journal of American Medical 
Association, 269(20), 2650-2658. 
Fourcade, R. O., Benedict, A., Black, L. K. Stokes, M. E. Alcaraz, A. &  Castro, R. 
(2009). Treatment costs of prostate cancer in the first year after diagnosis: A 
short-term cost of illness study for France, Germany, Italy, Spain and the UK. 
BJU International, 105, 49-56. 
Fowler, F. J., Barry, M. J., Lu-Yao. G, Wasson, J. H., & Bin, L. (1996). Outcomes of 
external-beam radiation therapy for prostate cancer: A study of medicare 
beneficiaries in three surveillance, epidemiology, and end results areas. Journal of 
Clinical Oncolcology, 14(8), 2258-65. 
 
Frankel, S., Smith, G. D., Donovan, J., Neal, D. (2003). Screening for prostate cancer. 
Lancet, 361, 1122–28 
Gacci, M., Livi, L., Paiar, F., Detti, B., Litwin, M. S., Bartoletti, R., et al. (2005). Quality 
of life after radical treatment of prostate cancer: Validation of the Italian version 
of the University of California-Los Angeles Prostate cancer index. Urology 66, 
338–343. 
Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. (2002). Quality of life measurement: 
bibliographic study of patient assessed health outcome measures.  Quality of life 
measurement: bibliographic study of patient assessed health outcome measures. 
British Medical Journal, 324 (7351), 1417-21. Retrieved 15 March from the 
British Medical Journal website: 
http://www.bmj.com/cgi/content/full/324/7351/1417. 
 
Garvin, T. and Eyles, J. (2001).  Public health responses for skin cancer prevention: the 
policy framing of Sun Safety in Australia, Canada and England. Social Science & 
Medicine, 53(9), 1175-1189.  
228 
Georgetwon University, Child Development Center. (2009). Meeting the health care 
need of children in the foster care system: Framework for a comprehensive 
approach: Critical components. Retrieved march 1, 2009 from the Georgetwon 
University center for child and human development website at: 
http://gucchd.georgetwon.edu/files/products_publications/fccomponents.pdf.  
 
Giacaman, R., Abdul-Rahim, H. F., & Wick, L. (2003). Health sector reform in the 
Occupied Palestinian Territories (OPT): targeting the forest or the trees? Health 
Policy Plan, 18(1), 59-67.  
Gorin, S. S., Gauthier, J., Hay, J. Miles, A., & Wardle, J. (2008). Cancer screening and 
aging: research barriers and opportunities. Cancer, 113(12 suppl), 3493-504. 
Gotay, C.C. & Muraoka, M.Y. (1998). Quality of life in long-term survivors of adult-
onset cancers. Journal of the National Cancer Institute, 90, 656-667. 
Green, A. L., McSweeney, J., Ainley, K., and Bryant, J. (2009). Comparing parents‟ and 
children‟s views of children‟s quality of life after heart transplant. Journal for 
Specialists in Pediatric Nursing, 14(1), 49 – 58. 
Green, B. L., Krupnick, J. L., Rowland, J. H., Epstein, S. A., Stockton, P., Spertus, I., et 
al. (2000). Trauma history as a predictor of psychologic symptoms in women with 
breast cancer. Journal of Clinical Oncology, 18, 1084-1093. 
Green, H. J., Pakenham, K. I., Headley, B. C., & Gardiner, R. A. (2002). Coping and 
health-related quality of life in men with prostate cancer randomly assigned to 
hormonal medication or close monitoring. Psycho-Oncology, 11, 401-414. 
Guidry, J. J., Aday, L. A., Zhang, D., & Winn, R. J. (1997). Transportation as a barrier to 
cancer treatment. Cancer Practice, 5(6), 361-6. 
Gunning-Schepers, L. J.,  and Stronks, K. (1999). Inequalities in Health: Future Threats 
to Equity. Acta Oncologica,  38(1),  57–61.  
Gupta, D. K. (2001). Analyzing public policy: Concepts, tools, and techniques. 
Washington, D. C.: CQ Press. 
Harden, J., Schafenacker, A., Northouse, L., Mood, D., Smith, D., Pienta, K., et al. 
(2002). Couples' experiences with prostate cancer: Focus group research. Focus 
group research. Oncology Nursing Forum, 29(4), 701-709. 
Harris, R. and Lohr, K. N. (2002). Screening for Prostate Cancer: An Update of the 
Evidence for the U.S. Preventive Services Task Force. Annals of Internal 
Medicine, 137, 917-933. 
 
229 
Head, B. A. (2007). Development and validation of a scale to measure health-related 
socioeconomic well-being in persons with a cancer diagnosis. Ph.D. dissertation, 
University of Louisville, United States -- Kentucky. Retrieved August 21, 2008, 
from Dissertations & Theses: A&I database. (Publication No. AAT 3267088). 
 
Hedestig, O., Sandman, P., Tomic, R., & Widmark, A. (2005). Living after external beam 
radiotherapy of localized prostate cancer. Cancer Nursing, 28(4), 310-317. 
Heidenreich, A., Aus, G., Abbou, C.C., Bolla, M., Joniau, S., Matveev, V. et al. (2008). 
European Association of Urology. EAU guidelines on prostate cancer. European 
Urorologyl. 53: 68–80. Retrieved January, 10, 2010 from the European 
Association of Urology website: 
http://www.uroweb.org/fileadmin/user_upload/Guidelines/07_Prostate_Cancer_2
007.pdf. 
 
Held-Warmkessel, J. (2007). Pocket guide to prostate cancer. Boston: Jones And Bartlett 
publishers.  
Hoedemaeker RF, van der Kwast TH, Boer R, et al. de Koning, H. J., Roobol, M., Vis, A. 
N. & Schröder, F. H. (2001). Pathologic features of prostate cancer found at 
population-based screening with a 4-year interval. Journal of the National Cancer 
Institute, 93(15),1153-1158. 
Hoff, B. & Pow-Sang, J. M. (2001). Observation in the management of prostate cancer. 
Cancer Control, 8(2), 151-154. 
Holmberg, H., Carlsson, P.,  Löfman, O., & Varenhorst, E. (1998).  Economic evaluation 
of screening for prostate cancer: a randomized population based programme 
during a 10-year period in Sweden. Health Policy, 45, 133-147. 
 
Holstein, J.A., & Gubrium, J.F. (1997). Active interviewing. In D. Silverman (Ed.), 
Qualitative research: Theory, method and practice (pp. 113–129). Thousand 
Oaks, CA: Sage. 
Horan, A. H. & McGehee, M. (2000). Mean time to cancer-specific death of apparently 
clinically localized prostate cancer: Policy implications for threshold ages in 
prostate-specific antigen screening and ablative therapy. BJU International, 85, 
1063-1066. 
Hugosson, J., Aus, G., Lilja, H., Lodding, P., & Pihl, C. G. (2004). Results of a 
randomized, population-based study of biennial screening using serum prostate-
specific antigen measurement to detect prostate carcinoma. Cancer, 100(7), 1397-
1405.  
230 
ICRC. (2009). Gaza: 1.5 million people trapped in despair. Retrieved January, 25, 2010 
from the ICRC website: http://www.icrc.org/web/eng/siteeng0.nsf/html/palestine-
report-260609. 
 
Ilic, D., O‟Connor, D., Green, S., Wilt, T. (2007). Screening for prostate cancer: A 
Cochrane systematic review. Cancer Causes Control, 18, 279–285.  
Inoue, S., Shiina, H., Hiraoka, T., Wake, K., Sumura, M., Honda, S. et al. (2009). Five-
year longitudinal effect of radical perineal prostatectomy on health-related quality 
of life in Japanese men, using general and disease-specific measures. BJU 
International, 104, 1077–1084. 
Ishihara, M., Suzuki, H., Akakura, K., Komiya, A., Imamoto, T., Tobe, T., et al. (2006). 
Baseline health-related quality of life in the management of prostate cancer. 
International Journal of Urology, 13, 920–925. 
 
Janecka, I. P. (2009). Is U.S. health care an appropriate system? A strategic perspective 
from systems science. Health Research Policy and Systems, 7(1), 1-13. Retrieved 
March, 1, 2009 from the Health Research and Policy Systems website at: 
http://www.health-policy-systems.com/content/pdf/1478-4505-7-1.pdf.  
Jayadevappa, R., Chhatre, S. Whittington, R., Bloom, B. S., Wein, A. J. & Malkowicz, S. 
B. (2006). Health-related quality of life and satisfaction with care among older 
men treated for prostate cancer with either radical prostatectomy or external beam 
radiation therapy. BJU International, 97, 955–962.  
Jo, Y., Junichi, H., Tomohiro, F., Yoshinari, I. & Masato, F. (2005). Radical 
prostatectomy versus high-dose rate brachytherapy for prostate cancer: Effects on 
health-related quality of life. BJU International, 96, 43-47.  
Jonler, M, Ritter, M. A., Brinkmann, R., Messing, E., Rhodes, P. & Bruskewitz, R. 
(1994). Sequelae of definitive radiation therapy for prostate cancer localized to 
the pelvis. Urology, 44 (6), 876-882. 
Kakehi, Y.,  Kamoto, T.,  Ogawa, O., Arai, Y., Litwin, M. S., Suzukamo, Y. et al. (2002). 
Development of Japanese version of the UCLA Prostate Cancer Index: A pilot 
validation study. International Journal of Clinical Oncology, 7(5), 306–311. 
 
Kalant, H., Grant, D. M., & Mitchell, J. (2007). Principles of medical pharmacology. 
Toronto: Saunders Elsevier. 
Karakiewicz, P. I., Kattan, M. W., Tanguay, S.  Elhialli, M. M., Bazinet, M., Scardino, 
P.T., et al. (2003). Cross-cultural validation of the UCLA Prostate Cancer Index.  
Urology, 61, 302–307. 
 
231 
Kim, H. S., Schwarz-Barcott, D., Holter, L.M., Lorensen, M. (1995).  Developing a 
translation of the McGill pain questionnaire for crosscultural comparison: An 
example from Norway. Journal of Advanced Nursing, 21, 421–426. 
 
King, C. R. (2006). Advances in how clinical nurses can develop and improve quality of 
life for individuals with cancer. Oncology Nursing Forum, 33(1), 5-12. 
 
Kingdon, J. W. (1995). Agenda, alternatives, and public policies. New York: Harper 
Collins. 
 
Kline, R. B. (1998). Principles and practice of structural equation modeling. New York, 
NY: Guilford Press. 
Korfage, I. J., Essink-Bot, M., Madalinska, J. B., Kirkels, W. J., Litwin, M. S. & de 
Koning, H. J. (2003). Measuring disease specific quality of life in localized 
prostate cancer: The Dutch experience. Quality of Life Research, 12, 459–464. 
Kvåle, R., Auvinen, A., Adami, H. O., Klint, A., Hernes, E., Møller, B., et al. (2007). 
Interpreting trends in prostate cancer incidence and mortality in the five Nordic 
countries. Journal of the National Cancer Institute, 19, 1881-1887.  
 
Labrie, F., Candas, B., Cusan, L., Gomez, J. L., Be´langer, A., Brousseau, G. et al. 
(2004). Screening Decreases Prostate Cancer Mortality: 11-Year Follow-Up of 
the1988Quebec Prospective Randomized Controlled Trial. The Prostate, 59, 311-
318.  
 
Labrie, F., Candas, B., Dupont, A., Cusan, L., Gomez, J., Suburu, R. E. et al. (1999). 
Screening decreases prostate cancer death: First analysis of the 1988 Quebec 
prospective randomized controlled Trial. The Prostate, 38, 83–91. 
 
Leplege, A., & Hunt, S. (1997). The problem of quality of life in medicine. Journal of the 
American Medical Association, 278(1), 47-50. 
 
Library index. (2009). The Nation's Health Care System - The Components Of The 
Health Care System. Retrieved February 28, 2009 from the library index website 
at: http://www.libraryindex.com/pages/1817/Nation-s-Health-Care-System-
COMPONENTS-HEALTH-CARE-SYSTEM.html.  
 
Lin K, Lipsitz R, Miller T, & Janakiraman S. (2008). Benefits and harms of prostate-
specific antigen screening for prostate cancer: an evidence update for the U.S. 
Preventive Services Task Force. Annals of Internal Medicine, 149,192–199.  
Litwin, M. S. (1994). Measuring health related quality of life in men with prostate cancer. 
The Journal of Urology, 152, 1882-1887. 
232 
Litwin, M. S. (1994). UCLA Prostate Cancer Index (UCLA-PCI), including the RAND 
36-Item Health Survey v2 (SF-36 v2) Health-Related Quality of life: Scoring 
instructions. Retrieved March 10, 2009 from the Patient-Reported Outcome and 
Quality of Life Instruments Database (PROQOLID) website: 
www.proqolid.org/proqolid/content/download/5312/48954/version/1/file/scoring-
ucla-pci.pdf. 
 
 Litwin, M. S., Hays, R. D., Fink, A., Ganz, P., Leake, B. & Brook, R. T. (1998). The 
UCLA Prostate Cancer Index development, reliability, and validity of a health-
related quality of life measure.  Medical Care, 36 (7), 1002-1012.  
 
Litwin, M. S., Hays, R. D., Fink, P, Ganz, P. A., Leake, B., Leach, G. E. et al (1995). 
Quality-of-life outcomes in men treated for localized prostate cancer. JAMA, 
273(2), 129-135. 
Litwin, M. S. & McGuigan, K. A. (1999). Accuracy of recall in health-related quality-of-
life assessment among men treated for prostate cancer. Journal of Clinical 
Oncology, (17) 9, 2882-2888. 
Litwin, M. S., McGuigan, K. A., Shpall, A. I., & Dhanani, N. (1999). Recovery of health 
related quality of life in the year after radical prostatectomy: Early experience. 
The Journal of Urology, 161(2), 515–519.  
Litwin, M. S., Melmed, G. Y., & Nakazon, T. (2001). Life after radical prostatectomy: a 
longitudinal study. Journal of Urology, 166(2), 587-592. 
 
LoBiondo-Wood, G., and Haber, J. (2006). Nursing research: methods and critical 
appraisal for evidence-based practice. Louis: Mosby Elsevier.   
Lubeck, D. P., Litwin, M. S., Henning, J. M. & Carroll, P. R. (1997). Measurement of 
health-related quality of life in men with prostate cancer: The 
CaPSURETMdatabase. Quality of Life Research, 6, 385–392. 
Lubeck, D. P., Litwin, M. S., Henning, J. M. and Carroll, P. R. (1997). Measurement of 
health-related quality of life in men with prostate cancer: the CaPSURE" 
database. Quality of Life Research, 6, 385. 
 
Lu-Yao GL, McLerran D, Wasson J, &  Wennberg, J. E. (1993). An assessment of 
radical prostatectomy: time trends, geographic variation, and outcomes. Journal 
of the American Medical Association 269(20), 2633-2636. 
 
 
233 
Madalinska, J. B., Essink-Bot, M., de Koning, H. J., Kirkels, W. J., van der Maas, P. J., 
&  Schröder, F. H. (2001). Health-related quality-of-life effects of radical 
prostatectomy and primary radiotherapy for screen-detected or clinically 
diagnosed localized prostate cancer. Journal of Clinical Oncology, (19)6, 1619-
1628.  
Mäkinen, T., Tammela, T.L., Stenman, U. H., Määttänen, L., Aro, J.,  Juusela, H. et al. 
(2004). Second round results of the Finnish population-based prostate cancer 
screening trial. Clinical Cancer Research, 10(7), 2231-223 6.  
Mandelblatt, J. S., Yabroff, K. B., & Kerner, J. F., (1999). Equitable access to cancer 
services: A review of barriers to quality care. Cancer, (86)11, 2378-2390. 
 
Margolis, P. A., Carey, T., Lannon, C. M., Earp, J. L., and Leininger, L. (1995). The rest 
of the access-to-care puzzle. Archives of Pediatric and Adolescent Medicine, 149, 
541-545. 
 
Marieb, E. N. & Hoehn, K. (2007). Human anatomy & physiology. New York: Pearson 
Benjamin Cummings.   
Martinez, A. A., Gonzalez, J. A., Chung, A. K., Kestin, L. L., Balasubramaniam, M., 
Diokno, A. C., et al. (2000). A comparison of external beam radiation therapy 
versus radical prostatectomy for patients with low risk prostate carcinoma 
diagnosed, staged, and treated at a single institution. Cancer, 88(2), 425–432. 
 
Mataria, A., Donaldson, C., Luchini, S., and Moatti, J. P. (2004). A stated preference 
approach to assessing health care-quality improvements in Palestine: from 
theoretical validity to policy implications. Journal of Health Economics, 23 (6), 
1285–1311.  
 
McCance, K. L. & Huether, S. E. (2006). Pathophysiology: The biologic basics for 
disease in adults and children. St. Louis: Elsevier Mosby.  
 
McCullock-Melnyk, K. A. (1998). Barriers: A critical review of recent literature. Nursing 
Research, 37(4), 196-201.  
 
McKinlay, J. B. (1972). Some approaches and problems in the study of the use of 
services - An overview. Journal of Health and Social Behavior, 13(2), 115-152. 
 
Meadowcroft, J. (2008). Patients, Politics, and Power: Government Failure and the 
Politicization of U.K. Health Care. Journal of Medicine and Philosophy , 33, 427 
- 444.  
234 
Melmed, G. Y., Kwan, L., Reid, K., & Litwin, M. S. (2002). Quality of life at the end of 
life: Trends in men with metastatic prostate cancer. Urology, 59(1), 103–109.  
Middleton, R. G., Thompson, I. M., Austenfeld, M. S., Cooner, W. H., Correa, R. J., 
Gibbons, R. P., et al. (1995). Prostate Cancer Clinical Guidelines Panel Summary 
report on the management of clinically localized prostate cancer. The American 
Urological Association. The Journal of Urology, 154(6), 2144-2348. 
 
Ministry of Health (1999).  National strategic health plan (1999–2003). Palestinian 
National Authority, Palestine. 
 
Ministry of Health. (2005). Heath status in Palestine: Annual report 2004. Gaza: 
Ministry of Health 
 
Ministry of Health. (2006). Annual report 2006. Retrieved February, 15, 2009 from the 
Ministry of health website: http://MoH.ps/en/. 
 
Ministry of Health. (2006). Annual report, 2005. Retrieved June, 11, 2008 from the 
Palestinian Ministry of Health web site: 
http://MoH.ps/data_all_img/1190458675.pdf. 
 
Ministry of Health. (2009). Genocide carried out in Gaza Strip by Israeli military forces: 
Report of the 23th  day of massacres- From 27-12-2008 to 18-01-2009. Retrieved 
February 15, 2009 from the Ministry of Health website: 
http://www.MoH.gov.ps/?action=repd.  
Ministry of health (2010). Martyrs of the blockade. Retrieve March, 9 from the 
Palestinian Ministry of health web site: 
http://www.moh.gov.ps/newsite/ar/index.php?action=view&page=siegevictims&a
rchive=true. 
Moul, J. W. (1998). Treatment options for prostate cancer: part 1–stage, grade, PSA, and 
changes in the 1990‟s. The American Journal of Managed Care, 4(8), 1031-1038. 
 
Muldoon, M. F., Barger, S. D., Flory, J. D. & Manuck, S. B. (1998). What are quality of 
life measurement measuring? British Medical Journal, 316(7139), 542-545. 
 
Munden, J. (2007). Lippincott manual of nursing practice series: Pathophysiology. 
Philadelphia : Lippincott Williams & Wilkins. 
Munro, B. H. (1997). Statistical methods for health care research. New York: Lippincott. 
 
Najjar, K, Awad, R, & Thabet, K. (2002). Cancer 1995-2000: Palestine. State of 
Palestine: Ministry of Health. 
235 
Namiki, S., Ishidoya, S., Saito, S., Satoh, M., Tochigi, T., Ioritani, N., et al. (2006). 
Natural history of voiding function after radical retopubic prostatectomy. 
Urology, 68, 142–147. 
Namiki, S., Takegami, M., Kakehi, Y., Suzukamo, Y., Fukuhara, S., & Arai, Y. (2007). 
Analysis linking UCLA PCI with expanded Prostate Cancer Index composite: An 
evaluation of health related quality of life in Japanese men with localized prostate 
cancer. The Journal of Urology, 178, 473-477.  
Namiki, S., Tochigi, T., Kuwahara, M., Ioritani, N., Yoshimura, K., Terai, A., et al. 
(2004). Recovery of health related quality of life after radical prostatectomy in 
Japanese men: a longitudinal study. International Journal of Urology, 11(9), 742-
794. 
 
Navon, L., & Morag, A. (2003). Advanced prostate cancer patients' ways of coping with 
the hormonal therapy's effect on body, sexuality, and spousal ties. Qualitative 
Health Research, 13(10), 1378-139. 
 
Neema, S. (2005). The impact of health policies and health sector reform on the 
readiness of health systems to respond to women’s health needs, with special 
focus on reproductive health, reproductive rights and HIV/AIDS. United Nations 
Division for the Advancement of Women (DAW) Expert Group Meeting 
Enhancing Participation of Women in Development through an Enabling 
Environment for Achieving Gender Equality and the Advancement of Women. 
Bangkok, Thailand. Retrieved march 7, 2009 from the United Nations website at: 
http://www0.un.org/womenwatch/daw/egm/enabling-
environment2005/docs/EGM-WPD-EE-2005-EP.11%20%20S.pdf. 
 
Nelson, W. G., De Marzo, A. M., & Isaacs, W. B. (2003). Prostate cancer. The New 
England Journal of Medicine, 349: 366-381. 
 
Neuman, W. L. (2006). Social research methods. Qualitative and quantitative 
approaches. Boston: Pearson Education.  
Nguyen, L. N., Pollack, A., & Zagars, G. K. (1998). Late effects after radiotherapy for 
prostate cancer in a randomized dose-response study: Results of a self-assessment 
questionnaire. Urology, 51(6), 991-997. 
Oliffe, J. (2005). Constructions of masculinity following prostatectomy-induced 
impotence. Social Science & Medicine, 60, 2249-2259. 
Osoba, D. (1991). Measuring the effect of cancer of quality of life. In D. Osoba (Ed.), 
Effect of cancer on quality of life (pp. 25-40). Boston: CRC Press. 
 
Oxford Dictionary. (2009). Barrier. Retrieved May 15, 2009 from Oxford Dictionary 
website: http://www.askoxford.com/concise_oed/barrier?view=uk.  
 
236 
Padilla, G. V., Ferrel, B., Grant, M. M., & Rhiner, M. (1990). Defining the content 
domain of quality of life for cancer patients with pain. Cancer Nursing, 13, 108-
115.  
 
Palestine History (2009). Palestine brief history. Retrieved January, 22, 2009 from 
Palestine History website: 
http://www.palestinehistory.com/history/brief/brief.htm#02.   
 
Palestinian Central Bureau of Statistics. (2008). Population, housing and establishment 
census-2007. Press conference on the preliminary findings: Population, 
buildings, housing units and establishments. Retrieved January, 21, 2009 from the 
Palestinian Central Bureau of Statistics website: 
http://www.pcbs.gov.ps/Portals/_pcbs/PressRelease/census2007_e.pdf.  
 
Palestinian Central Bureau of Statistics. (2009). Literacy rate of Palestinian population 
(15 years and over) by age groups, sex and region, 1995, 1997, 2000, 2001, 2002, 
2003, 2004, 2005, 2006, 2007. Retrieved February, 23, 2009 from the Palestinian 
Central Bureau of Statistics website: 
http://www.pcbs.gov.ps/Portals/_pcbs/educatio/edut1.htm.   
Palestinian Central Bureau of Statistics. (2009). Population, Housing and Establishment 
Census 2007: Main Indicators by Locality Type. Retrieved on January, 27, 2010 
from the Palestinian Central Bureau of Statistics website: 
http://www.pcbs.pna.org/Portals/_pcbs/census2007/ind_loca_09.pdf. 
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997). Cancer statistics 1997. CA 
Cancer J Clin, 47, 5–27. 
Patient-Reported Outcome and Quality of Life Instruments Database. (2009). UCLA 
Prostate Cancer Index (UCLA-PCI), including the RAND 36-Item Health Survey 
v2 (SF-36 v2). Retrieved March 10, 2009 from the Patient-Reported Outcome and 
Quality of Life Instruments Database (PROQOLID) website:  
www.proqolid.org/proqolid/content/download/5309/48945/version/1/file/ucla-
pci%2520&%2520sf-36%2520v2.pdf.  
 
Patrick, D. L. and Erickson, P. (1993). Health status and health policy: quality of life in 
health care evaluation and resource allocation. Oxford: Oxford University Press.  
 
Patton, M. Q. (2002). Qualitative research and evaluation methods. Thousand Oaks: 
Sage.  
 
Pender, N. J. (1996). Health Promotion in Nursing Practice. Stamford, Connecticut: 
Appleton & Lange. 
 
 
237 
Pender, N. J., Murdaugh, C. L., & Parsons, M.A. (2002). Health Promotion in Nursing 
Practice. Upper Saddle River, NJ: Prentice Hall.  
Pender, N. J., Murdaugh, C. L., & Parsons, M. A. (2006). Health promotion in nursing 
practice. Upper Saddle River, NJ: Prentice Hall. 
Penson, D. F., & Litwin, M. S. (2003). Quality of life after treatment for prostate cancer. 
Current Urology Reports, 4(3), 185–195. 
 
Penson, D. F., Feng, Z., Kuniyuki, A., McClerran, D., Albertsen, P. C., Deapen, D., et al. 
(2003). General quality of life 2 years following treatment for prostate cancer: 
What influences outcomes? Results from the prostate cancer outcomes study. 
Journal of Clinical Oncology, 21(6), 1147-1154 
 
Peters, R. G. (2004). American public policy: Promise and performance. Washington, 
D.C.: CQPress.  
 
Polit, D. F. and Beck, C.T. (2006).The Content Validity Index: Are you sure you know 
what‟s being reported? Critique and recommendations. Research in Nursing & 
Health, 29, 489–497. 
 
Polit, D. F., & Beck, C. T. (2004). Nursing research principles and methods. 
Philadelphia: Lippincott Williams & Wilkins. 
 
 Polit, D. F. and Beck, C. T. (2008). Nursing research: generating and assessing 
evidence for nursing practice. Philadelphia: Lippincott Williams & Wilkins. 
Potosky, A. L., Davis, W. W., Hoffman, R. M., Stanford, J. L., Stephenson, R. A., 
Penson, D. F., et al. (2004). Five-year outcomes after prostatectomy or 
radiotherapy for prostate cancer: The prostate cancer outcomes study. Journal of 
the National Cancer Institute, 96(18), 1358-1367. 
 
Potosky, A. L., Harlan, L. C., Stanford, J. L., Gilliland, F. D., Hamilton, A. S., Albertsen, 
P. C., et al. (1999). Prostate cancer practice patterns and quality of life: The 
prostate cancer outcomes study. Journal of the National Cancer Institute, 91(20), 
1719-1724. 
 
Potosky, A.L., Legler, J., Albertsen, P.C., Stanford, J. L., Gilliland, F. D., Hamilton, A. 
S., et al. (2000). Health outcomes after prostatectomy or radiotherapy for prostate 
cancer: Results from the prostate cancer outcomes study. Journal of the National 
Cancer Institute, 92(19), 1582-1592. 
Powell, I., Gelfland, D., Parzuchowski, J., Heilbrun, L., & Franklin, A. (1995). A 
successful recruitment process of African American men for early detection of 
prostate cancer. Cancer, 75, 1880–1884. 
 
238 
Punch, K. (2005). Introduction to social research: Qualitative and quantitative 
approaches. London: Sage. 
Ramos, C. G., Carvalhal, G. F., Smith, D. S., Mager, D.E., & Catalona, W. J. (1999). 
Retrospective comparison of radical retropubic prostatectomy and 125iodine 
brachytherapy for localized prostate cancer. The Journal of Urology, 161(4), 
1212-1215.  
Reis, F., Netto, N. R., Reinato, J. A., Thiel, M., & Zani, E. (2004). The impact of 
prostatectomy and brachytherapy in patients with localized prostate cancer. 
International Urology and Nephrology, 36, 187-190. 
 
Ries, L., Melbert, D., Krapcho, M., Stinchcomb, D., Howlader, N., Horner, M., Mariotto, 
A., et al. (2008). SEER Cancer Statistics Review, 1975-2005, National Cancer 
Institute. Bethesda, MD. Retrieved July, 11, 2008 from Surveillance 
Epidemiology End Result (SEER) web site:  
http://seer.cancer.gov/csr/1975_2005/results_single/sect_01_table.01.pdf. 
Robinson, A. B., Ashley, M., Haynes, M.A. (1996). Attitudes of African Americans 
regarding screening for prostate cancer. Journal of the National Medical 
Association, 88, 241–243. 
 
Roemer, M. I. (1991). National health systems of the world. New York, Oxford 
University Press. 
Rutten, L. J., Nelson, D. E., & Meissner, H. I. (2004). Examination of population-wide 
trends in barriers to cancer screening from a diffusion of innovation perspective 
(1987–2000). Preventive Medicine 38, 258-268. 
 
Sabbah, I, Drouby, N., Sabbah, S., Retel-Rude, N., & Mercier, M. (2003). Quality of Life 
in rural and urban populations in Lebanon using SF-36 Health Survey. Health and 
Quality of Life Outcomes, 1, 30-43. Retrieved May, 1, 2009 from the Health and 
Quality of Life Outcomes website: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=194221.  
Saigal, C. S., Gornbein, J., Reid, K. & Litwin, M.S. (2002). Stability of time trade-off 
utilities for health states associated with the treatment of prostate cancer. Quality 
of Life Research, 11, 405–414. 
Schröder, F. H. (2008).  Screening for prostate cancer (PC)-an update on recent findings 
of the European Randomized Study of Screening for Prostate Cancer (ERSPC). 
Urologic Oncology, 26(5), 533–541. 
Scott, C. (2005). Value-adding policy analysis and advice: New roles and skills for the 
public sector. Policy Quarterly, 1(3), 10-15. 
239 
 Secchi, G. & Strepparava, M. G. (2001). The quality of life in cancer patients: A 
cognitive approach. European Journal of Internal Medicine 12, 35–42. 
Sennfalt, K., Sandblom, G., Carlsson, P., & Varenhorst, E. (2004). Costs and effects of 
prostate cancer screening in Sweden: A 15-year follow-up of a randomized trial. 
Scandinavian Journal of Urology and Nephrology, 38, 291–8. 
 
Shafritz, , J. M. and Russell, E. W. (1997). Introducing public administration. New York. 
Longman.  
Shafritz, J. M. & Russell. E. W. (1999). Introducing public administration. New York: 
Longman. 
 
Shier, D., Butler, J, & Lewis, R. (2007). Hole’s Human anatomy & physiology. Boston: 
McGraw Hill Higher Education.  
Shikanov, S. A., Eng, M. E., Bernstein, A. J., Katz, M., Zagaja, G. P., Shalhav A. L., et 
al. (2008). Urinary and sexual quality of life 1 year following robotic assisted 
laparoscopic radical prostatectomy. The Journal of Urology, 180, 663-667. 
Shrader-Bogen, C. L., Kjellberg, J. L., McPherson, C. P., & Murray, C. L. (1997). 
Quality of life and treatment outcomes: Prostate carcinoma patients' perspectives 
after prostatectomy or radiation therapy. Cancer, 79(10), 1977-1986. 
 
Sneed, N.V., Paul, S., Michel, Y., Vanbakel, A., and Hendrix, G. (2001). Evaluation of 3 
quality of life measurement tools in patients with chronic heart failure. Heart 
Lung, 30, 332-340. 
Sommers, S. D. & Ramsey, S. D. (1999). A Review of Quality-of-Life Evaluations in 
Prostate Cancer. Pharmacoeconomics, 16 (2), 127-140. 
 
Sprangers, M. G. & Schwartz, C. E. (1999). Integrating response shift into health-related 
quality of life research: a theoretical model. Social Science & Medicine (48)11, 
1507-1515.  
Stanford, J. L., Feng, Z., Hamilton, A. S., Gilliland, F. D., Stephenson, R. A., Eley, J. W., 
et al. (2000). Urinary and sexual function after radical prostatectomy for clinically 
localized prostate cancer: the prostate cancer outcomes study. The Journal of the 
American Medical Association, 283(3), 354-360. 
 
Tabachnick, B. G., & Fidell, L. S. (2001). Using multivariate statistics (4th ed.). Boston: 
Allyn & Bacon. 
Tewari. A., Johnson, C. C., Divine, G., Crawford, E. D., Gamito, E. J., Demers, R., et al. 
(2004). Long-term survival probability in men with clinically localized prostate 
cancer: A case-control, propensity modeling study stratified by race, age, 
treatment and comorbidities. The Journal of Urology, 171, 1513-1519.  
240 
The Center for Universal Design and The North Carolina Office on Disability and Health. 
(2009). Removing barriers to health care: A guide for health professionals. 
Retrieved May, 5, 2009 from the University of North Carolina, FPG Child 
Development Institute website: http://www.fpg.unc.edu/~ncodh/rbar/.  
 
The RAND Palestinian State Study Team. ( 2007). Building a Successful Palestinian 
State. Retrieved March 2, 2009 from RAND Corporation website at: 
http://www.rand.org/pubs/monographs/2007/RAND_MG146-1.pdf.  
Turini, M., Redaelli, A., Gramegna, P., & Radice, D. (2003). Quality of life and 
economic considerations in the management of prostate cancer. 
Pharmacoeconomics, 21(8), 527-541. 
 
UCLA Health System. (2009). Prostate cancer - Symptoms treatment and diagnosis. 
Retrieved March 17, 2009 from the University of California, Los Angeles 
website: http://urology.ucla.edu/body.cfm?id=152.   
 
University of Kentucky Department of Surgery. (2009). UCLA Prostate Cancer Index 
(UCLA-PCI), including the RAND 12-Item Health Survey v2 (SF-12 v2).  
Retrieved March, 5, 2009 from the University of Kentucky Department of 
Surgery.website:   www.mc.uky.edu/surgery/Uro/clinic/prostate-index.pdf. 
 
Uszok, A., Bradshaw, J., Jeffers, R., Suri, N., Hayes, P., Breedy, M., et al. (2003). KAoS 
policy and domain services: toward a description-logic approach to policy 
representation, deconfliction, and enforcement. Policies for Distributed Systems 
and Networks, 2003. Proceedings. POLICY 2003. IEEE 4th International 
Workshop on 4-6 June 2003, pp. 93-96. Retrieved march 5, 2009 from the IEEE 
website: 
http://ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=1206963&isnumber=27164.  
Van Erps, P., van den Weyngaert, D, & Denis, L. (1998). Surgery or radiation: Is there 
really a choice for early prostate cancer. Critical Reviews in 
Oncology/Hematology, 27 (1): 11-27.  
 
Varricchio, C. G. (2006). Measurement issues in quality-of-life assessments. Oncology 
Nursing Forums, 33(1), 13-21. 
 
Visser, A.,  van Andel, G., Willems, P., Voogt, E., Dijkstra, A., Rovers, P., Goodkin, 
K., Kurth K. (2003). Changes in health-related quality of life of men with prostate 
cancer 3 months after diagnosis: the role of psychosocial factors and 
comparisment with benign prostate hyperplasia patients. Patient Education and 
Counseling, 49(3):225-32. 
 
241 
Wakatsuki, M., Tsuji, H., Ishikawa, H., Yangi., Kamada, T., & Nakano, T. et al. (2008). 
Quality of life in men treated with carbon ion therapy for prostate cancer. 
International Journalof Radiation Oncology Biology Physics. 72(4), 1010–1015.  
Walker, W. E. (2000). Policy analysis: A systematic approach to supporting 
policymaking in the public sector. Journal of Multi-Criteria Decision Analysis, 9, 
11–27. 
 
Walters, S.J., Munro, J.F., Brazier, J. E. (2001). Using the SF-36 with older adults: A 
cross-sectional community-based survey. Age Aging, 30,337–343.  
Ward, J. F., Zincke, H., Bergstralh, E. J., Slezak, J. M., Myers, R. P., & Blute, M. L. 
(2004). The impact of surgical approach (nerve bundle preservation versus wide 
local excision) on surgical margins and biochemical recurrence following radical 
prostatectomy. The Journal of Urology , 172(4), 1328-1332. 
 
Ware, J. E. & Sherbourne, C. D. (1992). The MOS 36-item Short Form Health Survey 
(SF36): 1. Conceptual framework and item selection. Medical Care, 30(6), 473-
483. 
 
Ware, J. E., Snow, K. K., Kosinski, M., & Gandek, B. (1993). SF-36 health survey: 
Manual and interpretation guide. Boston: The Health Institute, New England 
Medical Center.  
 
Ware, J.E., Jr. (2000). SF-36 Health Survey update. Spine, 25, 3130-3139. Retrieved 
from Sf-36.org website: http://www.sf-36.org/tools/SF36.shtml, and 
http://74.125.95.132/search?q=cache:R_w-0zogFFQJ:www.sf-
36.org/tools/SF36.shtml+%22SF-
36+health+survey+update%22&cd=1&hl=en&ct=clnk&gl=us.  
Wei, J. T., Dunn, R. L., Sandler, H. M., McLaughlin, P. W., Montie, J. E., Litwin, M. S., 
et al. (2002). Comprehensive comparison of health-related quality of life after 
contemporary therapies for localized prostate cancer. Journal of Clinical 
Oncology, 20(2), 557–566. 
Weimer, D., L. & Vining, A. V. (1999) Policy Analysis: Concepts and Practice. New 
Jersey: Prentice Hall. 
 
 
 
 
 
 
 
 
242 
Weinick, R. M., Zuvekas, S. H., and Drilea, S. K. (1997). Access to health care—
Sources and barriers, 1996. Rockville: (MD) Agency for Health Care Policy and 
Research. MEP Research Finding No. 3. AHCPR Pub. No 98-0001. Retrieved 
may, 11, 2009 from the Agency for Health Care Policy and Research website: 
http://www.meps.ahrq.gov/mepsweb/data_files/publications/rf3/rf3.pdf#xml=http
://meps.ahrq.gov/cgi-
bin/texis/webinator/search/pdfhi.txt?query=barriers+to+heath+care&pr=MEPSFU
LLSITE&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=
500&sufs=0&order=r&cq=&id=49faf9c9102 
Weinrich, S., Reynolds, W., Tingen, M., & Starr, C. R.  (2000). Barriers to prostate 
cancer screening. Cancer Nursing, 23(2), 117-121.  
Wikipedia. (2009). Prostate. Retrieved March 5, 2009 from Wikipedia website at: 
http://en.wikipedia.org/wiki/Prostate.  
 
Willig, C. (2001). Introducing qualitative research in psychology: Adventures in theory 
and method. Buckingham, Philadelphia: Open University Press. 
Wilson, L. S., Tesoro, R., Elkin, E. P., Sadetsky, N., Broering, J. M., Latini, D. M., et al. 
(2007). Cumulative Cost Pattern Comparison of Prostate Cancer Treatments. 
Cancer, 109, 518–27. 
Woolf, S. H. (1995). Current concepts: Screening for prostate cancer with prostate-
specific antigen: An examination of the evidence. The New England Journal of 
Medicine, 333(21), 1401-1405. 
 
World Health Organization Quality of Life Group. (1993). Study protocol for the World 
Health Organization project to develop a quality of life assessment instrument. 
Quality of Life Research, 2, 153-159. 
 
World Health Organization Quality of Life Group. (1996). Measuring quality of life: The 
World Health Organization quality of life instruments. Retrieved August, 11, 
2008 from the World Health Organization website: 
http://www.who.int/mental_health/media/68.pdf.    
 
World Health Organization. (2000). The World health report 2000 : health systems : 
improving performance. Retrieved February, 28, 2009 from the World Health 
Organization website at: http://www.who.int/whr/2000/en/whr00_en.pdf.  
 
World Health Organization. (2000a). The work of WHO in the eastern Mediterranean 
region: Annual report of the regional director, 1 January- 31 December, 2000: 
Health systems and services development. Retrieved March, 3, 2009 from the 
World Health Organization website at: 
http://www.emro.who.int/RD/AnnualReports/2000/Chapter3-Part2.htm.  
 
243 
World Health Organization. (2001). World health day 2001: Stop exclusion-day to care, 
Country profiles: The Palestinian population. Retrieved February, 28, 2009 from 
the World Health Organization website at: 
http://www.emro.who.int/mnh/whd/CountryProfile-PAL.htm.  
 
World Health Organization. (2005). Country Cooperation Strategy for WHO and the 
Occupied Palestinian Territory 2006–2008. Retrieved February, 27, 2009 from 
the World Health Organization website at: 
http://www.healthinforum.net/files/who/CCS-Palestine.pdf.  
 
 
World Health Organization. (2006). Integrated health systems strengthening:An 
operational framework. Retrieved February, 28, 2009 from the World Health 
Organization website at: 
http://www.searo.who.int/LinkFiles/GAVI_HSS_operation_frame.pdf.  
World Health Organization: West bank & Gaza. (2010). Gaza health fact sheet. Retrieve 
February, 11 from the World Health Organization: Regional office for the Eastern 
Mediterranean website: 
http://www.emro.who.int/Palestine/reports/advocacy_HR/advocacy/Gaza_health_
fact_sheet_20Jan2010.pdf.  
 
Young, K. J., & Longman, A. J. (1983). Quality of life and persons with melanoma: A 
pilot study. Cancer Nursing, 3, 219-225. 
 
 
 
 
 
 
 
 
 
 
 
244 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
245 
APPENDIX A 
A PREVIEW ABOUT GAZA STRIP 
 
The territories of the Palestinian National Authority (PNA) (Figure A-1) are 
comprised of two geographically separated areas known as the West Bank and Gaza 
Strip. The Gaza Strip is a narrow strip of land that lies along the southeastern coast of the 
Mediterranean Sea. It is about 41 KM (about 25 miles) long and 6 to 12 KM (4-7.5 miles) 
in width.  The geographical area of the Gaza Strip is estimated at 360 square kilometers 
(about 139 square miles) (Ministry of Health, 2004) and it consists of 5 governorates: 
Northern Governorate, Gaza Governorate, Middle Governorate, Khanyounis 
Governorate, and Rafah Governorate (Figure A-2).  
According to the1993 census, the Palestinian population was about 3.7 millions, 
36.7 % (1.4 million) of whom lived in about 60% of the Gaza strip (Palestinian Central 
Bureau of Statistics, 2003). In 2007, the total population of Palestine was 3,761,646. 
About 37.7% (1,416,539) of them live in Gaza Strip with an average household of 6.5 
people per house (Palestinian Central Bureau of Statistics, 2008). In July, 2008, the 
population of Gaza was estimated to be 1,500,202 (Central Intelligence Agency, 2009). 
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Figure A-1: Map of West Bank and Gaza Strip. 
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Figure A-2: Map of Governorates of Gaza Strip 
 
Historical Palestine was ruled by Ottoman Turks for about 400 years. After the 
First World War, the British colonized and administered Palestine. In 1912, the British 
government issued the Belfour Declaration that promised to establish a homeland for the 
Jews in Palestine. In 1947, Britain decided to leave Palestine. In November, 1947, the 
United Nations (UN) adopted a plan calling for partition of Palestine into two states, 
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Israel and Palestine. The Arab states protested that plan as it gave the majority of the 
Palestinian land to the Jews who were a small minority in Palestine at that time. In 1948, 
the Jews won the war against the Arab countries and occupied most of Palestinian land 
(with the exception of West Bank and Gaza Strip) and declared the State of Israel 
(Palestine History, 2009). In 1967 Israel occupied Gaza Strip and West Bank. Between 
1948 and 1967, the West Bank was administered by Jordan, while the Gaza Strip was 
administered by Egypt. In 1987, the Palestinians demonstrated their rejection for the 
Israeli occupation for Gaza Strip and West Bank through a series of uprisings (Palestine 
History, 2009). Between September 1993 and September 1999, Israel with the Palestinian 
Liberation Organization (PLO) signed several agreements that resulted in interim self-
government for Palestinians in Gaza and West Bank populated areas. Israel kept control 
of most of the Land between the Palestinian cities. The Palestinian National Authority 
(PNA) became responsible for administering civilian issues such as education, health, 
and municipality in the Palestinian-populated areas of the West Bank and Gaza (Central 
Intelligence Agency, 2009). In 2000, President Clinton hosted negotiation between the 
Palestinian President, Yasser Arafat, and the Israeli Prime Minister, Eyhude Barak, in an 
attempt to solve the Palestinian- Israeli conflict. After a failure of negotiations and 
postponement of the proposed date for a permanent status, a second Intifada erupted in 
September, 2000 and Israel reoccupied most of the Palestinian-controlled areas (Central 
Intelligence Agency, 2009). 
In September 2005, Israel decided to withdraw its military soldiers and settlers 
from Gaza Strip, but continuing to control over the borders of Gaza Strip. This allowed it 
to control the entrance of all goods to Gaza including medical supplies. The only way 
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Palestinians could leave Gaza Strip is through the borders with Egypt which was 
administered by Palestinians and monitored by Europeans. After the 2006 elections 
which resulted in the win of the Islamic Resistant Movement (HAMAS) of the 
Palestinian legislative Council, the international community, led by Israel and the United 
States, refused to deal with a government lead by HAMAS and economic sanctions and a 
blockade were imposed against Gaza Strip including the port between Gaza and Egypt. 
Sanctions and blockage were tightened in June 2006. In June 2007, clashes between 
HAMAS and FATAH, the other major political group in Palestine, ended with HAMAS 
taking over all government and military institutions in Gaza (Central Intelligence 
Agency, 2009). 
After that, the Palestinians have two governments, one headed by HAMAS and 
resided in Gaza, and the other government was appointed by President Abbas and resided 
in Ramallah at West Bank. As a result, sanctions and blockade against Gaza were 
severely tightened until Israel started to prevent fuel and electricity to get to Gaza. The 
port between Gaza and Egypt now is completely blocked. As a result of this blockade, 
273 Palestinian died (up to February24th, 2010, 368 patients) because they could not 
travel abroad for treatment (Ministry of Health, 2009a).  
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ع٘دح اىؾٞبح ٗاىَؼٞقبد ىيؾق٘ه ػيٚ اىخذٍبد اىقؾٞخ 
 ىَشمٚ عشهبُ اىجشٗعزبرب فٜ قطبع غضح
 
  
 
 اٌغٕخ      اٌشٙش   اٌ١َٛ
 
  اىغلاً ػيٞنٌ ٗ سؽَخ الله/ ٛ اىؼضٝضدٗاه
 
  :إُ ٕزا الاعزجٞبُ ٖٝذف إىٚ
مٞف ٝؤصش ٗ ثؾنو خبؿ  ,اىزؼشف ػيٚ ع٘دح اىؾٞبح ىذٙ ٍشمٚ عشهبُ اىجشٗعزبرب ثؾنو ػبً. 1
  .أٗ ػلاعٔ ػيٚ ع٘دح ؽٞبرٌٖرب عشهبُ اىجشٗعزب
رؾذٝذ اىؼ٘ائق اىزٜ ٝ٘عٖب ٍشمٚ عشهبُ اىجشٗعزبرب فٜ اىؾق٘ه ػيٚ اىخذٍبد اىقؾٞخ أصْبء . 2
  .فزشح اىؼلاط
 
 
 الإعبثخٍِ  ٍزأمذاإرا ىٌ رنِ . اىشعبء قشاءح مو عؤاه فٜ ٕزا الاعزجٞبُ ثؼْبٝخ قجو الإعبثخ ػيٞٔ
اة ٗرزمش أّ لا ٝ٘عذ ط. الأقشة ىَب رؾؼش ثٔ أّٖباس الإعبثخ اىزٜ رؼزقذ ٛاىشعبء اخذ ,ػيٚ أٛ عؤاه
اىشعبء , عؤاه ٛر٘مٞؼ أمضش ػِ أإىٚ ىشعبء إرا ؽؼشد ثأّل رؾزبط ا. خبهئفؾٞؼ أٗ ع٘اة 
  . عؤاه اىجبؽش ٗ ثذُٗ رشدد
 
ألا ٝنؾف ػْٖب لأٛ اىجبؽش ٍِ عٖزٔ ٝؼذ ثأُ ٝؾبفظ ػيٚ عشٝخ اىَؼيٍ٘بد اىزٜ ع٘ف رذىٜ ثٖب ٗ 
اىَؼٍ٘بد اىزٜ عزؼطٖٞب . ؽخـ آخش ٗ أّٔ عٞقً٘ ثبعزخذاً ٕزٓ اىَؼيٍ٘بد فقو ىغشك اىجؾش
, ٍضو ؽنشرل, ىيجبؽش عٞزٌ إمبفزٖب إىٚ اىَؼيٍ٘بد اىزٜ عٞؾقو ػيٖٞب اىجبؽش ٍِ ٍشمٚ آخشِٝ
ػِ  سٝش اىْٖبئٜاىزقىِ ٝزٌ رمشك ثبلاعٌ  أّذ أٗ أٛ ؽخـ آخش ٍؾبسك فٜ ٕزا اىجؾش ػْذ مزبثخ  ٗ
  .ّزبئظ ٕزا اىجؾش
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  .عٕخ___________                           .مٌ رجيغ ٍِ اىؼَش اىًٞ٘. 1
 
  ٍب ٕ٘ أػيٚ ٍغز٘ٙ ثيغزٔ فٜ اىزؼيٌٞ؟. 2
   ٌُ أر٘ت إٌٝ ِذاسط. 1      دْٚ الاثزذائٟ . 2                           
  اٌّشؽٍخ الاثزذائ١خ          . 3  اٌّشؽٍخ الإػذاد٠خ.  4      
      
  اٌزؼٍ١ُ اٌغبِؼٟ    . 6اٌّشؽٍخ اٌضبٔٛ٠خ                                  . 5
 
  ٕو رؼٞؼ ٍغ صٗعزل؟. 3
  لا. 2ٔؼُ                             . 1           
 
  أِٝ رغنِ؟. 4
  ِؾبفظخ غضح. 2 ِؾبفظخ اٌشّبي                                  . 1      
  ِؾبفظخ خبٔ١ٛٔظ. 4ِؾبفظخ اٌٛعطٝ                                  . 3      
  ِؾبفظخ سفؼ. 5     
 
  ك رأٍِٞ فؾٜ؟دٕو ٝ٘عذ ػِ. 5
  لا  . 2ٔؼُ                             . 1
 
  ٕو ٝ٘عذ ػْذك عشهبُ آخش ثغبّت عشهبُ اىجشٗعزبرب؟. 6
  لا. 2          ٔؼُ                  . 1 
 
  أٛ عشهبُ رٌ رؾخٞقٔ أٗلا؟, اىغؤاه اىغبثق ّؼٌ إعبثخمبّذ  إرا. 7
  .رُ رشخ١ص اٌغشغبْ ا٢خش أٚلا.  2                     . رُ رشخ١ص عشغبْ اٌجشٚعزبرب أٚلا. 1     
  
  ٍزٚ رٌ رؾخٞـ ٍشك عشهبُ اىجشٗعزبرب ػْذك؟. 8
  
 
  ربرب فٜ اى٘قذ اىؾبىٜ؟ٕو رزيقٚ أٛ ػلاط ىغشهبُ اىجشٗط .9
  ٔؼُ. 1       لا. 2                      
 
  اىؼلاط اىزٜ ريقٞزٖب أٗ رزيقبٕب ؽبىٞبً؟ عٞيخ ٗ ٍٛٓب . 01
  .عشاؽخ لاعزئصبي اٌجشٚعزبرب. 2.                         ح ػلاطيٌُ ٠ىٓ ٕ٘بن أٞ ٚعٟ. 1   
  . شؼبع اٌزسٞاٌؼلاط ثبلإ. 4          اٌؼلاط ثبٌٙشِٛٔبد                           . 3   
  اٌشعبء روش٘ب. ٚع١ٍخ أخشٜ. 6ثبٌى١ّبٚٞ                                         طاٌؼلا. 5   
  
  أِٝ رزيقٚ أٗ ريقٞذ اىؼلاط ىغشهبُ اىج٘عزبرب؟. 11
  فٟ اٌخبسط. 3                 اٌّغزشفٟ الأٚسٚثٟ. 2ِغزشفٝ اٌشفبء                      . 1      
 
 
 
 ث١بٔبد ػبِخ
 352
  ٕو رؼبّٜ ؽبىٞب أٗ مْذ رؼبّٜ فٜ أٛ ٗقذ عبثق ٍِ أٛ ٍِ اىؾبلاد اىزبىٞخ؟ . 21
 
 اىشعبء اخزٞبس ّؼٌ أٗ لا ىنو ؽبىخ ٍِ اىؾبلاد اىزبىٞخ ّؼٌ لا
  ِشض اٌغىشٞ. أ 1 2
  َ فٟ اٌصذسآلارثؾخ صذس٠خ أٚ . ة 1 2
  عٍطخ دِبغ١خ. ط 1 2
  ثزش أؽذ الأغشاف. د 1 2
  ِشبوً فٟ اٌذٚسح اٌذِٛ٠خ فٟ الأسعً أٚ الألذاَ. ٖ 1 2
  أٚ ِشبوً فٟ اٌزٕفظ, اِفبص٠ّب, سثٛ. ٚ 1 2
  . لشؽخ فٟ اٌؼذح أٚ اظطشاثبد فٟ الأِؼبء. ص 1 2
  ِشض فٟ اٌىٍٝ. ػ 1 2
  اوزئبة ٔفغٟ. غ 1 2
  صشع  أٚ ٔٛثبد ِٓ اٌزشٕظ. ٞ 1 2
  رذخٓ ؽبٌ١ب أٚ وٕذ رخٓ فٟ اٌغبثك. ن 1 2
  
اىشعبء رمشٓ , اىشعبء اُ مْذ رؼبّٜ ٍِ أٛ ٍشك أٗ ؽبىخ فؾٞخ رؼزقذ أّٖب رؤصش ػيٚ ع٘دح ؽٞبرل. 31
  :فٜ اىفشاغبد اىزبىٞخ
 ______________________                     __________________________
 ______________________                     __________________________
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   : ثشىً ػبَ ٚظؼه اٌصؾٟ ٌغٛدح اٌصؾخ ٚالأعئٍخ اٌزبٌ١خ رجؾش فٟ ِذٜ ِزبثؼزه 
:  ثؾنو ػبً، َٝنْل أُ رق٘ه أُ فؾزل  .41
1 ------------------------ِّزبصح            )اخزش عٛاثباً ٚاؽذااً (            
2 ----------------------ع١ذح عذااً        
3 ----------------------------ع١ذح      
   4 --------------------------ٚعـػ         
  5 --------------------------عـ١ئخ         
 
 
 63-FSاعزجٞبُ ػِ اىقّؾخ 
 452
  ؟اُٟ، مٞف رُقٌَّٞ فؾزل ثؾنو ػبً  ثبىَقبسّخ ٍغ اىغْخ اىَبمٞخ.   51
  )اخزش عٛاثباً ٚاؽذااً (
 1-----------ا٢ْ، أفعً ثىض١ش  ِٓ اٌغٕخ اٌّبظ١خ            
2 ------ا٢ْ، أفعً إٌٝ ؽذ ِب، ِٓ اٌغٕخ اٌّبظ١خ            
 3------------------ا٢ْ، رمش٠جباً ِضً اٌغٕخ اٌّبظ١خ           
4 --------ا٢ْ أعٛأ إٌٝ ؽذ ِب، ِٓ اٌغٕخ اٌّبظ١خ            
5 ------------ا٢ْ، أعٛأ ثىض١ش ِٓ اٌغٕخ اٌّبظ١خ            
 
 
 
ٕو رؾؼش . اىْؾبهبد اىزبىٞخ  ٍِ اىْؾبهبد الاػزٞبدٝخ اىزٜ َٝنْل اىقٞبً ثٖب  ٍٝ٘ٞب رُؼزجش.  61
ظغ دائشح (ثبُ فؾزل رؼٞقل ػِ اىقٞبً ثجؼل ٕزٓ اىْؾبهبد ؟  فٜ ؽبه ّؼٌ، إىٚ أٛ ٍذٙ ؟
  )ؽٛي اٌشلُ إٌّبعت ِٓ وً عطش
 
ّؼٌ رؼٞقْٜ   دإٌشبغب
 مضٞشاً 
ٔؼُ رؼ١مٕٟ 
 لٍ١لااً 
ٌُ رؼمٕٟ 
 أثذااً 
ؽم١جخ (وبٌشوط، سفغ أش١بء صم١ٍخ  اهبد ػْٞفخّؼ. أ
  .اٌزٟ رزطٍت عٙذااً وج١شااً   ، اٌش٠بظخ)ِضلااً 
 3 2 1
وزؾش٠ه غبٌٚخ، دفغ ِىٕغخ  ّؾبهبد ٍز٘عطخ. ة
  ....وٙشثبئ١خ، اٌؼًّ فٟ اٌؾذ٠مخ
 3 2 1
 3 2 1  .سفغ أٚ ؽًّ و١ظ اٌخعبس أٚ اٌجمبٌخ. ط
 3 2 1  .ه٘اثق ىؼذح :صؼٛد اٌذسط . د
 3 2 1  .هبثق ٗاؽذ: اٌذسط صؼٛد . ٖ
 3 2 1  .الأؾٕبء ٚاٌشوٛع. ٚ
 3 2 1  ) .أٌف ِزش فّب فٛق( ىَغبفخ ه٘ٝيخاٌغ١ش . ص
 3 2 1  ) .ألً ِٓ أٌف ِزش(  ىَغبفخ ٍز٘عطخاٌغ١ش . ػ
 3 2 1  ) .ِبئخ ِزش أٚ ألً( ىَغبفخ ققٞشحاٌغ١ش . غ
 3 2 1 . الاعزؾّبَ أٚ ٌجظ اٌض١بة.ٞ
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، ٕو ٗاعٖزل إؽذٙ اىَؾبمو اىزبىٞخ فٜ ػَيل أٗ ّؾبهبرل  الأعبثٞغ الأسثؼخ اىَبمٞخخلاه . 71
  ؟ىقؾزل اىغغذٝخاىٍٞ٘ٞخ مْزٞغخ 
  )ظغ دائشح ؽٛي اٌشلُ إٌّبعت ِٓ وً عطش(                            
 اىَؾبمو
مو 
 اى٘قذ
ٍؼظٌ 
 اى٘قذ
عضءا ً
مجٞشا ًٍِ 
 اى٘قذ
ثؼل 
 اى٘قذ
قيٞلاً 
ٍِ 
 اى٘قذ
ِع١زـٗ فٟ أاٌزٞ  مَٞخ اى٘قذأٔمصَذ ِٓ . أ
  .اٌؼًّ أٚ إٌشبغبد الأخشٜ
 5 4 3 2 1
 5 4 3 2 1  .أْ رٕٙ١ــٗ أقو ٍَب مْذ ر٘دأٔـٙ١َذ . ة
أٚ  ٍقٞذا ًٍِ ؽٞش ّ٘ع اىؼَووَٕذ . ط
  .إٌشبغبد الأخشٜ
 5 4 3 2 1
أٚ  فؼ٘ثخ فٜ اىقٞبً ثبىؼَوٚاعَٙذ . د
 . )إظبف١باً ِضلااً ثزٌذ عٙذااً (إٌشبغبد الأخشٜ 
 5 4 3 2 1
 
، ٕو ٗاعٖزل إؽذٙ اىَؾبمو اىزبىٞخ فٜ ػَيل أٗ ّؾبهبرل  الأعبثٞغ الأسثؼخ اىَبمٞخخلاه . 81
  ؟) مبىؾؼ٘س ثبلإؽجبه أٗ اىقيق( ىؾبىزل اىْفغٞخاىٍٞ٘ٞخ مْزٞغخ 
  )ظغ دائشح ؽٛي اٌشلُ إٌّبعت ِٓ وً عطش(                                
اىَؾبمو 
مو 
 اى٘قذ
ٍؼظٌ 
 اى٘قذ
عضءا ً
مجٞشا ًٍِ 
 اى٘قذ
ثؼل 
 اى٘قذ
قيٞلاً 
ٍِ 
 اى٘قذ
اٌزٞ أِع١زٗ فٟ  مَٞخ اى٘قذأٔمصَذ ِٓ .أ 
  .اٌؼًّ أٚ إٌشبغبد الأخشٜ
 5 4 3 2 1
 5 4 3 2 1  .أْ رٕٙ١ٗ أقو ٍَب مْذ ر٘دأٔـٙ١َذ . ة
فٟ إٔغبص ثؼط الأػّبي أٚ  إَٔيذتَ . ط
  .إٌشبغبد الأخشٜ
 5 4 3 2 1
 
، إىٚ أٛ ٍذٙ أصشد ؽبىزل اىقؾٞخ ٗاىْفغٞخ ػيٚ ػلاقبرل الأعبثٞغ الأسثؼخ اىَبمٞخخلاه  .91
  ؟  الاعزَبػٞخ رغبٓ ػبئيزل، أفذقبئل، عٞشاّل أٗ اىغَبػبد الأخشٙ
                                                                                
  )اخزش عٛاثباً ٚاؽذااً (    1 -----------------------------أثذااً                                        
  2-----------------------------لٍ١لااً                                         
 3----------------------------ثبػزذاي                                        
  4------------------------------وض١شااً                                       
 5--------------------------وض١شااً عذااً                                        
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  ؟الأعبثٞغ الأسثؼخ اىَبمٞخاىغغذٛ  اىزٛ ػبّٞذ ٍْٔ خلاه  الأىٌٍب ٕ٘ ٍقذاس . 02
  )اخزش عٛاثباً ٚاؽذااً (        1-------------------------لا شٟء                                        
 2-------------------------لٍ١ً عذااً                                        
 3-----------------------------لٍ١ً                                        
 4-----------------------------ٚعػ                                       
 5-------------------------------ؽبد                                       
 6---------------------------ؽبد عذااً                                       
 
،إىٚ أٛ ٍذٙ  الأعبثٞغ الأسثؼخ اىَبمٞخخلاه . 12 
  ؟) اىَْٖٜ أٗ اىَْضىٜ(ىٍٜٞ٘ اىغغذٝخ ٍغ هجٞؼخ ػَيل ا آلاٍلرؼبسمذ 
   )اخزش عٛاثباً ٚاؽذااً (           1---------------------------أثذااً                                      
 2--------------------------لٍ١لااً                                       
 3--------------------ثشىً ِؼزذي                                      
 4--------------------------وض١شااً                                      
 5----------------------وض١شااً عذااً                                      
 
 
 
 
 
اىشعبء إػطبء . الأعبثٞغ الأسثؼخ الأخٞشحالأعئيخ اىزبىٞخ رذٗس ؽ٘ه هجٞؼخ ؽؼ٘سك خلاه . 22
  :الأعبثٞغ الأسثؼخ اىَبمٞخمٌ ٍِ اى٘قذ خلاه . ىغ٘اة الأقشة ىَب ؽؼشد ثٔ ا
  )ظغ دائشح ؽٛي اٌشلُ إٌّبعت ِٓ وً عطش(
مو  
 اى٘قذ
ٍؼظٌ 
 اى٘قذ
عضءا ً
مجٞشا ًٍِ 
 اى٘قذ
ثؼل 
 اى٘قذ
قيٞلاً ٍِ 
 اى٘قذ
 أثذاً 
 6 5 4 3 2 1  .ٍيٜء ثبىؾٞ٘ٝخ؟شؼشَد أٔه . أ
 6 5 4 3 2 1  .عذااً؟  ػقجٞبً وَٕذ شخصباً . ة
شؼشَد ثبٌىآثخ ٌذسعخ أْ لا شٟء . ط
  .٠ّىٓ أْ  ٠فشؽه؟
 6 5 4 3 2 1
 6 5 4 3 2 1  . ٕبدئب ًٗفج٘ساً؟وَٕذ . د
 6 5 4 3 2 1  . ّؾٞطبً؟وَٕذ . ٖ
 6 5 4 3 2 1  .ؽضِٝ؟شؼشَد أٔه . ٚ
 6 5 4 3 2 1  .ٍشٕق؟شؼشَد أٔه . ص 
 6 5 4 3 2 1  .عؼٞذ؟شؼشَد أٔه . ػ 
 6 5 4 3 2 1  .ٍزؼت؟أٔه  شؼشد َ. غ 
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  ٍغ  ؽبىزل اىقؾٞخ أٗ اىْفغٞخ،مٌ ٍِ اى٘قذ رؼبسمذ  الأعبثٞغ الأسثؼخ اىَبمٞخخلاه . 32
  ؟ )صٝبسح الإٔو، الأفذقبء، اىغٞشاُ أٗ اىغَبػبد الأخشٙ(ّؾبهبرل الاعزَبػٞخ 
  )اخزش عٛاثباً ٚاؽذااً (
 1-------------------------------وً اٌٛلذ                                       
 2-----------------------------ِؼظُ اٌٛلذ                                       
 3-----------------------------ثؼط اٌٛلذ                                       
 4---------------------------لٍ١لااً ِٓ اٌٛلذ                                       
 5-------------------------------------أثذااً                                       
 
 
 
  ثبىْغجخ إىٞل؟ خبهئخأٗ  فؾٞؾخإىٚ أٛ ٍذٙ رُؼزجش اىغَو اىزبىٞخ . 42
  )ظغ دائشح ؽٛي اٌشلُ إٌّبعت  ِٓ وً عطش( 
 فؾٞؾخ 
 ثبىزأمٞذ
فؾٞؼ
  غبىجـب ً ح
لا 
 أػيٌ
خبهئخ 
  غبىجـبً 
خبهئخ 
 ثبىزأمٞذ 
٠ظٙش أٟٔ أِشض . أ
  ثغٌٙٛخ أوضش ِٓ
  .إٌبط ا٢خش٠ٓ 
 5 4 3 2 1
أٔب عٍ١ُ وؤٞ . ة
  .شخص أػشفٗ 
 5 4 3 2 1
أرٛلغ أْ رغٛء . ط
  . ؽبٌزٟ اٌصؾ١خ 
 5 4 3 2 1
 5 4 3 2 1  .صؾزٟ ِّزبصح . د
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اىشعبء أُ رنغ  فٜ اػزجبسك ٗمؼل . اىزج٘ه ٕزا اىغضء ٝزؼيق ثبىغٖبص اىج٘ىٜ ٗ قذسرل فٜ اىزؾنٌ ثؼَيٞخ
  :فٜ الأسثغ أعبثٞغ الأخٞشح ػْذ الإعبثخ ػيٚ الأعئيخ اىزبىٞخ
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(                  1.......................................  ثشىً ٠ِٟٛ 
 2................. ؽٛاٌٟ ِشح ٚاؽذح فٟ الأعجٛع 
  3................ ْ ِشح ٚاؽذح فٟ الأعجٛع ألً َ
  4......................... لا ٠ششؼ ِٕٟ اٌجٛي أثذااً 
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(            1............. لا أعزط١غ اٌزؾىُ ثؼٍّ١خ اٌزجٛي إغلالب
 2.................... ٠ٛعذ رٕم١ػ ٌٍجٛي ثشىً ِزىشس 
 3. ................... ٌٍجٛي ثشىً ثغ١ػ ٠ٛعذ رٕم١ػ 
 4..................... أرؾىُ ثؼٍّ١خ اٌزجٛي ثشىً ربَ 
 
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(                                 1........................ ف َٛ غ أٚ أوضش ٠ِٛ١باً  3أعزخذَ 
 2............. ...أعزخذَ ف َٛ غخ  ٚاؽخ أٚ اصٕز١ٓ ٠ِٛ١ب 
  اً3.................................... لا أعزخذَ ف َٛ غ أثذااً 
 
 
 
 
  
ِشىٍخ 
 وج١شح
 
ِشىٍخ 
 ِزٛعطخ
 
ِشىٍخ 
 ثغ١طخ
 
ِشىٍخ 
ثغ١طخ 
 عذااً 
 
لا رشىً 
أٞ 
 ِشىٍخ
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ ِٓ وً عطش( 
  رٕم١ػ اٌجٛي أٚ ثًٍ ِلاثغه؟. أ 0 1 2 3 4
 4
سشؼ أٚ رٕم١ػ اٌجٛي ٠ؤصش ػٍٝ ؽ١بر١ه  .ة 0 1 2 3
 اٌغٕغ١خ؟
 
 
  مبُ اىج٘ه ٝشؽؼ إىٚ ٍلاثغل اىذاخيٞخ رقشٝجبً , فٜ الأسثغ أعبثٞغ الأخٞشح. 52
 
أٛ ٍِ اىؼجبساد اىزبىٞخ رقف ثؾنو أفنو قذسرل ػيٚ اىزؾنٌ فٜ ػَيٞخ اىزج٘ه فٜ الأعبثٞغ . 62
 الأسثغ الأخٞشح؟
اىزٜ رغزخذٍٖب ٍٝ٘ٞب ً) قطغ قَبػ أٗ ٍْبدٝو ٗسقٞخ(مٌ ػذد اىف ٘تَ ه , فٜ الأعبثٞغ الأسثغ الأخٞشح. 72
 ىزؾبفظ ػيٜ ّظبفخ ٍيجغل ٍِ اىج٘ه اىزٛ ٝشؽؼ ٍْل؟ 
  إىٚ أٛ ٍذٙ  رؾنو ىل مو  ٍِ  اىَغبئو اىزبىٜ رمشٕب ٍؾنيخ؟. 82
  ػَيٞخ اىزج٘ه ػَو اىغٖبص اىج٘ىٜ ٗ اىزؾنٌ فٜ
 952
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(                       1.............................  لا رّضً أٞ ِشىٍخ 
 2.............................. ِشىٍخ ثغ١طخ عذااً 
 3.................................. ِشىٍخ ثغ١طخ 
 4............................... وٍخ ِزٛعطخ ِش
  5.................................  ِشىٍخ وج١شح 
 
 
 
 
 
 
اىشعبء أُ رنغ  فٜ اػزجبسك ٗمؼل فٜ الأسثغ أعبثٞغ . ٕزا اىغضء ٝزؼيق ثؼَيٞخ اىزجشص ٗآلاً اىجطِ
  :الأخٞشح ػْذ الإعبثخ ػيٚ الأعئيخ اىزبىٞخ
 
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(                       1..................... فٟ اٌ١َٛ  أوضش ِٓ ِشح ٚاؽذح
 2....................... ؽٛاٌٟ ِشح ٚاؽذح فٟ اٌ١َٛ 
 3................ أوضش ِٓ ِشح ٚاؽذح فٟ الأعجٛع 
 4.................. ؽٛاٌٟ ِشح ٚاؽذح فٟ الأعجٛع 
 5....... ..................... ٔبدسااً أٚ ٌُ ٠ؾصً أثذااً 
 
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(                       1............................................... أثذااً 
 2............................................ ٔبدسااً 
3...... رمش٠جباً فٟ ؽٛاٌٟ ٔصف ػذد اٌّشاد 
 4............................ اد فٟ ِؼظُ الأٚق
  5........................................... دائّب 
 
 
 
 
 
  مٌ ٍشح أخشعذ ثشاصا ًػيٚ ؽنو إعٖبه؟, فٜ الأعبثٞغ الأسثغ الأخٞشح. 13
إىٚ أٛ ٍذٛ ؽنيذ ػَيٞخ ػذً اىزؾنٌ فٜ اىزج٘ه ٍؾنيخ ثبىْغجخ ىل فٜ الأسثغ أعبثٞغ , ثؾنو ػبً. 92
 اىَبمٞخ؟
  ػَيٞخ اىزجشص اىقذسح ػيٚ اىزؾنٌ فٜ
 
مٌ ٍشح غبىجب ؽؼشد ثبىؾبعخ اىؾذٝذح ىيزجشص ٗ ىنْل لا رغزطٞغ ,  فٜ الأعبثٞغ الأسثغ الأخٞشح. 03
 اىزجشص ػْذ رٕبثل إىٚ اىؾَبً؟
 062
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(              1................... ِؼبٔبح شذ٠ذح 
 2................ ِؼبٔبح ِزٛعطخ 
 4.....................ِؼبٔبح لٍ١ٍخ 
  5........... ػبٔبح ٌُ ٠غجت أٞ َ
 
 
 
 
 1............................ ػذح ِشاد فٟ اٌ١َٛ اٌٛاؽذ
 2........................... ؽٛاٌٟ ِشح ٚاؽذح فٟ اٌ١َٛ 
 3................................. ػذح ِشاد فٟ الأعجٛع
 4....................... ؽٛاٌٟ ِشح ٚاؽذح فٟ الأعجٛع 
 5......................... دح فٟ اٌشٙش ؽٛاٌٟ ِشح ٚاػ
  6................................. ٔبدسااً أٚ ٌُ ٠ؾذس أثذااً 
 
 
 
 
  ) اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(                       1...................................  ِشىٍخ وج١شح  
2 .................................ِشىٍخ ِزٛعطخ
 3.................................. ِشىٍخ ثغ١طخ 
  4............................. ِشىٍخ ثغ١طخ عذااً  
5.............................  ٌُ رّضً أٞ ِشىٍخ
 
 
 
 
 
 
 
 ع١ذ عذااً 
 
 ظؼ١ف ِزٛعػ ع١ذ
 
 ظؼ١ف
 عذااً 
اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ ِٓ وً ( 
  )عطش
ثخ ػٕذن ٌّّبسعخ اٌغٕظ اٌشؽ. أ 1 2 3 4 5
  )اٌّؼبششح اٌضٚع١خ/اٌغّبع(
  لذسح ػعٛن اٌزوشٞ ػٍٝ الأزصبة؟. ة 1 2 3 4 5
اٌمذسح ػٕذن ٌٍٛصٛي إٌٝ رسٚح إٌشٜٛ . ط 1 2 3 4 5
 اٌغٕغ١خ ٚ اٌمزف؟
 
 
اىزٛ عججزٔ ىل ػَيٞخ اىزجشص ػيٚ ٍذٙ الأعبثٞغ )  اىَؼبّبح اىْفغٞخ(ٍب ٕ٘ ٍذٙ اىزؼت اىْفغٜ . 23
  الأخٞشح؟ الأسثغ
  مٌ ٍشح أفبثل ٍغـ أٗ أىٌ فٜ اىجطِ أٗ ٍْطقخ اىؾ٘ك فٜ الأعبثٞغ الأسثغ الأخٞشح؟. 33
ٛ ٍضو ػذً اىزؾنٌ فٜ ػَيٞخ اىزجشص ٍؾنيخ ثبىْغجخ ىل فٜ الأسثغ أعبثٞغ إىٚ أٛ ٍذ, ثؾنو ػبً. 43
 اىَبمٞخ؟
 
  )اىَؼبؽشح اىضٗعٞخ(اىقذسح ػيٚ اىََبسعخ اىغْغٞخ 
 
 
  مٞف رقٌٞ مو ٍِ اىَغبئو اىزبىٞخ؟, فٜ الأعبثٞغ الأسثغ الأخٞشح. 53
 
 162
 
 
 
  )إعبثخ ٚاؽذح فمػاٌشعبء اخزبس (      1................................................ لا ٠ٛعذ أزصبة أثذا 
  2........ أزصبة خف١ف ٚ ٌىٓ لا ٠غذٞ ٌٍم١بَ ثّّبسعخ اٌغٕظ 
 3........ أزصبة ع١ذ ٚ ٌىٓ غ١ش وبفٟ  ٌٍم١بَ ثّّبسعخ اٌغٕظ 
 4.................... أزصبة ع١ذ ٚ وبفٟ  ٌٍم١بَ ثّّبسعخ اٌغٕظ 
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(          1............... ..........لا رزُ ػٍّ١خ الأزصبة أثذااً ػٕذِب أس٠ذ رٌه؟ 
2...... رزُ ػٍّ١خ الأزصبة ثّؼذي ألً ِٓ إٌصف ػٕذِب أس٠ذ رٌه 
 3................ رزُ ػٍّ١خ الأزصبة ثّؼذي إٌصف ػٕذِب أس٠ذ رٌه 
4..... رزُ ػٍّ١خ الأزصبة ثّؼذي أوضش ِٓ إٌصف ػٕذِب أس٠ذ رٌه 
 5........................... الأزصبة فٟ أٞ ٚلذ أس٠ذ رٌه  رزُ ػٍّ١خ
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(                 1................................................. لا ٠ؾذس رٌه أثذااً 
 2) ....... ِٓ اٌٛلذ% 52ألً ِٓ (٠ؾذس ٚ ٌىٓ ثشىً ٔبدس 
 3) ........ ألً ِٓ ٔصف اٌٛلذ(٠ؾذس ٚ ٌىٓ ثشىً ِزٛعػ 
 4) .............. أوضش ِٓ ٔصف اٌٛلذ(٠ؾذس ٚ ثشىً ِزىشس
 5) ............ ِٓ اٌٛلذ% 57أوضش ِٓ (٠ؾذس ٚ ثشىً دائُ 
 
 
 
 
  )فمػ اٌشعبء اخزبس إعبثخ ٚاؽذح(                                  1................................................. لا 
 2.................. ٚ ٌىٓ ٌّشح ٚاؽذح فمػ , ٔؼُ
 3........................... ٚ لأوضش ِٓ ِشح, ٔؼُ
 
 
 
 
  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(    1............................... ظؼ١فخ عذااً 
 2.................................... ظؼ١فخ 
 3................ ..................ِزٛعطخ 
 4....................................... ع١ذح 
  5.................................. ع١ذح عذااً 
 
 
  مٞف َٝنْل أُ رقف ع٘دح اّزقبة ػن٘ك اىزمشٛ؟. 63
  مٞف َٝنْل أُ رقف ػذد اىَشاد اىزٜ ْٝزقت ثٖب ػن٘ك اىزمشٛ؟. 73
  اّزقبة؟ٕو ٝؾذس ٗ أُ رغزٞقظ فٜ اىقجبػ أٗ أصْبء اىًْ٘ ٗ ٝنُ٘ ػن٘ك اىزمشٛ فٜ ؽبىخ . 83
  ٍبسعذ اىغْظ؟) قَذ ثبىَؼبؽشح اىضٗعٞخ(ٕو , فٜ الأعبثٞغ الأسثغ الأخٞشح. 93
  )اىَؼبؽشح اىضٗعٞخ/اىغَبع(مٞف رقٌٞ ٍقذسرل ػيٚ ٍَبسعخ اىغْظ , فٜ الأعبثٞغ الأسثغ الأخٞشح. 04
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  )اٌشعبء اخزبس إعبثخ ٚاؽذح فمػ(    1...................... لا ٠ّضً أٞ ِشىٍخ 
  2............... ٠ّضً ِشىٍخ ثغ١طخ عذااً 
 3.................. ..٠ّضً ِشىٍخ ثغ١طخ 
 4.................. ٠ّضً ِشىٍخ ِزٛعطخ 
  5....................٠ّضً ِشىٍخ  وج١شح 
 
 
 
  ٍب ٕٜ اىؼ٘ائق اىزٜ ٗاعٖزٖب فٜ اىؾق٘ه ػيٚ اىخذٍبد اىقؾٞخ؟, ثؼذ رؾخٞـ ٍشمل. 24
  اٌجشٚعزبرب أسعٛن أخجشٟٔ ػٓ اٌؾٛاعض ػٍٝ اٌشػب٠خ اٌصؾ١خ اٌزٟ رٛاعٗ ٌىُ ثؼذ رشخ١ص عشغبْ. 
 
 
 
 
 
 
 
 
 
 
 ٍلاؽظبد
 
 
 
 
 
 
 
 
 
 اىؼ٘ائق فٜ هشٝق اىؾق٘ه ػيٚ خذٍبد فؾٞخ
 ؽنشا عضٝلا ىزؼبّٗنٌ ٗ ثبسك الله فٞنٌ
اىَؼبؽشح /اىغَبع(إىٚ أٛ ٍذٛ  َٝضو ىل ٍ٘م٘ع اىقذسح ػيٚ اىََبسعخ اىغْغٞخ , ثؾنو ػبً. 14
  سثغ الأخٞشح؟ٍؾنيخ فٜ الأعبثٞغ الأ) اىضٗعٞخ
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APPENDIX C 
QUESTIONNAIRE USED IN THE STUDY (ENGLISH VERSION) 
 
264 
UCLA PROSTATE CANCER INDEX 
(UCLA-PCI), 
including the 
RAND 36-Item Health Survey v2 
(SF-36 v2) 
 
 
Today’s Date:  
 
Month    Day     Year 
 
The purpose of this questionnaire is to find out about your 
health in general and about how your prostate cancer and any 
treatment you received for it affects your quality of life. 
 
Please read each question carefully before answering. If you 
are unsure about how to answer a question, please give the best 
answer you can. Remember that there are no right or wrong 
answers. If you have any questions or if you needed further 
clarifications, please feel free to ask the interviewer. 
 
Your answers to this questionnaire will be kept confidential 
and will be used only for research purposes. The information 
you give will be combined with the responses of other patients 
completing this questionnaire, and you will not be identifiable 
in any way. 
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I. Demographic Data: 
1. What is your age today? ________________  Years. 
 
2. What is your highest level of education? 
1. No education   2. Some education below primary school 
3. Primary school   4. Secondary school                       
5.   High school                              6. Higher education 
 
3.   Do you live with your wife? 
1. Yes      2. No 
 
4. Where do you live? 
1. Northern Governorate   2. Gaza Governorate 
2. Mid-zone Governorate  4. Khanyounis Governorate 
5. Rafah Governorate 
 
5. Do you have a health insurance?  
1. Yes     2. No 
 
6. Do you have other cancers beside prostate cancer? 
1. Yes     2. No 
 
7. If the answer for the previous question was yes, which cancer was 
diagnosed first? 
1. Prostate cancer     2. The other cancer. 
 
8. When your prostate cancer was diagnosed? 
_________________  
 
9. Do you receive any treatment for your prostate cancer at the current 
time? 
1. Yes    2. No 
2.  
General information 
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10. Which treatment you are receiving now or had received in the past for 
your prostate cancer? 
1. I received no treatment.      2. Prostatectomy. 
3. Hormonal therapy.      4. Radiation therapy. 
5. Chemotherapy.                  6. Others, describe ______________. 
 
11. Where do/did receive your treatment? 
1. Shifa Hospital   2. Gaza European Hospital   
3. Abroad    4. Others _______________. 
 
 
II. Health-Related data: 
 
12. Have you ever had any of the following medical conditions? 
 
Please circle YES or NO for each item YES NO 
a) Diabetes 1 2 
b) Heart attack, chest pain 1 2 
c) Stroke  1 2 
d) Amputation  1 2 
e) Circulation problems in your legs or feet 1 2 
f) Asthma, emphysema, breathing problems 1 2 
g) Stomach ulcer, irritable bowel 1 2 
h) Kidney disease 1 2 
i) Major depression 1 2 
j) Seizer  1 2 
k) Current or past cigarette smoker 1 2 
 
13. Please, if you have any other chronic diseases or health condition that 
you think it affect your quality of life, list them bellow: 
_________________________  _______________________ 
 
 
 
_________________________  _______________________ 
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These first questions are about your health in general, BOTH RELATED and 
UNRELATED to your prostate cancer. Please give the best answer you can 
and remember there are no right or wrong answers. 
 
 
 
 
Excellent ...............................................1 (Circle one number.) 
Very Good.............................................2 
Good......................................................3 
Fair.........................................................4 
Poor .......................................................5 
 
 
 
 
Much better now than one year ago ...........................1 (Circle one number.) 
Somewhat better now than one year ago ....................2 
About the same as one year ago ..................................3 
Somewhat worse now than one year ago.....................4 
Much worse now than one year ago.............................5  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14. In general, would you say your health is: 
 
15.  COMPARED TO ONE YEAR AGO, how would you rate your 
health in general now? 
 
General Quality of Life (SF-36 v2) 
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(Circle 1, 2, or 3 on each line.) 
Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
a. Vigorous activities, such as running, 
lifting 
heavy objects, participating in strenuous 
sports…….. 
1 2 3 
b. Moderate activities, such as moving a 
table, 
pushing a vacuum cleaner, 
gardening……………... 
1 2 3 
c.  Lifting or carrying 
groceries……………………….. 
1 2 3 
d. Climbing several flights of 
stairs…………………… 
1 2 3 
e. Climbing one flight of 
stairs………………………... 
1 2 3 
f. Bending, kneeling, or 
stooping……………………... 
1 2 3 
g. Walking for long distance (more than a 
Kilometer)  
1 2 3 
h. Walking for several hundred 
meters……………… 
1 2 3 
i. Walking one hundred 
meters…………………….. 
1 2 3 
j. Bathing or dressing 
yourself………………………... 
1 2 3 
 
 
 
 
 
 
 
 
 
 
 
16. The following questions are about activities you might do during 
a typical day. Does your health now limit you in these activities? 
If so, how much? 
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(Circle one number on each line.) 
All 
of the 
time 
Most 
of 
the 
time 
Some 
of 
the 
time 
A 
little 
of the 
time 
None 
of 
the 
time 
a. Cut down on the amount of 
time you spent on work or 
other activities 
 
1 
 
2 
 
3 
 
4 
 
5 
b. Accomplished less than you 
would like 
 
1 
 
2 
 
3 
 
4 
 
5 
c. Were limited in the kind of 
work or other activities 
 
1 
 
2 
 
3 
 
4 
 
5 
d. Had difficulty performing the 
work or other activities (for 
example, it took extra effort) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
 
 
 
 
 
 
(Circle one number on each line.) 
All 
of the 
time 
Most 
of 
the 
time 
Some 
of 
the 
time 
A 
little 
of the 
time 
None 
of 
the 
time 
a. Cut down on the amount of 
time you spent on work or 
other activities 
 
1 
 
2 
 
3 
 
4 
 
5 
b. Accomplished less than you 
would like 
 
1 
 
2 
 
3 
 
4 
 
5 
c. Did work or other activities 
less carefully than usual 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
 
17. During the PAST FOUR WEEKS, how much of the time have you had 
any of the following problems with your work or other regular daily 
activities as a result of your physical health? 
18.  During the PAST FOUR WEEKS, how much of the time have you had 
any of the following problems with your work or other regular daily 
activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
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Not at all..................................................1 (circle one number.) 
Slightly ....................................................2 
Moderately...............................................3 
Quite a bit.................................................4 
Extremely.................................................5  
 
 
 
 
 
None ........................................................1 (circle one number.) 
Very mild.................................................2 
Mild .........................................................3 
Moderate .................................................4 
Severe ......................................................5 
Very severe .............................................6 
 
 
 
 
 
 
Not at all..................................................1 (Circle one number.) 
A little bit ................................................2 
Moderately..............................................3 
Quite a bit................................................4 
Extremely................................................5 
 
 
 
 
 
 
 
 
 
 
19.  During the PAST FOUR WEEKS, to what extent has your physical 
health or emotional problems interfered with your normal social activities 
with family, friends, neighbors, or groups? 
20.  How much BODILY pain have you had during the PAST FOUR 
WEEKS? 
21.  During the PAST FOUR WEEKS, how much did pain interfere with 
your normal work (including both work outside the home and 
housework)? 
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(Circle one number on each 
line.) 
All 
of the 
time 
Most 
of 
the 
time 
Some of 
the 
time 
A 
little 
of the 
time 
None 
of 
the 
time 
a. Did you feel full of 
life? 
1 2 3 4 5 
b. Have you been very 
nervous? 
1 2 3 4 5 
c. Have you felt so down 
in the dumps that 
nothing could cheer 
you up? 
 
1 
 
2 
 
3 
 
4 
 
5 
d. Have you felt calm and 
peaceful? 
1 2 3 4 5 
e. Did you have a lot of 
energy? 
1 2 3 4 5 
f. Have you felt 
downhearted and 
depressed? 
1 2 3 4 5 
g. Did you feel worn out? 1 2 3 4 5 
h. Have you been happy? 1 2 3 4 5 
i. Did you feel tired? 1 2 3 4 5 
 
 
 
 
 
 
All of the time.........................................1 (Circle one number.) 
Most of the time .....................................2 
Some of the time ....................................3 
A little of the time ..................................4 
None of the time.....................................5 
 
 
 
22.  These questions are about how you feel and how things have been 
with you during the PAST FOUR WEEKS. For each question, please give 
the one answer that comes closest to the way you have been feeling. How 
much of the time during the PAST FOUR WEEKS... 
23. During the PAST FOUR WEEKS, how much of the time has your 
physical health or emotional problems interfered with your social 
activities (like visiting with friends, relatives, etc.)? 
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Please continue on next page. 
 
 
(Circle one number on 
each line.) 
Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
a. I seem to get 
sick a little 
easier than other 
people 
 
1 
 
2 
 
3 
 
4 
 
5 
b. I am as healthy 
as anyone I 
know 
 
1 
 
2 
 
3 
 
4 
 
5 
c. I expect my 
health to get 
worse 
 
1 
 
2 
 
3 
 
4 
 
5 
d. My health is 
excellent 
 
1 
 
2 
 
3 
 
4 
 
5 
24.  How TRUE or FALSE is each of the following statements for you? 
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This section is about your urinary habits. Please consider ONLY THE LAST 
4 WEEKS. 
 
 
 
 
Every day.......................................... 1   (Circle one number.) 
About once a week........................... 2 
Less than once a week..................... 3 
Not at all........................................... 4 
 
 
 
 
No control whatsoever.................... 1   (Circle one number.) 
Frequent dribbling ........................... 2 
Occasional dribbling ....................... 3 
Total control .................................... 4 
 
 
 
 
 
3 or more pads per day.................... 1   (Circle one number.) 
1-2 pads per day............................... 2 
No pads............................................. 3 
 
 
 
 
 
(Circle one number on each 
line.) 
 
No 
Problem 
 
Very 
small 
problem 
 
 
Small 
Problem 
 
 
Moderate 
Problem 
 
 
Big 
Problem 
 
a. Dripping urine or wetting 
your pants? 
 
0 
 
1 
 
2 
 
3 
 
4 
b. Urine leakage interfering 
with your sexual activity? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
 
URINARY FUNCTION 
25. Over the LAST 4 WEEKS, how often have you leaked urine? 
 
26. Which of the following best describes your urinary control during the 
LAST 4 WEEKS? 
27. How many pads or adult diapers per day did you usually use to 
control leakage during the LAST 4 WEEKS? 
28. How big a problem, if any, has each of the following been for you? 
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No problem...................................... 1 (Circle one number.) 
Very small problem......................... 2 
Small problem.................................. 3 
Moderate problem........................... 4 
Big problem ..................................... 5 
 
 
 
 
 
This section is about your bowel habits and abdominal pain. Please consider 
ONLY THE LAST 4 WEEKS. 
 
 
 
 
More than once a day ...................... 1 (Circle one number.) 
About once a day.............................. 2 
More than once a week ................... 3 
About once a week........................... 4 
Rarely or never ................................ 5 
 
 
 
 
 
Never ................................................ 1 (Circle one number.) 
Rarely ............................................... 2 
About half the time .......................... 3 
Usually.............................................. 4 
Always .............................................. 5 
 
 
 
 
 
 
 
 
29. Overall, how big a problem has your urinary function been for you 
during the LAST 4 WEEKS? 
BOWEL ELIMINATION 
 
30. How often have you had rectal urgency (felt like you had to pass stool, 
but did not) during the LAST 4 WEEKS? 
31. How often have you had stools (bowel movements) that were loose or 
liquid (no form, watery, mushy) during the LAST 4 WEEKS? 
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 بّئاد ...........................................5  
 
 
 
Severe distress................................. 1 (Circle one number.) 
Moderate distress............................ 2 
A little distress ................................ 3 
No distress ....................................... 4 
 
 
 
 
 
 
Several times a day .......................... 1  (Circle one number.) 
About once a day.............................. 2 
Several times a week....................... 3 
About once a week........................... 4 
About once this month.................... 5 
Rarely or never ................................ 6 
 
 
 
 
 
 
Big problem ..................................... 1  (Circle one number.) 
Moderate problem........................... 2 
Small problem.................................. 3 
Very small problem......................... 4 
No problem...................................... 5 
 
 
 
 
 
 
 
 
 
Please continue to next page 
 
 
32. How much distress have your bowel movements caused you during the 
LAST 4 WEEKS? 
33. How often have you had crampy pain in your abdomen or pelvis 
during the LAST 4 WEEKS? 
34. Overall, how big a problem have your bowel habits been for you during 
the 
LAST 4 WEEKS? 
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(Circle one number on each 
line.) 
Very 
Poor 
Poor 
 
Fair 
 
Good 
 
Very 
Good 
a. Your level of sexual desire? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
b. Your ability to have an 
erection? 
 
1 
 
2 
 
3 
 
4 
 
5 
c. Your ability to reach orgasm 
(climax)? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
 
 
None at all................................................................ 1  (Circle one number.) 
Not firm enough for any sexual activity.................. 2 
Firm enough but can‟t have intercourse …….......... 3 
Firm enough for intercourse..................................... 4 
 
 
 
 
 
 
I NEVER had an erection when I wanted one..........................1(Circle one number) 
I had an erection LESS THAN HALF the time I wanted one...2 
I had an erection ABOUT HALF the time I wanted one............3 
I had an erection MORE THAN HALF the time I wanted one ..4 
I had an erection WHENEVER I wanted one...............................5 
 
 
 
 
 
 
 
SEXTUAL FUNCTION 
 
 
35. How would you rate each of the following during the LAST 4 WEEKS? 
 
36. How would you describe the usual QUALITY of your erections? 
37. How would you describe the FREQUENCY of your erections? 
277 
 
 
 
 
Never................................................................................... 1    (Circle one umber.) 
Seldom (less than 25% of the time)..................................... 2 
Not often (less than half the time) ....................................... 3 
Often (more than half the time)............................................ 4 
Very often (more than 75% of the time) .............................. 5 
 
 
 
 
 
No ......................................................1                   (Circle one number.) 
Yes, once.............................................2 
Yes, more than once...........................3 
 
 
 
 
 
Very poor........................................... 1 (Circle one number.) 
Poor.................................................... 2 
Fair ..................................................... 3 
Good................................................... 4 
Very good .......................................... 5 
 
 
 
 
 
 
No problem........................................ 1    (Circle one number.) 
Very small problem .......................... 2 
Small problem................................... 3 
Moderate problem ............................ 4 
Big problem....................................... 5 
 
 
 
 
38. How often have you awakened in the morning or night with an 
erection? 
39. During the LAST 4 WEEKS did you have a sextual intercourse? 
40. Overall, how would you rate your ability to function sexually 
during the LAST 
4 WEEKS? 
41. Overall, how big a problem has your sexual function been for you 
during the LAST 4 WEEKS? 
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42. Please tell me about the barriers to health care you faced after being diagnosed 
with prostate cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments: 
Thank 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you very much for your time! Please remember to 
mail your completed questionnaire in the supplied 
envelope. 
Barriers to Health Care 
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APPENDIX D 
UCLA-PCI, INCLUDING THE RAND 36-ITEM HEALTH SURVEY V2 (SF-36 V2) 
HEALTH-RELATED QUALITY OF LIFE 
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APPENDIX E 
PERMISSION FROM DR. LETWIN TO TRANSLATE AND USE UCLA-PCI  
IN THE STUDY 
 
 
Nasser Abu-El-Noor <nia1@zips.uakron.edu>  
 
A permission to use the UCLA-PCI 
4 messages  
 
Litwin, Mark M.D. <MLitwin@mednet.ucla.edu>  
Fri, May 22, 2009 at 6:14 
PM  
To: Nasser Abu-El-Noor <nia1@uakron.edu>  
Cc: "Lopez, Griselda" <GrLopez@mednet.ucla.edu>  
Fine. You must make sure to use rigorous methods to do a translation that is both semantic 
and cultural. There are many upblished methods for such translations. Please send me a 
copy of the final version once translated.  Thank you. 
 
One of my staff members will send you the UCLA-PCI in English for you to work with. 
 
 
Mark S. Litwin, MD, MPH 
Professor of Urology and Health Services 
UCLA Department of Urology 
Box 951738 
Los Angeles, CA  90095-1738 
(310) 206-8183 
________________________________________ 
From: Nasser Abu-El-Noor [nia1@uakron.edu] 
Sent: Thursday, May 21, 2009 7:15 PM 
To: Litwin, Mark M.D. 
Subject: A permission to use the UCLA-PCI 
 
Dear Dr. Litwin, Hello 
 
I hope this email finds you well. 
 
I am pursuing my PhD in health policy at the Department of Public 
Administration and Urban Studies and the University of Akron, OH. I 
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chose the topic of my dissertation to be "Quality of life and barriers 
to health care of prostate cancer survivors resideing in Gaza Strip: A 
discreptive study". I am planning to use the UCLA PROSTATE CANCER INDEX 
including the RAND 36-Item 
Health Survey v2 in my study after translating it into the Arabic Language. 
 
In this email, I would like to get your permission to translate the 
instruemtn and use it in my study. 
 
Fianally, I would like to thank you very much for your help and wish 
you all the best. 
 
 
 
My background is nursing and I am interested to evaluate the HRQOL for 
prostate cancer survivors in my country. 
While I was searching for a topic for my dissertation, I remember that 
there was a copy of the UCLA-PCI available on line. When I decided to 
use it for my study, I searched the internet several times looking for 
the instrument, but I never found it. 
Sir, I hope that I can get your permission to use the instrument in my 
study and I hope that you can instrunct me how I can get a copy of the 
instrument. 
 
Thank you very much for your help and wish you all the best. 
 
 
Nasser Abu-El-Noor 
Ph.D. Student 
Public Administration and Urban affairs 
The University of Akron 
 
IMPORTANT WARNING:  This email (and any attachments) is only intended for the use of 
the person or entity to which it is addressed, and may contain information that is privileged 
and confidential.  You, the recipient, are obligated to maintain it in a safe, secure and 
confidential manner.  Unauthorized redisclosure or failure to maintain confidentiality may 
subject you to federal and state penalties. If you are not the intended recipient, please 
immediately notify us by return email, and delete this message from your computer. 
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APPENDIX F 
SCORING INSTRUCTIONS FOR UCLA-PCI 
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APPENDIX G 
A PERMISSION FROM DR. IBTISSAM SABBAH TO USE  
THE ARABIC VERSION OF THE SF-36. 
 
 
Nasser Abu-El-Noor <nia1@zips.uakron.edu>  
 
Re: Arabic Sf-36 
 
 
ibtissam sabbah <imsab@terra.net.lb>  Sat, May 16, 2009 at 12:57 PM  
To: nia1@uakron.edu  
monsieur; 
je vous envoie la version de SF-36 utilise dans notre etude au Liban et valide dans la population 
generale, cependant, l'auteur de SF-36 recommande d'avoir son autorisation avant l'utilisation pour des 
raisons de commercialisation de sa part 
bon travail et bon courage de notre part 
Dr. Ibtissam SABBAH DROUBI 
Universite libanaise Saida, LIBAN 
----- Original Message ----- From: "nabil droubi" <nsdroubi@inco.com.lb> 
To: <imsab@terra.net.lb> 
Sent: Wednesday, May 13, 2009 3:01 PM 
Subject: FW: Arabic Sf-36 
 
 
 
-----Original Message----- 
From: Nasser Abu-El-Noor [mailto:nia1@uakron.edu] 
Sent: Wednesday, May 13, 2009 4:53 AM 
To: nsdroubi@inco.com.lb 
Subject: Arabic Sf-36 
 
 
Dear Dr. Droubi, Hello 
 
My Name is Nasser Abu-El-Noor. I am from Palestine, Gaza Strip and 
works as a lecturer at the College of Nursing at the Islamic 
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University-Gaza. At the time being, I have a study leave to have my 
Ph.D in Health Policy from the Department of Public Administration and 
Urban Studies at the University of Akron, Ohio, U.S.A. 
I am at the time being preparing for my dissertation which has the 
topic "Quality of life and barriers to health care of prostate cancer 
survivors in Gaza Strip: A descriptive study". Along with the UCLA 
Prostate Cancer Index (UCLA-PCI), I am using the SF-36 to measure the 
general quality of life. I was very pleased that you and your 
colleagues have worked to translate the SF-36 into the Arabic Language 
and checked it for reliability and validity. 
I hope that you will be generous and give me a permission to use your 
translated instrument in my study. If so, I hope that you can send a 
copy of the Arabic version. 
 
Thank you very much for your help and cooperation. 
 
Nasser Abu-El-Noor 
Ph.D. Student 
Public Administration and Urban affairs 
The University of Akron 
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APPENDIX H 
APPROVAL OF THE INTERNAL REVIEW BOARD (IRB)  
AT THE UNIVERSITY OF AKRON 
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APPENDIX I 
APPROVAL OF PALESTINIAN MINISTRY OF HEALTH  
TO CONDUCT THE STUDY 
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APPENDIX J 
APPROVAL OF HELSINKI COMMITTEE TO CONDUCT THE STUDY 
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APPENDIX K 
CONSENT TO PARTICIPATE IN THE STUDY 
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